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Abstract 
Plasmodium falciparum parasites have evolved numerous ingenious methods to 
subvert immune recognition, in order to survive within the human host. One such 
immune evasion mechanism features the expression of ligands which bind to the Fc-
portion of human IgM. The binding of IgM to P. falciparum-encoded PfEMP1 
molecules expressed on infected erythrocyte surfaces has been well characterised. 
Recently, two novel IgM-binding proteins expressed on merozoites were identified, 
known as DBLMSP and DBLMSP2. The aim of this project was to characterise the 
binding of these merozoite surface proteins to IgM, and to investigate what 
advantage IgM binding may afford P. falciparum merozoites.  
Although DBLMSP and DBLMSP2 have been implicated in camouflaging critical 
epitopes from immune responses, it is unknown whether these proteins function to 
alter the binding of IgM to IgM-receptors, such as the human Fcμ receptor. A panel 
of domain-swap antibodies, in which homologous domains are exchanged between 
human IgA and IgM, identified the Cμ4 domain of human IgM as the target of both 
the DBLMSP proteins and hFcμR. Despite this, the binding of DBLMSP and 
DBLMSP2 to IgM did not prevent its binding to hFcμR, suggesting the malarial 
proteins recognise an alternative region on IgM than that recognised by hFcμR. In 
fact, DBLMSP and DBLMSP2 engaged IgM bound to both hFcμR and DC-SIGN, 
which was found to facilitate interactions of these malarial proteins with IgM-
positive human lymphocytes. However, binding of recombinant DBLMSP and 
DBLMSP2 per se did not induce proliferation or apoptosis of human lymphocytes.  
A possible explanation for this is that DBLMSP and DBLMSP2 were found to exist 
in complex with IgM and other unidentified parasite molecules. This suggests that 
these proteins associate with other merozoite surface proteins in vivo, which could 
potentially induce functional consequences upon lymphocyte binding.  This thesis 
lays the foundation for future research into how native IgM-parasite protein 
complexes may function to bind to lymphocytes and modulate host immune 
responses. 
This thesis also presents data that hFcμR functions as an endocytosis receptor for 
human IgM, in which the binding and internalisation of human IgM occurs in a 
glycan-independent manner. 
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Chapter 1: Introduction 
1.1. Malaria 
Malaria is a disease caused by the protozoan parasite of the genus Plasmodium, 
which is transmitted by the bites of infected female Anopheles mosquitoes. Many 
different species of Plasmodium infect a wide range of animals, ranging from birds 
to humans 
1
.  The four species of Plasmodium which cause malaria in humans are 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium 
malariae. Recently, Plasmodium  knowlesi was confirmed as the fifth species to 
cause naturally acquired infections in humans 
2
.  
1.2. Malaria infections in humans 
Malaria is an ancient disease thought to have evolved alongside the human race 
3, 4
. 
Approximately 3.4 billion people, almost half of the World’s population, are at risk 
of malaria infection every year, one third of which are at high risk 
5
. In 2012 alone 
there were ~207 million clinical malaria cases and ~627,000 deaths reported, 90% of 
which occurred in sub-Saharan Africa 
5
. The majority of deaths are in children under 
the age of five, and it is predicted that a child dies every minute from the disease 
5
. 
The most common species eliciting infections in humans are P. falciparum and P. 
vivax, whereby P. falciparum cause severe malarial disease and subsequent 
mortality. Other Plasmodium species generate significant morbidity in infected 
individuals residing in endemic regions 
1
.  Due to the high prevalence and mortality 
of malaria caused by P. falciparum, this thesis will focus on P. falciparum  
infections.  
1.3. Life cycle of Plasmodium falciparum 
The lifecycle of P. falciparum is complex and multi-staged, occurring in both human 
and mosquito hosts. In the human host, infections are dichotomised into pre-
erythrocytic and erythrocytic stages (Figure 1.1). Due to the complexity of initial 
infection and dissemination of the parasite, mouse models of malaria (P. yoelli and 
2 
 
 
P. berghei) have been utilised to investigate the pre-erythrocytic stage. Malaria 
infection is initiated when an infected female Anopheles mosquito injects a small 
number of parasites (~20 sporozoites) under the subcutaneous tissue of the 
mammalian host, and less frequently directly into the bloodstream, when taking a 
blood meal 
6-8
. Within one hour of injection, some sporozoites leave the area of the 
bite and glide through the dermis to a blood vessel whereby they migrate through the 
circulatory system to reach the liver 
7, 9
. An alternative hypothesis proposes that 
sporozoites arrive at the liver via the lymphatic systems 
10, 11
. However, subsequent 
research showed that although ~30% of migrating sporozoites entered the lymphatic 
system, the majority were trapped in lymph nodes and digested by dendritic cells 
6
. 
Further research is required to confirm whether sporozoites migrate through the 
lymphatic system to reach the liver. Sporozoites are thought to cross the sinusoidal 
barrier of the liver principally by traversing kupffer cells 
12
. Sporozoites engage host 
cells via the binding of the circumsporozoite protein (CSP) and thrombospondin-
related anonymous protein (TRAP) expressed on sporozoite surfaces with heparan 
sulphate proteoglycans of liver cells 
13-15
. Subsequently, sporozoites traverse through 
several hepatocytes before settling within one, resulting in the formation of a 
parasitophorous vacuole which surrounds the parasite 
16
. Inside the hepatocyte, each 
sporozoite replicates and differentiates into thousands of asexual merozoites prior to 
their release into the bloodstream upon hepatocyte rupture 
17
.  
The erythrocytic stage of the life cycle is initiated once merozoites re-enter the 
bloodstream following heptacyte rupture 
1, 18, 19
. Merozoites then invade uninfected 
erythrocytes and develop through ring-shaped immature trophozoites to mature 
trophozoites (Figure 1.2).  Subsequent intraerythrocytic asexual replication of the 
parasite transforms the trophozoites into schizonts, which consist of ~16-30 daughter 
merozoites. Schizonts rupture and release the merozoites into the periphery, each of 
which has the ability to invade other erythrocytes and repeat the cycle of schizogony. 
The rupture of P. falciparum infected erythrocytes evokes the clinical symptoms of 
malaria, such as fever and rigor. Each cycle of schizogony takes approximately 48hr 
in P. falciparum, and the infection is amplified roughly 20-fold during each cycle in 
non-immune humans. The lifecycle continues until some merozoites escape the cycle 
to differentiate into the sexual parasitic stages, known as male and female 
gametocytes. A large proportion of gametocytes sequester in the extravascular space 
3 
 
 
of the bone marrow, whereby they undergo development before migrating to the 
circulation 
20
. The gametocytes then circulate in the blood until they are ingested by a 
mosquito taking a blood meal, thus completing the human stage of the Plasmodium 
life cycle 
21
.  
A pivotal step in the erythrocytic cycle is the invasion of erythrocytes by 
extracellular merozoites (Figure 1.2). The development of a fast and efficient 
invasion process has contributed to the evolutionary success of Plasmodium, since it 
limits the exposure of parasitic antigens to the host immune system 
1
. The invasion 
process commences with the egress of parasites from an infected cell, which occurs 
due to protease secretions and mounting intracellular pressure from merozoite 
growth 
22, 23
. Approximately 60 seconds after egress, merozoites quickly recognise, 
attach to, and invade uninfected erythrocytes 
1
.  Multiple antigens expressed on 
merozoite surfaces, such as merozoite surface protein 1 (MSP1), members of the 
erythrocyte binding ligand (EBL) and P. falciparum reticulocyte binding homologue 
(PfRH) protein families, initiate primary attachment of the merozoite to erythrocytes 
24-27
. These are referred to as adhesins as they function to bind directly to specific 
ligands expressed on erythrocyte surfaces 
28
. Although little is known about the 
receptor-ligand interactions which permit attachment of the merozoite to 
erythrocytes, the interaction between PfRH5 and Ok blood group antigen basigin was 
recently found to be essential for erythrocyte invasion in all tested P. falciparum 
strains 
25
.   
Following primary attachment, the apical end of the merozoite orientates towards the 
erythrocyte surface forming an irreversible attachment, referred to as tight junction 
formation 
29, 30
. Tight junction formation between the merozoite and erythrocyte is 
mediated by parasitic invasins, such as apical membrane antigen 1 (AMA1) or 
rhoptry neck protein (RON) complex 
31, 32
. These interact with the actinomyosin 
system of the merozoite and are translocated towards its posterior end, which propels 
the parasite in a forward motion into the erythrocyte. The parasite then induces 
invagination of the erythrocyte membrane around itself and enters a parasitophorous 
vacuole within the erythrocyte. Upon invasion, proteases cleave antigens from the 
merozoite surface coat resulting in their release into the periphery 
33
.  
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Figure 1.1 P. falciparum life cycle in the human host. The Anopheles mosquito bites a human and 
deposit sporozoites under the dermis. These migrate to the liver to invade hepatocytes (liver stage), 
whereby they transform into exoerythrocytic merozoites which are released into the blood stream 
upon hepatocyte rupture. In the blood, merozoites quickly invade erythrocytes to form early rings, 
which then develop into trophozoites and mature schizonts (blood stage). Next, erythrocytes burst and 
release merozoites which reinvade uninfected erythrocytes. During the blood stage, some merozoites 
differentiate into gametocytes which are subsequently ingested by a feeding mosquito during the 
blood meal  
28
.  
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Each stage of the P. falciparum life cycle in humans is a possible target for 
therapeutics and/or targeting by vaccines. The erythrocytic stage of the life cycle has 
received much attention to date as antigens on the merozoite surface are exposed to 
the host immune system during this stage. Furthermore, the obligation of P. 
falciparum to invade host erythrocytes in order to survive represents an attractive 
weakness of the parasite which can be exploited in therapeutic or vaccine design 
1
. 
Designing therapeutics or specific antibodies (Abs) to block the entry of P. 
falciparum into erythrocytes can prevent its replication and amplification within 
cells. However, a greater understanding of host-parasite interactions is required for 
the development of new treatments and to identify potential vaccine candidates. 
1.4. Epidemiology of malaria 
There is marked variation in the risk of P. falciparum infection globally. The disease 
is most prevalent in sub-Saharan Africa (Figure 1.3), whereby transmission intensity 
helps to classify countries or regions as endemic, holo-endemic, or meso-endemic 
34
. 
There are numerous factors contributing to differences in geographical epidemiology 
of P. falciparum, including local vector species, transmission intensities, housing 
conditions and population densities 
35-37
. Another factor includes human genetic 
variation. A growing number of genes have been associated with conferring a degree 
of protection against P. falciparum infection and severe disease 
38, 39
. Early studies 
revealed that blood-related disorders which correlated with the historic incidence of 
malaria, such as sickle-cell trait and thalassaemia, confer protection against the 
disease 
40-42
. Polymorphisms in major histocompatibility complex (MHC) genes have 
been associated with tolerance or susceptibility of infection, as presentation of 
malarial epitopes on MHC molecules expressed by infected cells is essential for T 
cell recognition and priming of pre-erythrocytic immunity to malaria 
43-47
.  
Furthermore, certain polymorphisms within genes encoding Fcγ receptors (FcγRIIA 
and FcγRIIB) have also been shown to associate with both protection from and 
susceptibility to clinical malaria 
48, 49
, most likely as a consequence of altered binding 
of IgG subclasses to these receptors. Co-infections in hosts are also confounding 
factors of the disease. In areas of stable malaria transmission, infections with HIV 
and visceral leishmania increase susceptibility of P. falciparum infection and disease  
6 
 
 
 
 Figure 1.2 Invasion of red blood cells by merozoites. Invasion is initiated with attachment of the 
merozoite to the erythrocyte surface via low-affinity interactions, followed by the reorientation 
process in which the apical end of the merozoite is positioned adjacent to the erythrocyte surface to 
facilitate tight junction formation. The formation of high-affinity ligand-receptor interactions secures 
the merozoite whilst the tight junction moves from the apical to posterior end.  The merozoite surface 
coat is shed upon erythrocyte invasion, creating a parasitophorous vacuole within the erythrocyte 
1
.  
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severity 
50, 51
. Moreover, immune responses against P. falciparum cause decreased 
resistance to invasive non-typhoid Salmonella, a common and often fatal 
complication in malaria patients 
52
. 
The majority of the reported deaths occur in sub-Saharan Africa, where children 
under five and pregnant women are particularly susceptible to severe disease 
5
. 
Malaria has devastating consequences in addition to direct effects of mortality and 
morbidity, including impaired intellectual development due to reduced school 
attendance and productivity, onset of developmental abnormalities following cerebral 
malaria, and reduced yearly gross national product in malaria endemic countries 
53-55
. 
In endemic regions, pregnant women have a 2- to 3-fold increased risk of developing 
severe malarial disease compared to non-pregnant women 
32
. Furthermore, 
pregnancy-associated malaria causes adverse consequences such as maternal 
anaemia, intrauterine growth retardation, spontaneous abortions, low-birth weight, 
and infant mortality 
56, 57
.  International travellers who visit endemic regions are also 
highly susceptible to malaria infection, as approximately 10,000 cases and 150 
deaths are reported each year 
58
. In addition, individuals who emigrate from malaria 
endemic countries to more developed countries are at higher risk of infection when 
they return to their country of origin 
59
. Disease susceptibility in these vulnerable 
populations is thought to be associated with a decrease in clinical immunity against 
the parasite 
37, 59
. 
1.5. Pathology of malaria 
The clinical symptoms of malaria typically appear a week following an infective 
mosquito bite, and some of the most common clinical symptoms include fever, chills, 
headache, vomiting and splenomegaly 
60
. The severity of malarial disease is 
classified into three categories; severe and complicated, mild and uncomplicated, and 
asymptomatic 
61, 62
. Severe disease accounts for the mortality of P. falciparum 
infection, resulting from disease manifestations such as cerebral malaria, severe 
anaemia, acute renal failure, metabolic acidosis, hypoglycaemia, and pulmonary 
oedema 
61
. 
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Figure 1.3 Global distribution of P. falciparum malaria endemicity in 2010. Heat-map depicting 
mean point estimates of the age-standardised annual mean P. falciparum parasite rate in 2-10 year 
olds (PfPR2-10) in areas of stable transmission. Light grey areas on the map represent P. falciparum 
free geographic areas and dark grey as areas of no risk or unstable risk (MAP, Accessed 11
th
 October 
2014 from: http://www.map.ox.ac.uk/client_media/png/Pf_mean_2010/Pf_mean_2010_World.png). 
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A prominent characteristic of the pathogenesis of P. falciparum infection involves 
the parasite’s ability to cause infected erythrocytes (IEs) to adhere to the endothelium 
of capillaries. The sequestration of IEs to microvasculature contributes to severe 
malaria by obstructing blood flow through tissues resulting in hypoxia and 
inadequate tissue perfusion 
63
. Pathogenesis is also mediated by the destruction of 
erythrocytes. The direct rupture of IEs and indirect destruction of non-parasitised 
erythrocytes has been associated with the development of severe anaemia 
64, 65
. 
Furthermore, the delivery of oxygen to organs is compromised with the destruction 
of erythrocytes, which may account for the observed hypoxia.  The mechanisms 
governing P. falciparum pathogenesis are complex and are likely to involve 
numerous contributing factors. However, rapid expansion of IEs, erythrocyte 
destruction, microvascular obstruction, and ensuing inflammatory responses are 
considered key events in severe disease 
66
. 
1.6. Control of P. falciparum infections 
Increased efforts to control malaria have resulted in a global malaria incidence 
decrease of 17% and decreased malaria mortality rates of 26% between 2000-2010 
5
. 
This success was largely owing to the launch of the Roll Back Malaria Initiative by 
WHO 
67
, which has been widely endorsed 
68
. The strategy of this programme 
involved aggressive vector control in highly endemic regions to help lower 
transmission, increased research into potential vaccines and anti-malarial drug, 
improved diagnostic measures, and intervention through indoor residual spraying 
with insecticides and mass administration of bed nets 
5, 67
.  
Despite recent advances, the burden of malaria is still great and drug-resistance in P. 
falciparum is on the rise 
5, 69
. The emergence of drug-resistance in P. falciparum 
populations threatens to thwart global malaria elimination. Chloroquine resistance is 
widespread, and resistance to sulfadoxine-pyrimethamine has grown in countries 
utilizing the drug as a replacement for chloroquine 
70
. In a bid to reduce the 
emergence and spread of resistance, combination therapy composed of drugs with 
different modes of actions was adopted. Artemisinin-based combination treatments is 
the most widely promoted combination therapy and has shown promising efficacy in 
both Asia and Africa 
71, 72
. However, resistance to artemisinin and its derivatives is 
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well established in South-east Asia and poses the risk of spreading 
5, 69
. Furthermore, 
resistance to pyrethroids has rapidly emerged due to large-scale distribution of 
insecticide-treated bednets 
73
.  
Vaccination has proved to be the most effective method for the prevention of 
infectious diseases to date 
74
. However, a licensed malaria vaccine is still unavailable 
and initial findings from human trials for the leading vaccine candidate RTS,S/AS01 
reported moderate efficacy of 30-50% 
75, 76
. Moreover, the mechanisms by which this 
vaccine confers protection are poorly understood. The recent discovery of cross-
strain dependency on the interaction between basigin and PfRH5 for erythrocyte 
invasion offers an exciting avenue for the development of new therapeutics to 
combat the disease 
25
. The elimination of malaria requires a multifaceted approach, 
enlisting effective insecticides, chemotherapy and the development of an affordable 
yet efficacious vaccine 
77
. Our limited understanding of the biology of P. falciparum 
and how the parasite interacts with the immune system contributes to the difficulty in 
generating an effective vaccine 
78
. These gaps in knowledge need to be filled in order 
to facilitate malaria elimination efforts. 
1.7. Immunity to P. falciparum  
Immune protection from malaria is extremely complex and poorly understood. In 
areas of intense P. falciparum transmission, severe malaria disease is mainly a 
feature of childhood (Figure 1.4) 
5
. After several episodes of malaria, individuals 
develop incomplete immunity which helps to control parasitemia and protects from 
severe disease and death 
18
. Malaria in immune adults is regarded as 
“uncomplicated” and is characterised by low-grade parasitemia, fever, chills and 
rigors, however sterilizing immunity is most likely never achieved and wanes in the 
absence of re-exposure 
18, 79
. This suggests that continued exposure to P. falciparum 
antigens is required to generate and maintain immunity against malaria. Innate, 
cellular and humoral immune responses have all been implicated in protection 
against the disease, although the underlying mechanisms which govern this are 
unclear 
79
. 
In theory, any stage of the P. falciparum life cycle can be targeted by the host 
immune system. Nonetheless, responses against P. falciparum infection have been 
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traditionally divided into pre-erythrocytic and erythrocytic stages 
27
. Protection 
against pre-erythrocytic stages is well documented and is mainly attributed to cellular 
responses, whereas humoral responses are required for erythrocytic-stage protection 
27, 32
. Longitudinal studies in endemic regions highlighted that the pre-erythrocytic 
stages were unlikely to elicit naturally acquired immunity to P. falciparum infection 
80
. Although immunity to pre-erythrocytic stages is limited, immunisation with 
irradiated sporozoites or vaccination with sporozoite antigens elicited considerable 
immune responses against P. falciparum 
29, 81, 82
. In fact, these targets feature in the 
most advanced malaria vaccines available to date. For example, the leading vaccine 
candidate RTS,S is a recombinant antigen based on the P. falciparum 
circumsporozoite protein (CSP) and hepatitis B surface antigen 
83
. Although 
RTS,S/AS02 vaccination initiates partial protection against P. falciparum infection, 
protection wanes with time, as protection was not found to extend to 5 years 
following vaccination 
84
. This clearly highlights the need to further understand the 
complexities of immune responses against malaria, especially in regard to vaccine 
design. 
During erythrocytic stages, exposed P. falciparum-derived antigens on free 
merozoites and IE surfaces present attractive targets for immune responses 
85, 86
. 
Humoral immune responses are thought to govern naturally acquired immunity to 
erythrocytic stages as erythrocytes do not express MHC class I or II molecules on 
their cell surfaces 
79
. Early studies revealed a role of Abs in mediating immunity to 
malaria, as severe malarial disease was successfully treated through passive 
administration of immunoglobulins from malaria-immune adults 
87, 88
. Furthermore, 
broad antibody (Ab) responses against merozoite surface proteins (MSP2 and MSP3) 
were found to associate strongly with protection against clinical malaria 
89
. In P. 
falciparum infections, Abs function to block erythrocyte invasion by merozoites 
90
, 
opsonise IEs to increase their clearance by phagocytes 
86
, and to mediate Ab-
dependent cellular cytotoxicity 
91
.  
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Figure 1.4 Population indices of naturally acquired immunity to P. falciparum in endemic 
regions. Severe malaria is a feature of childhood, as the slow acquisition of immunity against P. 
falciparum appears to result in the development of mild or asymptomic malaria 
18
.  
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Intriguingly, a recent study discovered differing Ab responses for induced and 
naturally acquired immunity against P. falciparum 
92
.  Strong humoral immune 
responses against pre-erythrocytic stage antigens CSP and liver stage antigen 1 
(LSA1) were generated in individuals who were experimentally infected with P. 
falciparum whilst receiving chloroquine prophylaxis. Semi-immune individuals with 
naturally acquired immunity generated responses against numerous well-
characterised merozoite and erythrocytic antigens, which were not observed in the 
experimentally-infected individuals 
92
. This data implies that although vaccines 
targeting pre-erythrocytic stage are able to mount sufficient humoral responses when 
parasitemia was controlled by prophylaxis, immunity to erythrocytic stage antigens is 
pivotal for naturally acquired immunity. Therefore, vaccines targeting erythrocytic 
stages are more likely to generate long-lasting immunity against P. falciparum 
infections. 
Although protection against erythrocytic-stage parasites has been traditionally 
ascribed to humoral responses, recent studies have implicated cellular immunity and 
interferon (IFN)-γ production in mediating protection. In the absence of Abs, cellular 
responses against IEs contribute to protection due to proliferative CD8
+
 and CD4
+
 T 
cell responses, IFN-γ and nitric oxide production 30, 93. Furthermore, CD4+ T cell 
help is essential in generating Ab responses against P. falciparum 
94
 and there is 
mounting evidence that CD4
+
 T cell responses elicited through vaccination help 
protect against P. falciparum infections in humans 
30
.  
Despite the great strides made in understanding immunity to P. falciparum in recent 
years, relatively few studies have investigated the combined effects of innate, 
humoral, and cellular responses in governing protection against malaria 
95
. It is 
highly likely that these immune branches work synergistically to recognise, combat, 
and eliminate parasites in the human host. Understanding the low immunogenicity of 
P. falciparum is pivotal in the development of effective methods for malaria control, 
which include the design of efficacious vaccines.   
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1.8. Immune evasion mechanisms of P. falciparum 
The slow acquisition of protective immunity against malaria is likely a result of the 
diverse immune evasion mechanisms which P. falciparum have evolved as a 
consequence of strong selection pressure 
96, 97
. Immune evasion by P. falciparum is 
well researched and many comprehensive reviews have covered this topic in detail 
96-
100
. Briefly, P. falciparum immune evasion mechanisms characterised to date include 
intracellular parasitism, genetic polymorphism, IE adhesion, antigenic variation, 
camouflage, molecular smokescreens and immune response modulation.  
Intracellular parasitism is an ingenious way pathogens have evolved to avoid host 
immune detection. It is particularly effective in the erythrocyte-stage of malaria as 
merozoites infect erythrocytes, which inherently lack MHC molecules, thus putting 
the parasite beyond the clutches of Abs and T cell recognition. The parasites 
themselves are highly polymorphic, whereby parasite populations express 
antigenically distinct alleles of a gene 
101
. Extensive polymorphisms are common in 
parasite antigens which elicit immune responses, such as MSP1 and P. falciparum 
erythrocyte membrane 1 (PfEMP1) 
34, 102, 103
. This allows parasites expressing 
mutated alleles to escape specific immune responses and selectively expand, much 
like HIV 
104, 105
. Another way the parasite evades immunity is to trick the immune 
system into responding to an irrelevant antigen. Tandem repeats are often found in 
malaria antigens which are not targets of protective immunity 
106
, but function as 
immune-dominant B cell epitopes 
97
. The generation of Ab responses against tandem 
repeats provide a smokescreen for epitopes crucial for mediating parasite function. 
Moreover, these repeats are able to cross-link surface immunoglobulins on B cell 
surfaces resulting in suppressed Ab responses  
97
. 
Surface exposed P. falciparum antigens are vital for mediating host-parasite 
interactions, yet their extracellular location makes them targets of humoral responses. 
However, antigenic variation of these Ags allows parasites to evade humoral 
responses and elicit P. falciparum virulence mechanisms. For example, the 
expression of the highly polymorphic PfEMP1 molecule on IE surfaces mediates 
essential functions such as the adhesion of IEs to host endothelium 
107, 108
. Whereas 
the majority of malaria erythrocytic antigens are encoded from one allele per locus, 
PfEMP1 variants are encoded by the var multigene family (~60 genes per genome) 
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present in multiple loci on different chromosomes 
109, 110
. The transcription of var 
genes is mutually exclusive and only one PfEMP1 variant is expressed on the 
erythrocyte surface at a time, with the remaining var genes in a transcriptionally 
silent state 
111
. However, var gene expression is able to switch during each reinvasion 
112
, which facilitates the parasite to switch the expression of PfEMP1 variants on the 
surface of the IE once Ab responses have been generated 
107
. 
PfEMP1 molecules contribute to the pathogenesis of malaria by mediating 
cytoadhesion. This cytoadhesion either results in the sequestration of infected 
erythrocytes to host endothelia (preventing splenic clearance), in binding to non-IEs 
to form so-called rosettes, or in binding to platelets inducing platelet-mediated 
clumping 
113
. Several human receptors have been shown to be involved in 
cytoadhesion mediated by PfEMP1 variants, including intercellular cell adhesion 
molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), complement 
receptor 1 (CR1), chondroitin sulphate antigen (CSA), endothelial protein C receptor 
(EPCR), CD36, and immunoglobulin M (IgM) 
113, 114
. Which human receptor is 
being bound depends on which PfEMP1 variant is expressed on the surface of IEs. It 
is likely that other host receptors which bind PfEMP1 remain to be characterised. 
The vast majority of the immune evasion mechanisms described above are mediated 
by interactions between parasite-derived proteins and host ligands. Central to a 
number of these mechanisms is the surprising ability of P. falciparum to bind human 
IgM in a non-cognate manner 
100
. As it is impossible to cover the scope of the 
complex host-parasite interactions mediating immune evasion, the focal point of this 
thesis is in the understanding of how IgM-binding proteins facilitate immune evasion 
in P. falciparum infections. 
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1.9. Binding of non-immune IgM to P. falciparum-derived molecules 
The neutralisation of pathogens by Abs is pivotal for humoral immune responses and 
protection against infection and disease. To evade Fc-mediated destruction, human 
pathogens have evolved to express ligands on their cell surfaces which bind the Fc 
region of host immunoglobulins. The functions of these ligands expressed by 
bacteria and viruses, such as Staphylococcus aureus protein A Cowman strain and 
herpes simplex virus gE-gI, have been well characterised 
115-117
. However, 
surprisingly little is known about the role of immunoglobulin-binding molecules in 
parasitic infections.   
A notable exception is the highly variable parasite antigen PfEMP1. PfEMP1 
variants are composed of Duffy binding-like (DBL) domains categorised into six 
types (α-ζ) and cysteine-rich interdomain region domains (CIDR) categorised into 
three types (α-γ) 110. A number of different domains from PfEMP1 variants have 
been shown to bind non-immune human IgM 
100, 118
, which are summarised in Table 
1.1. The Cμ4 domain of IgM molecules bound PfEMP1 variants from six distinct 
parasites, suggesting distinct PfEMP1 variants from different parasite isolates utilise 
a conserved mechanism to adhere to IgM 
118-120
.   
The reasons why PfEMP1 variants bind non-immune IgM are still being discovered. 
To date, PfEMP1 has been implicated in immune evasion mechanisms such as 
cytoadhesion 
121, 122
, immunomodulation 
123
, and camouflage 
119
. Binding of non-
immune IgM to PfEMP1 was shown to correlate with severe malaria in both 
laboratory strains and field isolates 
120, 124
. Subsets of P. falciparum strains which 
bind non-immune IgM also possess specific phenotypes associated with virulence, 
such as rosetting 
124
 and CSA-binding in pregnancy-associated malaria 
125, 126
. 
Intriguingly, IgM-binding is believed not to be a feature of other common 
phenotypes such as ICAM-1 or CD36 binding 
124
. Studies investigating IgM binding 
by field isolates are rare and of insufficient coverage. In reality, it is not known how 
common or how important the IgM binding phenotype is to parasite virulence or 
survival. 
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Table 1.1 Known IgM-binding DBL domains in PfEMP1 variants adapted from 
100, 118
. 
 
 
PfEMP1 variant Domain 
FCR3S1.2var1 CIDR 
TM284S2var1 DBL2β 
FCR3var1csa DBL7ε 
FCR3var2csa DBL6ε 
3D7var2csa DBL2-X, DBL5ε, DBL6ε 
TM284var1 DBL4β 
HB3var6 DBLζ2 
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It is still unknown what advantage rosetting affords P. falciparum parasites 
113
. 
Although not all rosetting variants bind non-immune IgM, the involvement of IgM in 
rosette formation appears to be essential for the strains that do, as rosetting 
frequencies in two different parasite strains (R+PA1 and HB3VAR6) were reduced 
when IgM was depleted from human serum 
118, 122
. However, the presence of IgM 
alone did not restore rosetting frequency suggesting that other serum components are 
essential for rosette formation 
118
. Exactly how IgM-binding is involved in rosette 
formation has not yet been clarified, but there have been several suggestions. The 
binding of non-immune IgM may stabilise rosettes by strengthening interactions 
between infected and uninfected erythrocytes 
127
. For this to occur, IgM could either 
induce a conformational change in the PfEMP1 protein or bring several PfEMP1 
proteins together increasing affinity or avidity 
128
. In support of the latter hypothesis, 
a recent study found that one IgM molecule was able to bind two PfEMP1 molecules 
in vitro 
118
. Another possibility is that IgM could interact with receptors on 
uninfected erythrocytes as well as with PfEMP1 on IE surfaces 
124
, however this has 
yet to be proven. Finally, IgM could promote rosetting by recruiting C1q which 
could subsequently interact with the complement receptor 1 (CR1) expressed on 
uninfected erythrocytes 
120
. COS-7 cells expressing an IgM-binding PfEMP1 domain 
were still able to  bind IgM in the presence of complement factors, suggesting that 
both C1q and PfEMP1 can bind to the same IgM molecule  
120
. This was not the case 
for the non-rosetting, chondroitin sulfate A (CSA)-binding PfEMP1 variant 
VAR2CSA, as no binding was observed between C1q and IgM-opsonised 
VAR2CSA
+
-infected erythrocytes 
119
. However, this may be attributed to differences 
in IgM-binding between PfEMP1 variants or whether the IgM molecules already are 
bound to their epitopes or if they are in solution.  
Whether the binding of IgM also strengthens cytoadhesion of non-rosetting variants 
is unknown. PfEMP1 variants involved in pregnancy-associated malaria, known as 
VAR2CSA, mediate adhesion to CSA in the intervillious space of the placenta 
129
. 
Along with CSA adhesion, IEs expressing VAR2CSA also bind non-immune IgM, 
and the co-selection of CSA-and IgM-binding phenotypes is proposed to signify the 
role of non-immune IgM in parasite survival in the placenta 
119, 125, 130
. The 
expression of a putative IgM receptor on the placenta has not been identified to date, 
although it has been suggested that multimeric IgM molecules may permit 
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interactions with CSA-rich syncytial ‘knots’ in the placental circulation 125. The 
addition of non-immune IgM was not seen to increase binding of infected 
erythrocytes to placental cryosections 
119
. However, the addition of normal human 
serum did increase binding,  suggesting that other serum components can strengthen 
the binding or perhaps, as is the case for the rosetting variants, IgM coupled with 
additional serum component  could account for the increase in binding.  
P. falciparum parasites have also been shown to utilise non-immune IgM to shield 
immunogenic epitopes on the surface of IEs from PfEMP1-specific IgG recognition 
119
. The pre-incubation of IEs expressing VAR2CSA with non-immune IgM prior to 
treatment with VAR2CSA-specific monoclonal antibodies (mAbs) was shown to 
significantly reduce their internalisation into phagocytic cells 
119
. These IgM-
opsonised IEs were subsequently able to interact with CSA in the placenta, 
suggesting that the masking effect of nonspecific IgM could  conceal immunogenic 
epitopes whilst leaving epitopes critical for molecular functions exposed 
119
. Little is 
known regarding IgM binding PfEMP1 variants other than VAR2CSA, but a recent 
study showed that IgM binding by the rosetting variant HB3VAR6 did not lower IE 
phagocytosis 
118
. This suggests that the camouflage function of VAR2CSA is not a 
property shared by all IgM-binding PfEMP1 variants. Whether PfEMP1 variants 
bind IgM for different purposes, or if there is a common yet undiscovered purpose of 
IgM binding remains to be shown. 
Humoral immune responses are pivotal for controlling P. falciparum malarial 
disease, but immunity is slow to develop and relatively short-lived 
131
. This is partly 
attributed to antigenic diversity and complexity of the parasites, but there is emerging 
evidence that parasites actively alter B cell responses. Polyclonal B cell activation is 
often observed in malaria infections, resulting in hypergammaglobulinemia, elevated 
titres of autoAbs, and increased prevalence of B cell malignancies (e.g. Burkitt’s 
lymphoma) 
132, 133
.  Dontai et al. demonstrated that the direct binding of IEs to 
peripheral B cells from non-immune donors resulted in T-cell independent 
polyclonal activation 
123.  They identified the CIDR1α domain of the PfEMP1 variant 
FCR3S1.2 as a B cell mitogen. In addition to other proteins, non-immune IgM were 
shown to bind CIDR1α with low affinity, and its addition inhibited the binding of 
recombinant CIDR1α to B cells 123. Further studies reported preferential activation of 
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memory B cells by CIDR1α 133, however the direct binding of CIDR1α to memory B 
cells was not shown.   Gene expression profiling and functional data revealed that 
stimulation with recombinant CIDR1α induced tonsillar B cell survival and cell cycle 
progression 
133
. This was hypothesised to confer protection against spontaneous cell 
death and provide a potential explanation for the increased risk of endemic Burkitt’s 
lymphoma in areas of high transmission of P. falciparum 
133
.  These data led to the 
conclusion that CIDR1α stimulates B cell proliferation via the BCR 123. However, in 
a more recent study the authors found that the phosphorylation profile of CIDR1α 
stimulated B cells differed substantially from B cell receptor-activated B cells, which 
led to the conclusion that B cell activation by CIDR1α does not proceed through the 
BCR 
134
. This together with the observations that CIDR1α binding was never 
completely inhibited by IgM, along with the fact that the effect of anti-Ig on B cell 
binding was not shown, question whether the BCR is actually the main target in 
CIDR1α mediated B cell activation or if IgM binding simply sterically hinders the 
binding of CIDR1α to its receptor. Further studies should address these issues in 
order to clarify if CIDR1α is a bona fide IgM-binding molecule. 
Whether PfEMP1 permits additional functional consequences is yet to be 
determined. Czajkowsky et al. hypothesised that PfEMP1 molecules may function to 
alter the binding of IgM to host effector proteins, such as complement components or 
IgM-receptors (depicted in Figure 1.5) 
99
. IgM is a potent activator of complement 
due to its polymeric structure, which binds C1q via its Cµ3 domain 
135
. Although the 
binding of PfEMP1 to the Cµ4 domain of IgM does not directly block binding of 
C1q 
120
, it may induce a conformational change in the central core of IgM to alter the 
C1q-binding site or may bind IgM in such an orientation to occlude the C1q-binding 
site 
99
. However, this remains to be proven. Alternatively, P. falciparum DBL 
domains could function to interfere with IgM receptors, such as Fcµ, Fcα/µ receptor 
100
, or more recently the dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) 
136
.  
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Figure 1.5 Hypothetical functional consequences of the IgM-PfEMP1 interaction. The diagram 
depicts several potential mechanisms by which IgM-DBL interactions could alter IgM-effector 
mechanisms, such as blocking immunological synapse formation mediated by FcμR expressed on T 
cells (1), or B cell activation by disrupting BCR-FcμR (and CR1/2) interactions (2). Further, the IgM-
DBL interaction could affect interactions of IgM with Fcα/μR on FDC surfaces (4); the endothelial 
receptor CD300LG (6); or complement component C1q (7). The possibility for direct interaction 
between PfEMP1 molecules and BCR on B cell surfaces is also shown (3), which could result in B 
cell activation through receptor clustering, and the potential of IgM binding by PfEMP1 to shield 
immunogenic epitopes from humoral immune detection (5)
100
. 
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The bona fide high-affinity Fc receptor for IgM (FcµR) expressed on CD19
+
 B cells, 
CD4
+
/CD8
+ 
T cells, and CD56
+
CD3
-
 NK cells has been implicated in promoting cell 
survival and proliferation of B cells 
137, 138
. Therefore the binding of PfEMP1 to B 
cells via IgM bound to FcµR (and IgM
+
 BCR) may alter signalling pathways to 
induce polyclonal B cell activation, resulting in observed hypergammaglobulinemias 
139
. FcµR also triggers stimulatory intracellular signalling in NK cells 
140
, which 
could be hijacked by PfEMP1 to modulate IFN-γ secretion crucial in the early stage 
of infection 
141, 142
. Although the function of FcµR on T cells is yet to be defined, its 
expression has been proposed to facilitate immune synapse formation with IgM
+
 B 
cells and potentially enhance B cell activation and memory induction 
100, 137
. Finally, 
Fcα/µR plays a role in mediating endocytosis of IgM-coated pathogens 143, antigen-
presentation and B cell responses in the germinal center 
144
, and suppresses humoral 
immune responses against T-independent antigen by negatively regulating antigen 
retention by follicular dendritic cells (FDCs) in mice 
145
. Therefore, the binding of 
IgM to PfEMP1 could significantly interfere with these receptor functions in order to 
confer a significant advantage to the parasite under immune attack. The functions of 
IgM receptors must be understood before these possibilities can be fully investigated. 
A recent study using recombinant proteins and transgenic parasites characterised two 
P. falciparum proteins, DBLMSP and DBLMSP2, as novel IgM-binding proteins 
146
. 
In contrast to PfEMP1 which is expressed on IEs, these proteins are found on the 
surface of free merozoites 
146, 147
. DBLMSP and DBLMSP2 are members of the 
merozoite surface protein 3 (MSP3) family characterised by the presence of a 
NLR[K/N][A/G/N] motif at their N-terminus 
147, 148
. Most proteins within this family 
also contain a C-terminal acidic or a secreted polymorphic antigen associated with 
merozoites (SPAM) domain 
149
 and a coiled-coil region believed to be involved in 
oligomerisation of the proteins 
150
.  As well as being highly polymorphic 
151-153
, 
DBLMSP and DBLMSP2 are unique from other MSP3-family members in 
containing a DBL domain 
148, 149
. DBLMSP and DBLMSP2 directly and avidly 
bound the Cµ4 domain of non-immune IgM via their DBL domains, a function 
conserved across diverse strains and field isolates 
146
. 
Several studies have proposed mechanisms by which PfEMP1 facilitates immune 
evasion, yet much less is known about the functional consequences of IgM-mediated 
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binding by DBLMSP and DBLMSP2. How IgM-binding by DBLMSP and 
DBLMSP2 could facilitate immune evasion will be explored further in this thesis. In 
particular, this thesis will focus on how these proteins may function to alter IgM-
receptor interactions. 
1.10. Immunoglobulin M 
IgM is the oldest phylogenetic class of Ab which is expressed by all vertebrate 
species 
154
. IgM is the first Ab to be produced during humoral responses, do not 
undergo somatic hypermutation or Ab class switching and are therefore of low 
affinity 
155
. IgM exists as a membrane-bound form on B cells (BCR), in the 
circulation, and also on mucous membranes or in excretory gland secretions as 
secretory IgM 
155
. Circulatory IgM is present at ~1-2mg/ml in the blood of healthy 
adults, principally as a pentamer and occasionally as a hexamer 
156
.  Unlike other 
immunoglobulin isotypes, circulatory IgM can be divided into non-immune and 
immune IgM 
135
. Non-immune IgM molecules are low affinity and broadly reactive 
Abs which are generated by the B-1 subset of B cells in the absence of exogenous 
antigens 
157, 158
. The multimeric structure of non-immune IgM compensates for the 
low antigen-binding affinity by creating 10 identical antigen-binding sites (Figure 
1.6), which increase overall avidity when binding to multivalent antigens such as 
bacterial capsular polysaccharides 
135, 156
. In addition, the multimeric structure of 
IgM facilitates complement activation in a highly efficient manner. Immune IgM is 
produced by B-2 cells in response to pathogenic exposure and differs from natural 
IgM in its affinity, specificity repertoire, range of function, and antigen-binding site 
structure 
155
.  The majority of circulating IgM molecules are considered to be non-
immune IgM, as serum IgM levels are similar between animals grown in sterile 
conditions and normal animals 
155
.  However, both non-immune and antigen-specific 
IgM are crucial for Ab mediated responses against pathogens.   
IgM molecules share similar structure to other Ab isotypes, whereby two heavy 
chains are linked with two light chains to form an immunoglobulin (Ig) subunit of 
approximately 190kDa (Figure 1.6). The heavy chains (μ) defining the IgM isotype 
are composed of one variable (Vμ) and four constant Ig domains (Cμ1-Cμ4) 
155
. In 
addition, IgM molecules possess an 18-residue tail piece with no defined secondary 
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or tertiary structure 
155
. Pentameric IgM is composed of five subunits joined by a 
joining (J-chain), whereas hexameric IgM is composed of six subunits which lack a 
J-chain 
159, 160
.  The J-chain is a 15kDa protein which covalently associates with 
pentameric IgM, through disulphide bond formation between cysteine residues in the 
J-chain and μ-tailpiece 161. The J-chain was shown to regulate intracellular 
polymerisation of IgM 
162
, as well as mediating transport of secretory IgM across 
epithelia by binding to the polymeric Ig receptor (pIgR) 
161, 163
. Hexameric IgM 
molecules lacking J-chains are unable to bind to pIgR, possibly owing to the fact that 
hexameric IgM activates complement 15-20 times more efficiently than pentameric 
IgM 
164, 165
. If transported to the gut mucosa which contains high antigen loads, 
hexameric IgM could cause robust complement activation and ensuing inflammation, 
resulting in damage the host 
166
. Therefore, it is possible that these sparse Abs have 
evolved without a J-chain to play a role in humoral rather than mucosal immunity 
164, 
165
. 
Attempts at obtaining a crystal structure of monomeric or polymeric IgM have been 
unsuccessful to date, most likely owing to the size and flexibility of IgM molecules 
167
.  As IgM shares basic domain architecture to IgE, a recent study utilised the 
similarities between the two immunoglobulins to build a homology-based structural 
model of pentameric IgM 
135
. This model proposed a non-planar, mushroom-shaped 
complex for pentameric IgM, in which the central C-terminal domain portion 
protrudes out of the plane created by the Fab and Cµ2 domains 
135
. Cryo-atomic 
force microscopy confirmed this unexpected conformation by imaging individual 
human IgM molecules.  In this conformation, the protruding C-terminal domain 
could be targeted by Fc-binding proteins such as IgM receptors or IgM-binding 
malarial proteins 
135
. Under this assumption, the protrusion would be directed 
towards the cell surface upon formation of polyvalent attachments with antigen on 
the cell surface, resulting in a table-like conformation that would permit the exposure 
of its C1q binding site to the surrounding solution. 
135
.   
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Figure 1.6 Human IgM is a glycoprotein.  Pentameric IgM is composed of variable and constant 
heavy chain and light chain domains (VH and CH or VL and CL, respectively), and features a J-chain. 
Potential N-linked glycosylation sites are shown as black pentagons (adapted from 
168
). 
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A recent study determined the atomic details of mouse IgM Fc domains using X-ray 
crystallography, SAXS, and NMR spectroscopy 
167
. The structures of each domain 
(Cµ2, Cµ3, and Cµ4) were reconstructed to build a model for hexameric mouse IgM, 
which predicted a flexible star-shaped configuration around the inner Cµ4 core 
167
. In 
this model, the core structure (~180Å) projected out of the plane created by the Cµ2 
and Cµ3 domains 
167
, which supports previous structural data of human IgM 
135
. 
Despite these recent advances, obtaining a crystal structure of human IgM will be 
pivotal to provide a better understanding of how the Fc region of the molecule 
mediates its effector functions.  
There are five N-linked glycosylation sites present on each μ chain of circulatory 
IgM, located at Asn-171, Asn-332, Asn-395, Asn-402, and Asn-563. The light chains 
lack conserved N-linked glycosylation sites, and the J-chain contains a single site at 
Asn-48 (Figure 1.6). IgM is heavily glycosylated, as roughly 7-12% of the total mass 
of IgM is comprised of carbohydrates 
155
. Glycosylation of IgM is important for the 
secretion of IgM and its presentation on B cell surfaces. Complex glycans 
predominantly terminating in sialic acid or galactose occupy Asn-171, Asn-332, 
Asn-395, whereas Asn-402 and Asn-563 are 100% and 17% occupied with 
GlcNAc2Man5-9-containing oligomannose glycans, respectively 
168
. It is predicted 
that complex glycans are confined to the non-antigen binding face of IgM due to the 
mushroom-shape adopted by pentameric IgM 
135, 168
.  In this conformation, the 
glycans would be restricted from binding lectins once the Fab domain has bound 
antigens forcing IgM to adopt a crab-like conformation 
135
. This hypothesis is 
supported by the finding mannose-binding lectin (MBL) does not bind to Ag-bound 
IgM molecules 
168
. Therefore, these complex glycans may allow IgM to agglutinate 
lectin-containing microorganisms in the blood in the absence of specific antigen-
binding 
169
. In the case of non-immune IgM binding as seen with malaria Fcμ-
binding proteins, the orientation of IgM with respect to the parasite or erythrocyte 
plasma membrane is unknown. Intuitively, the orientation would be opposite to that 
seen with Fab bound IgM, with the C1q binding sites facing the plasma membrane 
and the IgM glycans therefore facing towards the solution. However, more research 
is required to clarify the orientation of IgM with respect to parasite IgM binding 
proteins, whether this be on the surface of merozoites or IEs. 
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1.11. IgM-Fc receptors 
The effector functions of IgM are primarily mediated through interactions of its Fc 
portion to cognate ligands, such as complement and IgM-receptors.  Soluble IgM is 
known to bind at least seven ligands including: polymeric Ig receptor (pIgR)
170
, Sp 
alpha 
171
, TRIM21 
172, Fcα/μR 173 and FcμR 137. CD22 (an inhibitory co-receptor on 
B cells) 
174
 and serum mannan-binding lectin (MBL) 
164
 can also bind IgM through 
complex glycans found on IgM 
168
. More recently work described in this thesis has 
shown DC-SIGN to be a novel receptor for human IgM 
136
. These receptors generally 
bind IgM with nanomolar affinity as a consequence of the polymeric structure of 
IgM that endows this molecule with high avidity interactions. With an IgM serum 
concentration of 1-2mg/ml, most of these receptors in vivo would be saturated with 
IgM. 
A receptor specific for the Fc portion of IgM was suggested over 40 years ago but 
remained unidentified until recently 
137
.  A bona fide receptor for the Fc portion of 
IgM (FcμR) was identified in humans and mice 137, 175. In mice, FcμR expression is 
restricted to B cell lineages 
23, 175, and in humans FcμR is expressed on B cells, T 
cells and NK cells 
137. Furthermore, FcμR expression is upregulated in patients with 
chronic lymphocytic leukaemia (CLL) 
137, 176-178
. There has been controversy over the 
expression of FcμR on innate cells, which still remains to be resolved 137, 179-181. The 
function of FcμR has largely been determined to-date using knock-out mouse 
models. FcμR-deficient mice exhibit raised levels of serum IgM, impaired germinal 
centre formation,  altered B cell populations, reduced thymus-dependent Ab 
responses, and increased autoAb production 
22, 138, 182
. These results suggest that 
FcμR mediates a significant portion of the effector functions of IgM, particularly the 
regulation of IgM homeostasis, autoimmune suppression and enhancing humoral 
immunity. Although these data may provide some insight into the function of FcμR, 
it is important to highlight that there may be functional and structural differences 
between human and murine FcμR. Significantly fewer studies have focused on the 
function of the human FcμR 140, 183, which still remains somewhat elusive (see 
Chapter 6). 
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1.12. Justification for study 
Improving our understanding of host-parasite interactions is crucial to improve the 
control of malaria. In light of the extensive immune evasion mechanisms employed 
by P. falciparum, strategies to overcome this will have to be considered in order to 
develop highly effective vaccines, which has so far been difficult to attain. 
With the recent discovery of two novel IgM-binding proteins expressed by P. 
falciparum, there is renewed interest into why the parasite expresses a number of 
molecules which selectively bind host immunoglobulins 
146
, particularly with respect 
to two different life cycle stages, the merozoite and/or infected erythrocytes. If IgM 
binding by merozoites serves the same purposes as binding by infected erythrocytes 
remains to be determined. The literature suggests numerous possible functions for 
one of these molecules, PfEMP1, in relation to how it may facilitate immune evasion 
100
. Although merozoite DBLMSP and DBLMSP2 have been implicated in 
complement activation and camouflaging critical epitopes from immune responses, it 
is unknown whether the binding of these molecules to the Fc portion of IgM can 
affect subsequent interactions with IgM receptors. Further, the function of human 
FcμR remains unclear and whether there are hitherto unidentified receptors which 
can bind IgM remains to be determined. 
This thesis aims to further characterise the DBLMSP-IgM interaction, and to 
determine why P. falciparum merozoites express DBL domains that bind non-
immune human IgM. To achieve this, the specific objectives include: 
I. Investigate the structural and biochemical requirements for 
DBLMSP and DBLMSP2 binding to human IgM 
II. Determine if IgM-binding by DBLMSP and/or DBLMSP2 
mediates immune evasion by: 
 Blocking interactions of IgM with receptors 
 Targeting IgM on hFcμR expressed on human lymphocytes 
 Promoting immunomodulation through binding lymphocytes 
III. Investigate the structural and biochemical requirements for IgM 
binding to IgM-receptors 
IV. Characterise the function(s) of human FcμR 
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Chapter 2: Materials and methods  
This chapter describes materials and methods used throughout the thesis. The 
majority of chemicals and reagents used were from Fisher Scientific (Leicestershire, 
UK), Sigma-Aldrich (Dorset, UK), Life Technologies (Renfrewshire, UK), New 
England Biolabs (NEB: Herts, UK), Qiagen (West Sussex, UK), Promega (Madison, 
USA), GE Healthcare LifeSciences (Buckinghamshire, UK), DAKO 
(Cambridgeshire, UK), SouthernBiotech (Birmingham, AL), Biolegend (San Diego, 
CA), BioRad (Hertfordshire, UK), BD Biosciences (Oxford, UK), eBioscience Ltd. 
(Hatfield, UK), Eurofins Genomics (Eberseber, Germany), Abnova (Taipei, Taiwan) 
and Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA).  
2.1. Molecular biology techniques 
2.1.1. Primer design 
Primers used for sequencing were designed manually and by using OligoPerfect
™
 
Designer (Life Technologies), taking into consideration the introduction of 
restriction endonuclease sites, base composition, length, and the avoidance of non-
specific primer annealing. The primers were synthesized by Eurofins MWG Biotech 
AG.   
2.1.2. Restriction endonuclease digests 
Enzymatic digestions of DNA were performed using the BamHI and XhoI restriction 
endonucleases and reaction buffers purchased from NEB, according to the 
manufacturer’s instructions. Diagnostic double digestion reactions typically 
consisted of 5μg plasmid DNA, 5μl of each restriction endonuclease, 10μl of 10x 
Buffer 3.1, made up to 100μl with nuclease-free water. To prepare plasmid DNA for 
subcloning, the DNA was double digested with a BamHI/ XhoI mixture as described 
above, digested at 37
°
C for 2hr or overnight, and dephosphorylated with Antarctic 
shrimp phosphatase (NEB) (5μl Antarctic phosphate buffer, 1μl Antarctic 
phosphatase, 4μl nuclease-free water) at 37°C for 30 min, followed by incubation at 
70
°
C for 5 min to inactivate phosphatases. The success of the digestion was 
determined by DNA gel electrophoresis.  
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2.1.3. DNA gel electrophoresis 
DNA samples were resolved by agarose gel electrophoresis. Agarose gels at 1% 
concentration were made by melting 1g of UltraPure Agarose (Life Technologies) in 
100 ml tris-acetate-EDTA (TAE) buffer. The running buffer was TAE with 0.5μg/ml 
ethidium bromide. DNA samples were loaded with blue gel loading dye (NEB) and 
electrophoresed at 80V for 1hr. A 1kb DNA ladder (NEB) was used as a molecular 
DNA marker, according to manufacturer’s instructions (Figure 2.1A). DNA samples 
were visualised using a UV illuminator (Biorad). 
2.1.4. Agarose gel extraction 
DNA bands were isolated from agarose gels using the QIAquick Gel Extraction kit, 
according to the manufacturer’s instructions (Qiagen). Briefly, bands of interest were 
excised from the agarose gels, solubilised, and the DNA precipitated with 
isopropanol. Free DNA was captured on the membranes of QIAquick spin columns 
using centrifugation, washed and eluted with Tris-EDTA buffer. Final DNA 
concentrations were measured using a ND-1000 spectrophotometer. 
2.1.5. DNA sequencing 
DNA was sequenced to confirm the correct insertion of sequences into the 
expression plasmids, using automated sequencing services provided by Source 
Bioscience Lifescience (Nottingham, UK). The generated nucleotide sequences were 
analyzed using publicly available databases; ExPASy Bioinformatics Resource 
Portal, ClustalW2 (EMBL-European Bioinformatics Institute), and the basic local 
alignment search tool (BLAST). 
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Figure 2.1 Molecular markers (A) NEB 1 kilobase (kb) DNA ladder. (B) Life Technologies 
SeeBlue
®
 Plus2 Pre-stained Protein Standard, on a NuPAGE
®
 Novex
®
 4-12% Bis-Tris Gel.  
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2.1.6. DNA Ligations 
DNA ligations were conducted using T4 DNA ligase (NEB). A typical reaction 
consisted of the cloning vector, the insert of interest, T4 DNA ligase and T4 DNA 
ligase reaction buffer (NEB).  To ensure high efficiency of ligation, 1:3 molar ratios 
of vector to insert were used. To calculate the required amount of insert, the 
following formula was used: 
Insert (ng) = vector (ng) x insert (kbp) 
vector (kbp) 
 
Unless otherwise stated, all ligations were performed at 16
°
 C for 16hr.  
2.1.7. Transformation of competent cells with plasmid DNA 
Ligated DNA (5μl of the ligation mix) was incubated on ice with 50l of competent 
One Shot
™ 
E. coli cells (TOP10 or DH5α, Life Technologies) for 30 min.  The cells 
were heat-shocked for 30 sec at 42
°
C, then incubated on ice for 2 min. 250 l of 
super optimal broth media (SOC; Life Technologies) was added to the bacteria 
which were then incubated for 1hr at 37
°
C in a shaking incubator. Transformed cells 
were plated onto LB-agar selection plates containing ampicillin (100μg/ml) or zeocin 
(25μg/ml), and incubated overnight at 37°C.   
2.1.8. Isolation of plasmid DNA from bacterial cultures:  miniprep and midiprep 
Single bacterial colonies from selective LB plates were grown overnight at 37
°
C, in 
5mls of LB medium with the relevant antibiotic, in a shaking incubator.  Plasmid 
DNA was retrieved from the bacteria by alkaline lysis, according to the 
manufacturer’s instructions (Qiagen miniprep kit) and typically gave 15-30μg of 
DNA in total. Variation in yield was dependent on plasmid copy number.  
The plasmid DNA derived from minipreps were digested with relevant restriction 
endonucleases (section 2.1.2) and checked by DNA gel electrophoresis (section 
2.1.3) to confirm the correct size of the inserts. DNA with correct inserts were sent 
for sequencing (section 2.1.5).  
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Plasmid DNA shown to be correct by sequencing were transfected again into 
competent bacteria, and 5ml LB + selection antibiotic cultures grown for several 
hours from single bacterial colonies.  These cultures were used to inoculate 250ml 
LB containing relevant selection antibiotic, and this volume was grown overnight.  
Plasmid DNA was isolated by alkaline lysis (Qiagen midiprep kit), and yields were 
typically 300-500g. 
2.2. Protein production 
2.2.1. Generation of DBLMSP and DBLMSP2 mammalian expression vectors 
Mammalian expression vectors were generated that contain the chemically 
synthesised genes for DBLMSP and DBLMSP2, either full-length (FL) or lacking 
the DBL domains (C). Incorporation of these gene inserts into the mammalian 
expression vector pcDNA 3.1(+) (Life Technologies) was outsourced to GeneArt by 
Life Technologies. The genes were codon-optimised for expression in mammalian 
cells, and potential N-linked glycosylation sites were mutated to prevent 
inappropriate glycosylation of parasite proteins. Two c-myc tags and a 6x histidine 
(his) tag were placed downstream of the genes, and the inserts were flanked by the 
BamHI and XhoHI restriction enzyme sites.  
To generate the pFUSE-MCS-DBLMSP/2 vectors, the genes for DBLMSP-FL/-C 
and DBLMSP2-FL/-C were excised from the pcDNA 3.1(+) vectors using BamHI 
and XhoHI restriction enzymes (section 2.1.2). Subcloning of the DBLMSP and 
DBLSMP2 genes was performed by Dr Pat Blundell. The mammalian expression 
vector pFUSE-MCS (Invivogen) was linearised by BamHI/ XhoI digestion and 
dephosphorylated (rSAP, NEB). Agarose gel electrophoresis (section 2.1.3) and gel 
elutions (section 2.1.4) were used to isolate the inserts and the linearised vector. The 
DBLMSP gene fragments were ligated into the linearised pFUSE-MCS vector 
(section 2.1.6), the ligation mixes were transformed into competent bacteria and 
plated onto selective LB agar plate. Plasmids with the correct insertions were isolated 
by the miniprep technique (Qiagen), and the correct sequences and vector maps are 
shown in Appendix II.  
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2.2.2. Preparation of DNA insert for mammalian cell transfection 
Transfection of mammalian cells using FuGENE
®
 transfection reagent (Promega) 
was performed according to the manufacturer’s guidelines. Briefly, 3μg of maxiprep 
vector DNA was transferred to a clean Eppendorf tube containing 100μl DMEM 
complete medium (see section 2.1.8). Following mixing, 9μl of FuGENE® was added 
directly to the mix, vortexed and allowed to stand for 12 min. This mixture was then 
resuspended in CHO-K1 or HEK293T cells (5 x 10
5
) in 10ml DMEM complete 
media, prior to transfer to a 100mm tissue culture dish and incubation for 24-48hr at 
37˚C and 5% CO2. Culture supernatant was then removed and replaced with 
selection media (DMEM complete media, 10% FBS and 400μg/ml zeocin). Cells 
were then cultured for up to 14 days at 37˚C to select for transfected cells.  
To store these polyclonal transfected cell lines, cells were trypsinised (0.5% trypsin 
in EDTA for 2 min) and transferred to 175cm
2 
flasks containing selection media, and 
at 70% confluency, the cell lines were frozen in fetal bovine serum (FBS)/ 10% 
DMSO for storage in liquid nitrogen For protein production, the cultures were grown 
to 70% confluency and the cells trypinised and passaged into 175cm
2 
flasks in 
selection media at 1:200 dilution (cells:medium), in order to expand the population at 
volume and under selection pressure. Cells were then incubated at 37˚C at 5% CO2 
for up to14 days to allow for protein production.  
2.2.3. Seeding for transfected CHO-K1 cell colonies 
Transfected CHO-K1 cells were grown for four weeks under selection until isolated 
colonies began to appear. Cell colonies were selected using sterile filter paper and 
sterile tweezers. Each filter paper was then placed into 1ml selection media in a 
single well of a 24-well plate, and incubated at 37˚C at 5% CO2 for up to14 days to 
allow for protein production. Immunoblotting was used to test for the presence of 
recombinant protein within culture supernatants. 
2.2.4. Expression trials for recombinant protein in mammalian cells 
Transfected cell culture media was harvested and filter sterilised (0.22μm), and 0.2% 
sodium azide added. Expression trials were then performed on culture supernatants 
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to detect secreted recombinant protein. For this, a mixture of immunoblotting, 
ELISA, SDS-PAGE and Western blotting techniques were used. The specific details 
for each protein expression trial are shown in Chapter 5.  
2.2.5. Generation of DBLMSP and DBLMSP2 bacterial expression vectors 
To generate bacterial expression vectors, the genes for DBLMSP-FL/-C and 
DBLMSP2-FL/-C were excised from the pFUSE-MCS-DBLMSP vectors using 
BamHI and XhoHI (section 2.1.2). These experiments were performed by Dr Pat 
Blundell. The pRSET-EmGFP vector (Life Technologies) was selected as it contains 
compatible restriction enzyme sites. Double digestion of this vector with BamHI/ 
XhoI resulted in the excision of the gene encoding the fluorescent protein. The 
DBLMSP genes were then cloned into the BamHI/XhoI sites (see Chapter 5 for 
further details).  
2.2.6. Bacterial expression of DBLMSP and DBLMSP2 
To initiate protein expression, the pRSET-DBLMSP plasmids (500ng) were 
transformed into BL21 Star (DE3) expression bacteria (Life Technologies) using the 
heat-shock method (section 2.1.7).  Successfully transformed BL21 Star (DE3) 
colonies were picked off LB selection plates, and expanded to a volume of 5.5ml in 
LB medium supplemented with ampicillin. Cells were grown to mid-log phase 
(OD600= 0.3-0.4) at 37˚C in a shaking incubator, then induced with 1mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) (see Chapter 5). Following induction, 0.5ml 
aliquots of cells were taken at 2hr intervals, pelleted and stored at -20˚C. Pelleted 
cells were then resuspended in 1x NuPAGE
®
 reducing buffer (Life Technologies) 
and analyzed by SDS-PAGE and Western blotting (see Chapter 5).   
2.3. Protein purification 
2.3.1. Affinity chromatography 
Recombinant proteins were purified on an anti-c-myc-sepharose column by affinity 
chromatography. Typically, 200-1000ml of filtered tissue culture supernatant was 
passed over the column using an ÄKTA Fine Performance Liquid Chromatography 
(FPLC) machine (GE Healthcare Life Sciences) at a flow rate of 0.5ml/ min. The 
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column was washed with 20ml of 1x Hank’s Balanced Salt Solution (HBSS) buffer 
containing 0.1M sodium phosphate (pH7.4). The fractions were eluted using a linear 
gradient of 0.1M glycine (pH2) and neutralised using 1M Tris-HCl (pH9).  
Fractions containing proteins were identified from the chromatogram profiles, 
ELISAs and dot blot assays (see Chapter 5).  
2.3.2. Size exclusion chromatography 
Proteins were assessed by size exclusion gel filtration using a Superdex 200 column 
(GE Healthcare Life Sciences) on an FPLC machine. The column was equilibrated in 
1x HBSS buffer prior to loading proteins onto the column via a 100μl or 400μl loop. 
The proteins were eluted into fractions by running a pre-set program. The eluted 
proteins were passed through a UV flow cell (high performance monitor UPC-900) 
to measure their UV absorbance at 280nM using a charged-coupled device (CCD) 
detector. Absorbances of eluted proteins were recorded as peaks on a chromatogram. 
Chromatograms show the elution profile of purified proteins, whereby a symmetric 
profile (or peaks) indicates homogenous protein and asymmetric profiles indicate 
partially aggregated proteins. 
 Gel filtration standards (BioRad) were used to enable molecular weight (MW) 
predictions of proteins based on their elution fractions (Figure 2.2). These were run 
prior to each round of protein purification.  
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Figure 2.2 Size exclusion markers. Gel filtration standard (Biorad) was separated by size exclusion 
using a Superdex 200 column. Gel filtration standard components corresponding to peaks A-E 
included: thyroglobulin (670kDa); γ-globulin (158kDa); ovalbumin (44kDa); myoglobin (17kDa); 
vitamin B12 (1.35kDa). 
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2.4. Protein analysis techniques 
2.4.1. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Protein samples were prepared with NuPAGE
®
 sodium dodecyl sulphate (SDS) 
sample buffer (Life Technologies), and loaded either under reducing or non-reducing 
conditions, using dithiothreitol (DTT; 160mM) as a reducing agent. The samples 
were centrifuged at 27,396 g for 30 sec and then heated at 95
°
C for 2 min before 
loading 5-15μg of protein into the wells of a NuPAGE® Novex 4-12% Bis-Tris pre-
cast gel. An XCellSureLock™ Mini-Cell electrophoresis system was used to run the 
gels in NuPAGE
®
 MES SDS Running Buffer (Life Technologies) at 200V constant 
for 45 min. SeeBlue
®
 Plus2 Pre-stained Protein Standard (Life Technologies) was 
used as a MW marker (Figure 2.1B). Gels were Coomassie stained (section 2.4.2) or 
transferred to a membrane for Western blotting (section 2.4.3). 
2.4.2. Coomassie staining of gels 
NuPAGE
®
 Novex 4-12% Bis-Tris pre-cast gels were removed from their housing 
cassettes and stained in Coomassie Brilliant Blue R-250 (BioRad) on a platform 
shaker (Stovall Life Sciences Inc., Ringer, UK), before being washed twice in 
deionised water and left to destain overnight in Coomassie Brilliant Blue R-250 
destaining buffer (BioRad). Protein bands were directly visualised on the destained 
gel and their respective molecular weights (kDa) were estimated by comparison with 
the molecular weight marker. Stained gels were scanned using an Epson Perfection 
1260 flatbed scanner (Epson, Telford UK). 
2.4.3. Western blotting 
NuPAGE
®
 Novex 4-12% Bis-Tris pre-cast gels were transferred to Protran 
nitrocellulose transfer membrane (GE Healthcare) in NuPAGE
®
 transfer buffer (Life 
Technologies) at 40V for 1hr, using an XCell II
™
 blot module according to 
manufacturer’s instructions (Life Technologies). To block non-specific binding, the 
membrane was rocked on a platform shaker with PBS-Tween (PBST; PBS with 0.1% 
Tween 20)/ 5% non-fat milk powder for 1hr, followed by at least three washes. 
Blocking, incubations and washings were performed in PBST. The membrane was 
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then incubated with primary Ab overnight on a rocker at room temperature (RT), 
followed by incubation with a secondary Ab conjugated to either horseradish 
peroxidase (HRP) or alkaline phosphatase (AP) for 3hr. Occasionally, the membrane 
was direct labelled with a conjugated Ab overnight.  
Proteins were visualised by developing HRP-conjugated Abs with the chromogen 
3’,3’-Diaminobenzidine (DAB; DAKO), or AP-conjugated Abs with a developing 
buffer composed of 5-bromo-4-chloro-indolyl-phosphate/ Nitrobluetetrazolium 
(BCIP/NBT; 100mM Tris/HCl, pH 9.5, 100mM NaCl, 5mM MgCl2), according to 
manufacturer’s instructions (Sigma-Aldrich).  Developed blots were then scanned 
and images stored. 
2.4.4. Immunoblotting 
Purified proteins or culture supernatants were dotted onto nitrocellulose membranes 
and air-dried for 30 min. Membranes were then blocked in PBST/5% non-fat milk 
powder for 1hr, washed three times in PBST and incubated with PBST-containing 
Abs to detect specific proteins and/ or tags. The presence of proteins on membranes 
was detected using the same method as for Western blots (section 2.4.3). 
2.5. Protein-protein interaction techniques 
2.5.1. Enzyme-linked immunosorbent assay (ELISA) 
Appropriate target antigen or capture Ab were coated onto wells of Nunc-maxisorp 
microtitre plates (Fisher Scientific) overnight at 4
°
C in fresh carbonate/ bicarbonate 
buffer, pH 9.6 (Sigma-Aldrich). Unless otherwise stated, proteins were coated at 
10μg/ml. Uncoated material was discarded and plate wells were washed extensively 
with PBST prior to being blocked with 200μl blocking buffer (PBST/ 5% non-fat 
milk powder) for 1hr at RT on a rocker.  Following the incubation, the plate wells 
were washed with 200μl of PBST at least six times prior to incubation with an 
appropriate dilution primary Ab for at least 3hr at RT. The plates were washed in 
PBST and incubated with appropriate dilutions of detecting Abs for 3 hr at RT. 
Typically, HRP-conjugated Abs were used at 1:2000 dilutions in PBST, and AP-
conjugated Abs at 1:5000 dilutions. HRP-conjugated Abs were detected using one 
tablet of 3,3’,5,5’-tetramethylbenzidine substrate (TMB; Sigma-Aldrich) dissolved in 
40 
 
 
10ml of 0.1M citrate phosphate buffer, whereby 100μl of the solution per well was 
allowed to develop until the desired contrast between control and positive wells was 
achieved. The reaction was terminated by adding 50μl of 2M H2SO4 to each well 
immediately before the absorbance was read at 450nm (HRP) on an Expert Plus plate 
reader (Biochrom, SLS). AP-conjugated Abs were detected using p-Nitrophenyl 
phosphate (1mg/ml) in 0.2M Tris buffer containing 5mM magnesium chloride 
(Sigma-Aldrich), and read at 405nm. Optical density readings were blank-corrected 
against the mean of duplicate control wells containing a negative control such as PBS 
or secondary Ab alone. 
2.5.2. Multi-channel surface plasmon resonance (SPR) 
Surface plasmon resonance experiments were performed in collaboration with the 
laboratory of Dr Daniel Mitchell (University of Warwick). Recombinant human DC-
SIGN was generated as described previously 
184
, as was IgM-Fc 
185
, mouse SIGNR1 
was from R&D Systems (Abingdon, UK), and Pentaglobin
™
 was kindly provided by 
and Biotest UK. DC-SIGN or SIGNR1 were immobilised on GLM sensor chips (Bio-
Rad) using amine coupling with sulfo-N-hydroxysuccinimide/1-Ethyl-3-[3-
dimethylaminopropyl] carbodiimide. For IgM binding experiments, doubling 
dilutions (10μM-0.32μM) of IgM-Fc or Pentaglobin™ were injected at flow time 0, 
and replaced with buffer at 300 sec. To determine the binding of DBLMSP to IgM on 
DC-SIGN, human IgM was injected into flow at time 0 and replaced with buffer at 
300 sec. Following this, DBLMSP or DBLMSP2 were injected at doubling dilutions 
from 10μM to 0.32μM into flow at time 900, and replaced with buffer at 1300 sec.  
Sensograms were recorded at 25˚C with the ProteOn XPR36 surface plasmon 
resonance biosensor (Bio-Rad) using a flow rate of 25μl/min. Kinetic parameters for 
protein-protein interactions were determined using the 1:1 Langmuir modeling 
algorithms included in the ProteOn Manager software suite (Bio-Rad).  
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2.6. Cell techniques 
2.6.1. Mammalian cell culture 
Human embryonic kidney (HEK) 293E and Chinese Hamster Ovarian (CHO-K1) 
cells were cultured in RPMI 1640 medium or DMEM containing 10% heat 
inactivated fetal bovine serum (FBS), 2mM L-glutamine, 100U/ml penicillin and 
100μg/ml streptomycin, and 50mM 2-mercaptoethanol (Gibco by Life Technologies) 
(referred to as complete media).   
Fcµ receptor cDNA-transfected cells (BW5147 T cells) were cultured in complete 
media supplemented with 0.1ng/ml puromycin 
137
. Untransfected BW5147 T cells 
were used as a negative control, and were maintained in complete media. FcμR 
cDNA-transfected and untransfected BW5147 T cells were kindly donated by Dr 
Hiromi Kubagawa (University of Alabama at Birmingham).  
Immature dendritic cells (iDCs) were derived from autologous-sorted CD14
+
 blood 
monocytes by culture with granulocyte-macrophage colony stimulating factor (GM-
CSF), interleukin (IL)-4 and tumor necrosis factor (TNF)-α for six days. These 
experiments were performed in the laboratory of Dr Britta Urban.  
All cells were incubated at 37
°
C with 5% CO2 for specific incubation periods or until 
semi-confluent. To prepare cells for freezing, cells (2 x 10
7
 cells/ml) were 
resuspended in ice-cold FBS and allowed to stand on ice for 20 min. The same 
volume of ice cold FCS/20% DMSO was added to cells and gently mixed prior to 
aliquoting 1ml cell suspensions into cryovials. Cryovials were immediately put into 
freezing containers and stored at -80
º
C for 24hr, then transferred to liquid nitrogen 
for long-term storage. 
2.6.2. Processing of blood samples and buffy coats 
Trained clinical officers took 10ml blood samples from malaria-naïve volunteers, 
which was collected into heparin tubes and processed immediately. Methods were 
approved by the Ethical Review Committee of the Liverpool School of Tropical 
Medicine. 
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Buffy coats from blood of healthy, malaria-naïve individuals were obtained from the 
National Health Service (NHS) Blood and Transplant Service, under the Liverpool 
School of Tropical Medicine Research Tissue Bank Approval (REC ref 11/H1002/9) 
and were held under the Human Tissue Authority license number 12548. 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque gradient 
centrifugation using Lymphoprep (Axis-Shield, Norway) and washed twice in RPMI/ 
10% FBS.  Cells were used immediately or cryopreserved at -140
°
C until use. Prior 
to each experiment, cells were rapidly thawed in a water bath at 37
°
C and washed 
three times in media. Cells were then rested for 3hr prior to trypan blue staining to 
determine cell viability and counts, and resuspended to desired concentrations. 
2.6.3. Plasmodium falciparum parasite cultures 
In vitro-adapted parasites used for this work include P. falciparum clones 3D7, 
ITGvar1, and ITGvar13. These experiments were kindly performed by Mohammad 
Alkurbi. Parasites were kept in continuous culture according to standard procedures 
186
. Briefly, parasite strains were cultured in RPMI-1640 supplemented with 4mM 
hypoxanthine, 25mM HEPES and 20μg/ml gentamycin with erythrocytes (O+) at 5% 
hemocrit and 10% AB
+
 serum in buffered culture (pH 7.4). Parasites were 
maintained at ~5-8% parasitemia, and were synchronised prior to experimentation by 
two consecutive treatments with 5% sorbitol for 10 min 
187
, to ensure a synchrony 
window of 6hr. The culture medium was changed when parasites entered the 
trophozoite stage. To harvest the supernatant following merozoite egress (invasion of 
erythrocytes), parasites were cultured for another 14hr to allow schizonts to burst and 
merozoites to reinvade. The development of the parasite cycle was monitored by 
Giemsa staining (2% Giemsa in PBS) and thin blood film analysis (Figure 2.3). 
Parasite culture supernatant was harvested at this time point (early ring stage) by 
transferring the culture to a 50ml falcon tube and centrifuging at 500g for 5 min. The 
supernatant was transferred to a sterile falcon tube and stored at 4˚C prior to use. In 
parallel, an equal quantity of uninfected erythrocytes were cultured and processed 
under the same conditions as above. The supernatant of the uninfected erythrocytes 
was used as a negative control. 
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Figure 2.3 Highly synchronised Plasmodium falciparum culture. 3D7 strain of P. falciparum was 
grown at 5-8% parasitemia prior to experimentation and synchronised by two consecutive treatments 
with sorbitol. Parasite stage was determined by Giemsa staining (2% Giemsa in phosphate buffer for 
30 min at RT) of thin blood films and examination by microscopy. Highly synchronised cultures were 
monitored and harvested at early ring stage for immunoprecipitation experiments.  
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2.7. Flow cytometry  
2.7.1. Reagents 
Abs to the following human antigens were used: fluoresceinisotheiocyanate (FITC)-
conjugated Abs specific for CD4, CD8, CD19 and CD56, goat F(ab’)2 anti-human-
IgM-RPE, goat F(ab’)2 anti-human lambda-RPE, and isotype controls were from 
SouthernBiotech. Anti-human CD4-Alexa-Fluor
®
 700 and anti-human CD19-PE-
Cy7 were from eBioscience. Anti human CD19-Brilliant Violet
™
 421, CD14-APC 
Cy7, CD8-PerCp, CD27-APC Cy7, CD21-Brilliant Violet
™
 421, CD10-PE, CD38-
Alexa-Fluor
® 
700, and anti-mouse IgG-APC were from Biolegend. Anti-CD27-PE-
Cy5 was from Beckman Coulter. CellTrace
™
 Violet Cell Proliferation Kit was 
purchased from Life Technologies, as were LIVE/DEAD
®
 Fixable Aqua Dead cell 
stain kit, propidium iodide, AbC
™
 anti-mouse and ArC
™
 amine reactive 
compensation bead kits. Anti-biotin-APC and anti-histidine (his)-PE Abs were from 
MilitenyiBiotec (Surrey, UK). 7-AAD, Annexin V-APC, and anti-human CD19-PE 
CF594, CD3-APC and CD3-Brilliant Violet
™
 421 were from BD Pharmingen.  
2.7.2. Generic technique 
Unless otherwise stated, 2 x 10
5
 cells were stained with fluorochrome-conjugated 
Abs in complete media or FACS buffer (PBS/ 0.1% BSA) for 1hr at 4
°
C, then 
washed three times in complete medium or FACs buffer by centrifugation at 598 g 
for 10 min. Following centrifugation, supernatants were discarded and cell pellets 
resuspended in FACs buffer. Flow cytometry was performed on BD LSRII flow 
cytometer with FACS Diva (BD) data acquisition.  
For hFcμR-transfected cells, values of the untransfected cells (e.g. background) were 
removed from transfected cell data. 
Live lymphocytes were identified on the basis of forward and side scatter, alongside 
the use of conjugated Abs specific for various lymphocyte populations. Data were 
analyzed using FlowJo software version 9.1. (FlowJoTreestar, OR, USA). Abs were 
titrated prior to use to determine optimal concentrations for staining. Typically, 
experiments were repeated at least three times using three different PBMC donors. 
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2.8. Production of recombinant DBLMSP and DBLMSP2 
Recombinant DBLMSP and DBLMSP2 proteins of the 3D7 cloned strain of 
Plasmodium falciparum were kindly provided by Dr Cecile Crosnier (The Wellcome 
Trust Sanger Institute, Cambridge). Details of the protein production have been 
previously described 
188
. Briefly, the coding sequence of full-length DBLMSP and 
DBLMSP2 (PF10_0348 and PF10_0355, respectively) were codon-optimised for 
expression in mammalian cells, so that any potential N-linked glycosylation sites 
(NXS/T sequence) were modified by substituting serine or threonine residues for an 
alanine (NXA). In some cases, the coding sequence of either the DBL domain or the 
C-terminal region containing the SPAM and coiled-coil domains (referred to as 
SPAM domain) was used 
146
. Inserts were flanked with NotI/AscI restriction enzyme 
sites and cloned downstream of an exogenous signal sequence of murine origin 
189
. 
The recombinant proteins feature a C-terminal rat Cd4-d3+4 tag 
190
 followed by 
either a biotinylation or a 6x-histidine (his) tag 
25
. Recombinant proteins of the Cd4-
d3+4 tag (referred to as Cd4-d3+4) alone were produced as a negative control. The 
proteins were produced recombinantly via transient transfection of HEK293E cells, 
which were cultured for six days at 37˚C with 5% CO2. Cell culture supernatants 
were then harvested and filtered. Biotinylated protein culture supernatant was 
dialysed in HEPES-buffered saline (HBS; pH 7) for 48hr. Concentrations of 
biotinylated proteins in the culture supernatants were determined by ELISA using 
streptavidin-coated microtitre plates (Nunc), which were detected using an anti-rat 
Cd4 Ab (OX68, Serotec) followed by incubation with an anti-mouse-AP secondary 
Ab. The concentrations of biotinylated proteins were normalised using spin 
concentrators (Vivascience, 10k MWCO) or by dilutions with conditioned tissue 
culture supernatant or PBS containing 0.2% BSA  
191
. His-tagged proteins were 
purified using His-Trap purification columns (GE Healthcare) on an ÄKTAxpress as 
previously described 
144
. Recombinant protein quality was assessed by Coomassie 
staining and Western blot analysis (Figure 2.4). 
In addition, recombinant DBLMSP and DBLMSP2 protein production was attempted 
in Chapter 5 (see Chapter for specific details). 
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Figure 2.4 Recombinant DBLMSP and DBLMSP2 protein analysis. Coomassie staining (left 
panels) and Western blot analysis (right panels) of recombinant biotin-tagged (A) and his-tagged (B) 
DBLMSP, DBLMSP2 and Cd4-d3+4 proteins. Bands corresponding to DBLMSP, DBLMSP2 and 
Cd4-d3+4 are seen at ~80kDa, ~98kDa and ~25 kDa, respectively. 
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2.9. Determining the domain of human IgM binding DBLMSP and 
DBLMSP2 by ELISA 
ELISA plates were coated with recombinant his-tagged DBLMSP, DBLMSP2, or 
Cd4-d3+4 proteins. After blocking, 10μg/ml human IgM was added to duplicate 
wells and incubated at RT for 3hr. In some experiments, a panel of domain-swap Abs 
described in a previous study 
120
 was used to determine which domain(s) of IgM bind 
DBLMSP and DBLMSP2 (performed by Professor Richard Pleass). For this, varying 
concentrations of domain-swap Abs were immobilised in duplicate onto microtitre 
plates (Nunc) and allowed to bind 10μg/ml recombinant his-tagged DBLMSP or 
DBLMSP2.  Binding of IgM and domain-swap Abs was detected using anti-human 
IgM-HRP (Sigma-Aldrich). 
The ability of the DBL and SPAM domains of DBLMSP and DBLMSP2 to bind 
human IgM was also investigated. Immobilised IgM was incubated with 100μl of 
normalised biotinylated DBL or SPAM domains, or biotinylated Cd4-d3+4, for 3hr 
at RT. Following washing, the binding of biotinylated proteins to IgM was detected 
using Extravidin
®
-Peroxidase.  
2.10. Investigating the binding of DBLMSP and DBLMSP2 to FcμR 
To determine if DBLMSP proteins blocked the binding of hIgM to FcμR, hFcμR-
transfected cell lines were incubated with hIgM (15μg/ml) preincubated with varying 
concentrations of his-tagged DBLMSP and DBLMSP2 (see Chapter 4 for details). 
Cells were washed and labelled with F(ab’)2-anti-human IgM-RPE for flow 
cytometric analysis. These experiments were performed by Professor Richard Pleass.  
To determine if DBLMSP proteins could engage IgM bound to FcμR, hFcμR-
transfected cell lines were opsonised with 15μg/ml hIgM for 1hr at 4˚C, washed and 
incubated with 100μl of normalised biotinylated DBLMSP or DBLMSP2 for 1hr at 
4˚C. Recombinant biotinylated DBLMSP, DBLMSP2 or Cd4-d3+4 proteins were 
initially titrated to determine working concentrations. Cells were washed three times 
with media and labelled with anti-biotin-APC.  
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Binding of DBLMSP proteins to PBMCs known to express FcμR, including CD4+ 
and CD8
+
 T cells, B cells, and NK cells 
137
, was also determined. For this, freshly 
isolated PBMCs (section 2.6.2) were incubated with complete media containing 
100μl normalised biotinylated DBLMSP, DBLMSP2, or Cd4-d3+4 for 1hr at 4˚C. 
Cells were then washed and incubated with anti-biotin-APC, and subsequently 
labelled with FITC-conjugated Abs specific for human CD4, CD8, CD19, and CD56. 
In some experiments, cells were labelled with F(ab’)2-anti-human IgM-RPE to 
determine if DBLMSP co-localised with IgM on lymphocytes. Individual DBL or 
SPAM domains (section 2.8) were used to determine which region of the DBLMSP 
proteins mediated binding to IgM-opsonised on FcμR. For this, 100μl normalised 
biotinylated DBL or SPAM domains were incubated with hFcμR-transfected cell 
lines or PBMCs for 1hr at 4˚C, washed and labelled with anti-biotin-APC prior to 
flow cytometric analysis. 
2.11. Staining of PBMCs with CellTrace™ Violet for determination of 
proliferation in culture 
Proliferation of PBMCs was monitored by using the CellTrace
™
 Violet Cell 
Proliferation Kit (Life Technologies). PBMCs (10
7
 cells/ml) were resuspended in 
10ml pre-warmed PBS and labelled with 1μM CellTrace™ Violet Cell stain for 10 
min at RT on a roller. Staining was quenched by adding 50ml of ice-cold media to 
the cells and immediate incubation on ice for 5 min. Cells were then washed three 
times by centrifugation before being placed into culture.  
2.12. Functional assays to determine in vitro effects of DBLMSP and 
DBLMSP2 
PBMCs isolated from malaria-naïve healthy donors were cultured at 2 x 10
5 
cells per 
200μl in U-bottomed 96-well culture plates (Nunc, Roskilde, Denmark) at 37˚C with 
5% CO2 and 95% humidity. All cultures were conducted in complete media. A 
schematic diagram of the experimental design for the functional assays is shown in 
Figure 2.5. 
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To determine the in vitro effects of DBLMSP proteins, PBMCs were incubated with 
varying concentrations of his-tagged recombinant DBLMSP, DBLMSP2, or Cd4-
d3+4 proteins (see Chapter 4), which were either added directly to the culture 
medium or coated overnight in carbonate bicarbonate buffer (pH 9.6) onto round-
bottom plates to induce receptor cross-linking 
192
. In experiments where the ability of 
the DBLMSP proteins to induce cellular proliferation was assessed, CellTrace
™
 
Violet-labelled cells were cultured with varying concentrations of his-tagged 
recombinant DBLMSP, DBLMSP2, or Cd4-d3+4 proteins for five days at 37
°
C in a 
5% CO2 incubator. In some experiments, recombinant proteins were preincubated 
with human IgM (5:1 ratio), or with PHA or CpG ODN 2006, for 30 min at RT prior 
to culture. Cells cultured with PHA (5μg/ml; Life Technologies) or CpG ODN 2006 
(1μg/ml; Hycult Biotech) were used as positive controls for T cell and B cell 
proliferation, respectively. Unstimulated cells cultured in complete media alone or in 
media supplemented with varying concentrations of bovine serum albumin (BSA) 
were used as negative controls.  Following five days of culture, cells were harvested 
and washed prior to labelling with anti-CD4-Alexa Fluor
®
 700, anti-CD8-FITC, and 
anti-CD19-PE Cy7. Proliferation of gated lymphocytes was shown by depletion of 
CellTrace
™
 Violet staining by flow cytometry (Figure 2.6). 
Apoptosis assays were set up alongside proliferation assays. For this, PBMCs were 
cultured with 50μg/ml of his-tagged DBLMSP, DBLMSP2 or Cd4-d3+4 proteins for 
24hr or 48hr at 37˚C with 5% CO2. PBMCs were harvested and labelled with Abs 
specific for anti-human CD3-Brilliant Violet
™
, anti-human CD19-FITC, and anti-
human CD8-FITC (Figure 2.6B for gating strategy). To quantify apoptotic cells, 
PBMCs were labelled with Annexin V-APC and 7-AAD according to the 
manufacturer’s instructions (BD Pharmingen). Briefly, cells were washed twice with 
ice cold PBS and resuspended in 1x Binding Buffer containing Annexin V-APC and 
7-AAD (1:10) and incubated for 15 min at RT in the dark. Following incubation, 
labelled cells were immediately analyzed by flow cytometry. UV irradiation-induced 
apoptosis in PBMCs was used as a positive control 
193
, whereby cells were harvested 
and subject to UV-radiation for 30 min at a wavelength of 230nm (UV 
transilluminator, UVP) prior to labelling. 
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Figure 2.5 Experimental design for the determination of the in vitro effects of DBLMSP and 
DBLMSP2. Cells were placed into culture on day 0, apoptosis was determined on days 1 and day 2, 
and proliferation and inhibition of proliferation were determined on day 5. Positive and negative 
controls are shown as (+) and (-), respectively. 
 
          
 
Figure 2.6 Gating strategies for PBMCs in functional assays. (A) Lymphocytes were identified on 
side scatter (SSC) and forward scatter (FSC) plot (shown by blue dots). Lymphocytes were further 
gated into CD4
+
 and CD8
+
 T cells and B cells based on expression of human CD4, CD8, and CD19, 
respectively. (B) Within the lymphocyte gate (shown as blue dots), cells were gated into CD19
+
 and 
CD3
+
. The CD3
+
 cell population was further gated into CD8
+
 T cells (CD3
+
CD8
+
) and CD8
-
 T cells 
(CD3
+
CD8
-
). Monocytic cells were identified on SSC and FSC plot (shown by green dots), which 
were further gated into CD3
-
CD19
-
 monocytic cells (shown as a black gate).  
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2.13. Parasite culture immunoprecipitation analysis 
To investigate if other malarial proteins are present within the DBLMSP-IgM 
complex, culture supernatant was harvested from P. falciparum parasite strains 3D7, 
ITGvar1, and ITGvar13 grown in the presence of 10% human serum (section 2.6.3) 
by centrifugation at 266 g for 10 min. Media from uninfected RBC cultures was used 
as a negative control. Anti-human IgM-agarose beads (Sigma-Aldrich) were 
incubated with culture supernatants in excess (to precipitate all of the IgM from the 
supernatants) for 2hr on a roller. Beads were pelleted by centrifugation (266 g, 5 
min), washed five times in PBS to remove unbound proteins, then added to reducing 
and non-reducing SDS-PAGE sample buffer and boiled for 5 min. Samples were 
separated by SDS-PAGE and transferred to nitrocellulose membrane by Western 
blotting (section 2.4.3). After blocking, blots were incubated with either 10μg/ml of 
IVIG (GammaGard
®
, Baxter Healthcare; purified from 3000 healthy donors) or 
10μg/ml of hyperimmune purified IgG from Malawians in malaria-endemic regions 
(immune sera; purified from 360 donors) in PBST overnight at RT. Blots were 
extensively washed in PBST and incubated with anti-human IgG-AP for the 
detection of immunoreactive parasite proteins. In some experiments, membranes 
were incubated with polyclonal rabbit anti-DBLMSP Abs (kindly provided by Dr 
Cecile Crosnier) and anti-rabbit IgG peroxidase (1:1000; Sigma-Aldrich) to detect 
DBLMSP/ DBLMSP2. 
To determine if IgM-parasite protein complexes could still engage FcμR, 50μl of 
culture supernatants (predicted to contain 5μg hIgM) were incubated with hFcμR-
transfected cells for 1hr at 4˚C, washed extensively and labelled with F(ab’)2-anti-
human IgM-RPE and analysed by flow cytometry. 
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2.14. IgM binding to cell surfaces  
The binding of hIgM to GFP-gated hFcμR-transfected cells (Figure 2.7) was 
determined by labelling with F(ab’)2-anti-human IgM-RPE. To determine the 
optimal concentration of hIgM for subsequent binding assays, hFcμR-transfected 
cells were incubated with media alone or media supplemented with varying 
concentrations of hIgM (see Chapter 3), labelled with F(ab’)2-anti-human IgM-RPE 
and analyzed by flow cytometry.  The optimal concentration of IgM was determined 
as 15μg/ml. In some experiments, a panel of domain-swap Abs, in which the 
domains of IgA were replaced with domains of IgM 
120
, were used to determine the 
domain(s) of IgM which bind hFcμR, detected using F(ab’)2-anti-human lambda-
RPE. The ability of gated lymphocytes to bind 15μg/ml hIgM or 10% human serum 
was also investigated (see Chapter 3).  
2.15. Immunofluorescence microscopy to determine IgM levels on 
lymphocyte surfaces  
PBMCs from healthy donors were incubated for 1hr on ice with media alone or 
media supplemented with 15μg/ml human IgM. Cells were washed three times in 
media to remove unbound IgM. After washing, 1 x 10
5
 PBMCs per sample were 
prepared on Superfrost plus slides using the Shandon Cytospin 4 (Fisher Scientific) 
to generate cytospins. Protective coverslips were mounted on the slides, and the 
PBMC cytospins were permeabilised in methanol for 5 min. Cytospins were washed 
three times in PBS, blocked in complete media and washed three more times. After 
air drying, PBMCs were labelled with a cocktail of Abs including anti-human 
CD4/8/19/56-FITC and F(ab’)2-anti-human IgM-RPE for 1hr at 4
º
C. Cytospins were 
washed three times in PBS, air-dried, then stained with the Prolong Gold anti-fade 
reagent with DAPI (Life Technologies) according to manufacturer’s guidelines. 
Cytospins were examined using a Zeiss Axioskop microscope and Carl Zeiss AIM 
software (Carl Zeiss Microscopy). For each cytospin, ten individual images were 
taken at random points to determine overall levels of surface IgM on lymphocytes. 
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Figure 2.7 Gating strategy for IgM binding to GFP
+
 human FcμR-transfected cell lines. (A) Live 
cells were identified on side scatter (SSC) and forward scatter (FSC) plot (shown by blue dots). (B) 
Within the live cell gate, hFcμR-transfected cells were identified based on the expression of green 
fluorescent protein (GFP) (shown as blue dots) which (C) were further gated to IgM
+
 cells (shown by 
blue dots) to determine mean intensity fluorescence values for IgM binding.  
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2.16. Flow cytometry analysis to determine FcμR-mediated 
internalisation of IgM 
Internalisation of IgM via FcμR was investigated using a previously described 
protocol with modifications 
183
.  Briefly, hFcμR-transfected cells or PBMCs were 
incubated for 1hr on ice with media alone or media supplemented with 15μg/ml 
human IgM or 10% human serum. In some experiments, artificially-induced IgM 
immune complexes (15μg/ml) formed using heat-aggregation (62°C for 30 min) 194 
were used to determine if IgM-immune complexes could bind to and be internalised 
by hFcμR. Cells were then washed in ice-cold media and incubated at 37°C for 
varying periods to allow for receptor internalisation. Samples maintained on ice were 
used as a control for maximal binding of IgM (time 0). The immediate addition of 
ice-cold media to cells and incubation on ice was used to halt internalisation. Cells 
were washed twice and labelled with F(ab’)2-anti-human IgM-RPE.  
To investigate IgM internalisation into lymphocyte subsets, a lymphocyte staining 
panel was formed. For this, Abs were initially titrated to determine relevant working 
concentrations. The panel consisted of anti-CD19-Brilliant Violet
™ 
421, anti-CD3-
APC, anti-CD4-Alexa Fluor
®
 700, anti-CD8-PerCP, and anti-CD56-FITC to 
differentiate B cells, T cells, and NK cells (see Chapter 6).  Internalisation assays 
were performed as above. 
2.17. Flow cytometry analysis to determine FcμR internalisation  
hFcμR-transfected cells were incubated with 1μg anti-hFcμR mAb (Abnova) for 1hr 
at 4
º
C prior to internalisation assays (section 2.16). Following internalisation, cells 
were washed and labelled with anti-mouse IgG-APC for 1hr at 4
º
C, labelled with 
F(ab’)2-anti-human IgM-RPE and analyzed by flow cytometry.  
2.18. Determination of expression of FcμR on lymphocytes 
Lymphocyte subsets expressing FcμR were determined in PBMCs by flow cytometry 
(see Chapter 6). The expression of hFcμR on cells was determined using an anti-
FAIM3 (hFcμR) mAb (1μg; Abnova) and secondary anti-mouse IgG-APC Ab for 
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labelling. To determine expression on B cell subsets, the following Abs were used: 
anti-CD19-PE CF594, anti-CD10-PE, anti-CD38-Alexa Fluor
®
 700, anti-CD21-
Brilliant Violet
™ 
421, and anti-CD27-APC Cy7 (B cell panel). Expression on T cells 
and NK cells were determined with anti-CD3-Brilliant Violet
™
 421, anti-CD4-FITC, 
anti-CD8-PerCp and anti-CD56-Alexa Fluor
®
 700 (T/NK cell panel). Cell viability 
was determined with LIVE/DEAD
®
 Fixable Aqua Dead Cell staining according to 
the manufacturer’s instructions (Life Technologies).  
2.19. Cellular activation of PBMCs to determine effects on IgM 
internalisation 
Purified PBMCs were activated in order to investigate the effect of cellular activation 
on IgM internalisation. Stimulants were added to PBMCs at predetermined 
concentrations (Table 2.1), on ice immediately before incubation at 37°C for 
internalisation assays.  
Induction of PBMC activation was measured alongside the internalisation assay. To 
determine cellular proliferation, CellTrace
™
 Violet stained cells (2 x 10
5
 cells/well) 
were stimulated and incubated for five days at 37˚C with 5% CO2. Following 
incubation, cells were harvested, washed, and labelled with anti-CD19-Brilliant 
Violet
™
 421 and anti-CD3-APC. 
2.20. Endoglycosidase treatment of human IgM 
Glycans were removed from hIgM using peptide-N-glycosidase F (PNGase F), α1-6 
mannosidase, and neuraminidase according to the manufacturer’s protocol (NEB).  
Briefly, 50μg of hIgM was incubated overnight at 37˚C with appropriate 
endoglycosidase and buffer solutions. Solutions of hIgM and buffer alone were used 
as controls (non-treated IgM). The success of endoglycosidase treatment was 
determined by separating 5μg of treated or untreated IgM under reducing and non-
reducing conditions by SDS-PAGE, followed by Coomassie staining (section 2.4.2 
and section 2.4.3, respectively). 
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Table 2.1 Details of various stimulants used to activate lymphocytes.  The working concentrations, 
cellular targets, and mechanisms of action are highlighted.  
 
Stimulant  Stimulant   Target Mechanism of action Concentration 
PHA T cells Unknown  5μg/ml 
Anti-CD3 T cells Receptor cross-linking 1:3000 dilution 
Anti-IgM T/ B cells Surface Ig/ receptor cross-linking 2μg/ml 
Anti- 
IgA+IgG+IgM 
T/ B cells Surface Ig/ receptor cross-linking 2μg/ml 
CpG ODN 2006 B cells TLR 9 agonist 1μg/ml 
LPS B cells TLR 4 agonist 10μg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
 
2.21. Glycan assays 
To determine the role of glycans in mediating IgM-FcμR interactions, 
endoglycosidase-treated IgM was incubated with hFcμR-transfectants for 1hr on ice, 
then washed and labelled with F(ab’)2-anti-human IgM-RPE. Untreated IgM was 
used as a positive control for binding.  
To determine if glycans are required to mediate interactions between DBLMSP 
proteins and IgM, his-tagged recombinant DBLMSP and DBLMSP2 and Cd4-d3+4 
proteins were immobilised onto 96-well Maxisorb microplates (Nunc) in triplicate. 
Following blocking, plates were incubated with varying concentrations of 
endoglycosidase treated- and non-treated hIgM for 3hr. Plates were washed, and 
binding was detected with anti-human IgM-AP.  
The ability of PNGase-cleaved hIgM and IVIG to bind DC-SIGN was assessed by 
ELISA. For this, recombinant DC-SIGN was coated to microtitre wells (Nunc). The 
wells were washed and blocked with TSM (20mM Tris-HCl, 150mM NaCl, 2mM 
CaCl2, 2mM MgCl2, 5% BSA) buffer (pH 7.4) for 2hr at RT, prior to four washes 
with TSM and overnight incubation at 4˚C with 10μg/ml digested (+) or undigested 
(-) Abs in duplicate. After overnight incubation, wells were washed and incubated 
with anti-human IgM-AP for 3hr, then developed as in section 2.5.1.  
 
2.22. Flow cytometry analysis to determine FcμR-mediated 
internalisation of endoglycosidase-treated IgM  
hFcμR-transfected cells or PBMCs were incubated with 15μg/ml endoglycosidase-
treated or non-treated IgM for 1hr at 4
º
C prior to internalisation assays, as described 
in section 2.16. Cells were then washed and labelled with F(ab’)2-anti-human IgM-
RPE, anti-CD19-FITC, anti-CD3-Brilliant Violet
™ 
421, anti-CD4-AF700, anti-CD8-
PerCp, prior to analysis by flow cytometry.  
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2.23. Stimulant binding ELISA 
The binding of human immunoglobulins (Ig) to various stimulants was assessed by 
ELISA. Goat anti-human IgM Fc5μ fragment-specific and goat anti-human 
IgA+IgG+IgM (H+L) Abs were from Jackson ImmunoResearch Laboratories Inc. 
(West Grove, PA, USA). Horseradish peroxidase- and alkaline phosphatase-
conjugated Abs against hIgM, hIgG, and hIgA were purchased from Sigma-Aldrich, 
as were IgM from human serum, lectin from Phytolaccaamericana (pokeweed, 
PWM), lectin from Phaseolus vulgaris (phytohaemagglutinin, PHA), and 
lipopolysaccharide from Escherichia coli (LPS). Human IgG and IgA from plasma 
were from Calbiochem (La Jolla, CA, USA). CpG B-DNA (ODN 2006) was from 
Hycult Biotech (Uden, The Netherlands).  
For this, stimulants were coated in duplicate onto wells of a microtitre plate (Nunc). 
Plates were washed extensively and blocked. After three washes with PBST, 
10μg/ml of human IgM, IgG or IgA were added to wells and incubated for 3hr at RT. 
Subsequent washes with PBST were used to remove unbound Igs. Binding of 
immunoglobulins to stimulants was detected using mouse anti-human Ig-HRP Abs 
specific for each Ig isotype. 
2.24. Molecular dynamic simulations 
Molecular dynamic simulations were performed in collaboration with the laboratory 
of Dr Daniel Czajkowsky at the Shanghai Jiao Tong University. The homology 
model of DBLMSP was generated based on the known structures of members of the 
DBL family 
195, 196
. The working atomic model of IgM and the model of the 
IgM/DBL interaction have been described previously 
197, 198
. The on-line server, 
Phyre2, was used to produce homology models of FcμR 199. This server identified 
two regions of FcμR that exhibited homology with proteins with known structures, 
with exceptional confidence. One region is the expected transmembrane domain of 
FcμR 200 that exhibited homology (predicted with ~70% confidence) to the 
transmembrane domain of ErbB2 receptor tyrosine kinases (pdb: 2KS1)
201
. The other 
region, expected to be an Ig-like domain that directly contacts IgM 
200, 202-204
, 
exhibited homology (predicted with 99.6% confidence) to the extracellular domain of 
the IREM-1 (PDB: 2NMS)
205
. The putative dimer of the Ig-like region was generated 
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based on the Cα3 domains of human IgA1 (PDB:1OW0) using Deep View/ Swiss-
PdbViewer)
206
, although other dimeric Ig domains produce similar results.  
Homology models were evaluated with Ramachandran plots using VMD 
207-209
. 
2.25. Statistical analysis 
The data were analysed using the GraphPad Prism 6 statistical software. P values 
below 0.05 were considered to be significant, and those below 0.01 as highly 
significant. Data that were skewed were subject to non-parametric tests for 
comparisons between groups. In particular, the Mann-Whitney test was used to 
compare percentages of IgM on cell surfaces during internalisation assays, and 
Dunn’s multiple comparison tests were used to investigate statistical significance in 
the binding of DBLMSP and/or DBLMSP2 to endoglycosidase-treated and non-
treated IgM. Multiple t-tests were used for the comparison of binding or percentage 
positive cells in normally distributed data  
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Chapter 3: Characterizing the binding of human 
IgM to receptors 
3.1. Literature review 
3.1.1. IgM 
The varied roles of IgM are still being discovered after a century of investigation. 
The characteristics and functions of IgM are well established and have been 
extensively reviewed 
155, 156, 210
. As selective IgM deficiencies are rare in humans, 
studies utilizing knock-out mice, which lack secretory IgM (sIgM
-/-
) have highlighted 
the importance of IgM in immunity 
211, 212
.  These mice are  more susceptible to viral 
213
, parasitic 
214, 215
, fungal 
216, 217
 and bacterial 
218, 219
 infections, exhibited impaired 
germinal centre (GC) formation and reduced responses to T cell dependent antigens 
212, 220
. Other well-documented effector functions of IgM include: 
 Agglutination of pathogens and pathogenic-products 181 
 Activation of the classical and lectin complement pathways 135, 165 
 Regulating the development and survival of B cells in naïve mice 221, 222 
 Clearance of apoptotic cells  and apoptotic microparticles released from 
dying cells 
223-226
 
 Maintaining immune homeostasis and reinforcing immune tolerance 227-229 
 Regulating autoimmunity and atherosclerosis 159, 161, 162, 230 
The profound effect of IgM on both protective immunity and immune homeostasis is 
attributed to interactions of its Fc region with effector molecules such as complement 
and Fc receptors (FcRs). FcRs mediate a plethora of biological functions including 
phagocytosis of Ab-opsonised pathogens, induction of cellular cytotoxicity, 
regulation of hypersensitive responses, and B cell activation 
160, 231, 232
. The elusive 
receptor for the Fc portion of IgM (FcμR) was recently identified by screening for 
immunoglobulin (Ig) domain sequences with homology to the other known IgM 
receptors, including the Fcα/μR and polymeric Ig receptor (pIgR) 137, 175.  
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3.1.2. FcµR 
FcµR is a 60kDa type-I integral membrane protein containing a single V-set Ig-like 
domain 
137, 175
. It is encoded by a single copy gene (FCMR) located on the same 
region of chromosome 1 (1q32.3) as Fcα/μR and pIgR 175. Mouse FcμR shares 36% 
and 43% amino acid sequence homology with Fcα/μR and pIgR respectively, and 
there is 57.7% homology between human and mouse FcμR 175. FcμR cDNA is 
predicted to encode a 390 amino acid (aa) protein, with signal peptide (17aa), 
extracellular region (236aa), transmembrane region (19aa), and a cytoplasmic tail 
(118aa) (Figure 3.1) 
137
.  The extracellular region has no identifiable domain 
characteristic except for a single V-set Ig-like domain, which shares sequence 
homology with pIgR and Fcα/μR within its N-terminal region. Pentameric IgM binds 
to FcμR  via its Fc portion (Fc5µ), which occurs at a high affinity (10.8 ± 9.2nM) 
when assuming a 1:1 stoichiometry 
137
. Due to this high affinity, it is predicted that 
FcμR is occupied by IgM in vivo 137. Neuraminidase treatment of hFcμR-transfected 
cells slightly enhanced IgM binding, suggesting the involvement of sialic acid in the 
interaction 
137
. 
FcµR differs from the other IgM receptors as it binds soluble IgM, but not IgA or 
IgG 
175
. Kubagawa et al. hypothesised that this was owing to a shorter 
complementarity determining region 1 (CDR1) loop, predicted to contact the Ig 
ligands, for FcµR compared to Fcα/µR or pIgR, which contained non-charged 
residues (Met, Leu, or Thr) at the corresponding IgA docking site in pIgR (position 
Arg31) 
137
. The cytoplasmic tail of FcµR is relatively long and contains nine 
conserved serine residues, which are potential sites for protein kinase C (PKC) 
phosphorylation or casein kinase 2 phosphorylation, and three conserved tyrosine 
residues which do not match signalling motifs such as immunoreceptor tyrosine-
based inhibitor motif (ITIM), immunoreceptor tyrosine-based activation motif 
(ITAM), or switch motifs 
137
. Phosphorylation of these residues occurred within three 
minutes of receptor cross-linking by IgM molecules, whereby phosphorylation of the 
serine residues was more prominent after 30 min whereas tyrosine phosphorylation 
had subsided by that time 
137
.  Murakami et al. identified the DDYINV motif at the 
end of the FcμR cytoplasmic tail as a potential signalling motif, as fits the criteria for 
the hemi-ITAM (hemITAM) and Ig-tail tyrosine (ITT) signalling motifs 
140
. 
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Figure 3.1 Predicted protein structure of human FcμR. Human FcμR cDNA encodes a type 1 
transmembrane protein with a peptide core of ~41kDa.  Numbers indicate amino acid residues of the 
signal peptide in the extracellular (236aa), transmembrane (19aa), and cytoplasmic (118aa) domains. 
The N-terminal portion of the extracellular region contains a single V-set Ig-like domain (blue oval), 
and the remaining region has no known domain structure adapted from 
137
. 
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Receptor ligation with mouse IgM resulted in phosphorylation (PLCγ2 and ERK) of 
FcμR in the natural killer (NK) cell line YTS and human NK cells 140. Maximal 
stimulation of ERK was observed 30 min following ligation of FcμR with murine 
IgM 
140, similar to that observed for serine phosphorylation in FcμR-transfected cells 
137. Together this data supports the role of FcμR in the propagation of signalling 
pathways, although the downstream effects of FcμR-mediated signalling are 
currently being resolved. 
FcμR contains no N-linked glycosylation motifs, but is heavily O-glycosylated 137, 
175, 183
. Three sites of extensive O-glycosylation were identified on the 60kDa form of 
FcμR, and mutations in these sites were found to disrupt trafficking of FcμR to the 
cell surface 
183
. In addition to its cell surface localisation, a substantial quantity of 
FcμR was found to reside intracellularly, where it co-localised extensively with the 
trans-Golgi network (TGN) and less so with early or late endosomes 
183
. It is 
unknown whether this localisation serves as an intracellular storage site capable of 
rapidly releasing FcμR under certain conditions 183. However, FcμR is not trans-
located to TGN following its internalisation in FcμR-transfected HeLa cells 183. 
Unique to other FcRs, the expression of FcμR is restricted to adaptive immune cells 
137
. FCMR mRNA is strongly expressed in the spleen, thymus, and peripheral blood 
leukocytes in humans, and in the spleen, thymus, bone marrow and lymph node of 
mice 
175
.  In mice, FcμR is expressed on the surfaces of B cells, but not T cells, 
dendritic cells (DCs) or macrophages 
175
. In humans, the receptor is expressed on the 
surface of B cells, CD4
+
 and CD8
+
 T cells, and at low densities on CD56
+
/CD3
- 
NK 
cells. Kubagawa et al. reported no detectable FcμR expression on the surface of 
erythrocytes, platelets, CD14
+
 monocytes, or CD13
+
 granulocytes 
137
. Intriguingly, 
FcμR is the only FcR constitutively expressed on T cells, and there is no clear 
demarcation between T cells positive and negative for FcμR 137. In addition to CD22, 
FcμR is the only IgM-binding ligand identified to date that is expressed on the 
surface of B cells 
137, 233
. 
There has been controversy over the expression of FcμR on innate immune cells. 
Kubagawa et al. reported no detectable surface levels FcμR on innate cells, even 
following overnight culture in IgM-free media to induce FcμR expression 137.  
However, Lang et al. disputed this by claiming that FcμR (Toso) was expressed on 
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innate cells such as monocytes and granulocytes in mice 
180
. They proposed that 
Toso maintains activation thresholds for reactive oxygen species (ROS) production 
in granulocytes, regulates cytokine production, and mediates phagocytosis 
180
. In 
response to these findings, Honjo et al. further analysed the expression of FcμR on 
innate immune cells and found no surface expression of FcμR on granulocytes or 
macrophages from the bone marrow or spleen of wild-type mice 
179
. Neither could 
they find any detectable expression of FcμR by myeloid cells at both protein and 
RNA levels using reverse transcription (RT)-PCR. They concluded that the 
expression of FcμR on myeloid cells as reported by Lang et al. could be an artefact 
due to non-specific reactivity of murine mAbs specific for FcμR due to a lack of 
FcγR blocking 179.  
Despite the recent characterisation of a bona fide Fc receptor for IgM, the 
mechanism by which IgM binds to human FcμR (hFcμR) is yet to be determined. In 
order to understand why P. falciparum binds non-immune IgM, it is essential to 
know how IgM binds to its receptors. In this chapter, the binding of IgM to hFcμR is 
investigated through the identification of the domain(s) of IgM which mediate 
binding, and by determining features of IgM which govern the interaction. 
Furthermore, the structural aspects of IgM binding to hFcμR are evaluated using 
molecular dynamic simulations.   
 
3.2. Objectives 
Characterise the binding of human IgM to hFcμR through structural and biochemical 
analysis. The specific objectives were: 
I. To determine the mechanisms by which human IgM bind hFcμR 
II. To generate a structural model of human hFcμR 
III. To identify novel ligand(s) for human IgM 
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3.3. Results 
3.3.1. Human FcμR is a receptor for IgM 
Although FcμR has been characterised as a bona fide Fc receptor for IgM 137, 140, it is 
unknown whether IgM-immune complexes (ICs) can bind to the receptor. Here, we 
confirm human IgM (hIgM) and heat-aggregated IgM bind to BW5147 cells 
transfected with hFcR (kindly provided by Professor Kubagawa). The ability of 
human IgM (hIgM) to bind to green fluorescent protein (GFP)-positive hFcμR-
transfected cell lines 
137
 was analysed by flow cytometry. For this, GFP
+
 live cells 
were gated (Figure 3.2) and IgM binding was determined by staining cells with 
F(ab’)2-anti-human IgM-RPE. Initially, hIgM was titrated to determine the optimal 
concentration to be used for subsequent binding assays (Figure 3.3A), which was 
determined to be 15μg/ml.  
To study the interaction of immune complexes with hFcμR, IgM-ICs were formed by 
heat-aggregation, as previously described 
194
. Size exclusion chromatography 
verified IgM-IC formation, which contained oligmers of higher molecular mass 
relative to hIgM alone (shown as a pink trace) (Figure 3.4). The predicted molecular 
mass of IgM is 900kDa: the major peak for heat-aggregated hIgM (shown as a blue 
trace) lies within the void volume of the column used, while uncomplexed hIgM 
appears at ~900kDa. Although hIgM did not complex completely, heat-aggregation 
was found to successfully complex ~50% of hIgM molecules.  
The binding of heat-aggregated hIgM (15μg/ml) to hFcμR-transfected cell lines was 
assessed by flow cytometry. As shown in Figure 3.3B, IgM-ICs bind hFcμR, which 
appeared to bind significantly better than the same concentration of uncomplexed 
IgM (Figure 3.3A). The observed increase in RPE fluorescence could be explained 
by the enhanced ability of IgM-ICs to bind to hFcμR-transfected cells, via cross-
linking of cell surface receptors, or it may be that IgM-ICs bound to a single FcμR 
would provide more targets for the detecting Ab. Regardless the data confirms the 
ability of IgM-ICs to engage hFcμR. 
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Figure 3.2 Gating strategy for GFP
+ human FcμR-transfected BW5147 cell lines. Live cells were 
identified on side scatter (SSC) and forward scatter (FSC) plot (left panel; shown by blue dots). 
Within the live cell gate, hFcμR-transfected cells were identified based on the expression of green 
fluorescent protein (GFP) (right panel; shown by blue dots). Data are representative of more than 10 
repeat experiments. 
 
 
 
     
Figure 3.3 Human FcμR is a receptor for IgM. (A) Human IgM binds to hFcμR-transfected cells in 
a concentration dependent manner. hFcμR-transfected cells were incubated with media alone (grey 
trace), or media supplemented with 150μg/ml (green trace), 75μg/ml (orange trace), 37.5μg/ml (pink 
trace) or 15μg/ml (blue trace) hIgM for 1hr at 4˚C. Cells were washed extensively and labelled with 
F(ab’)2-anti-human IgM-RPE to detect IgM binding to hFcμR by flow cytometry. (B) IgM-immune 
complexes (ICs) bind hFcμR. IgM-ICs were formed by heat-aggregation by incubating hIgM at 63˚C 
for 20 min. Complex formation was then confirmed by size exclusion chromatography (Figure 3.4). 
hFcμR-transfected cells were then incubated with 15μg/ml heat-aggregated hIgM for 1hr at 4˚C, 
washed and labelled with F(ab’)2-anti-human IgM-RPE prior to flow cytometric analysis (n=3).  
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Figure 3.4 Size exclusion of IgM-immune complexes. (A) Pentaglobin
™ 
(12% IgM, 12% IgA and 
76% IgG by weight) was separated by size exclusion chromatography on a Superdex
®
 200 column, 
and used as a marker to predict the fraction at which hIgM was eluted. (B) Overlay of the hIgM 
(Sigma-Aldrich; shown as blue trace) and heat-aggregated IgM (shown as pink trace) size exclusion 
chromatogram profiles. Untreated hIgM appears to be aggregated compared to the IgM of 
Pentaglobin
™ 
(as shown in A). Heat-aggregation of hIgM resulted in the formation of oligomers of 
high molecular mass, as depicted by a ~50% reduction in the peak corresponding to ~900kDa 
(fraction A6) when compared to hIgM (blue trace).  The major peak for heat-aggregated hIgM lies 
within the void volume for the column used. Data are representative of two repeat runs.  
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3.3.2. The Cμ4 domain of IgM forms the binding site for human FcμR 
Previous studies showed the Fc region of pentameric IgM (Fc5μ) bound hFcμR 
137
. 
To determine the domain of the IgM-Fc molecule critical for interaction with hFcμR, 
a panel of domain-swapped Abs described in a previous study 
120
 were used, in 
which homologous domains are exchanged between human IgA and IgM (Figure 
3.5). The ability of gated hFcμR-transfected cells to bind domain-swapped Abs was 
analyzed by flow cytometry (Figure 3.5). Abs that contained only the Cμ4 domain 
were able to interact with hFcμR, whereas no binding was observed with human IgA 
and only weak binding was seen with the α1μ2μ3α3 domain-swap Abs lacking the 
Cμ4 domain. This shows that the Cμ2 and/or Cμ3 domains are involved in binding 
hFcμR, although the contribution of either of these domains is less important than the 
Cμ4 domain. The slight reduction in binding of α1α2μ4 compared to hIgM or 
α1μ2μ3μ4 suggests that the Cμ2 and/or Cμ3 domain, in conjunction with the Cμ4 
domain, enhance binding of hIgM to hFcμR.  
3.3.3. IgM glycosylation is not involved in FcμR binding 
Since glycosylation of the Fc region of immunoglobulins can modulate Fc receptor 
binding 
169
, we sought to determine whether glycosylation of IgM-Fc is crucial for 
permitting interactions with hFcµR. IgM molecules are heavily glycosylated 
168
. The 
Cμ4 domain of IgM containing a single N-linked glycan attachment site at Asn563 
that is occupied with GlcNAc2Man5-9 oligosaccharide types, whereas the Cμ3 domain 
contains N-linked glycan sites at Asn395 and Asn402 which are occupied with sialic 
acid- or galactose-terminating complex glycans and GlcNAc2Man5-9-containing 
oligomannose glycans, respectively 
168
.   
To investigate if glycans contribute to the binding of hIgM to hFcμR, these 
carbohydrates were removed from hIgM with a range of endoglycosidases including 
peptide N-glycosidase (PNGase) F, α1-6 mannosidase, and neuraminidase (Figure 
3.6), and their ability to bind hFcμR investigated by flow cytometry (Figure 3.7). De-
glycosylated hIgM was still able to bind hFcμR demonstrating that PNGase F, α1-6 
mannosidase or neuraminidase susceptible glycan(s), such as the aforementioned 
high mannose or sialic acid residues, do not contribute to hIgM binding of hFcμR. 
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Figure 3.5 The Cμ4 domain of IgM binds to human FcμR. hFcμR-transfected cells were incubated 
with media supplemented with domain-swap Abs (blue trace), hIgM (black trace), or media alone 
(grey trace) for 1hr at 4
º
C, then washed extensively. Binding of Abs was determined by staining with 
F(ab’)2-anti lambda-RPE and subsequent flow cytometry analysis. The binding of domain swap Abs 
containing the Cμ4 domain of IgM (α1μ2μ3μ4 and α1α2μ4)  to hFcμR was comparable to hIgM, and 
partial binding was observed with domain-swap Abs containing the Cμ2 and Cμ3 domains (α1μ2μ3 
α3). Data are representative of three repeat experiments (performed by Professor Pleass).  
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Figure 3.6 Endoglycosidase digestion of human IgM. Human IgM (50μg; Sigma-Aldrich) was 
digested in the presence (+) or absence (-) of 10μl (5,000 units) of PNGase F, α1-6 mannosidase, or 
neuraminidase according to manufacturer’s instructions (New England Biolabs). After overnight 
incubation at 37˚C, 5μg of each Ab preparation was run under reducing (R) or non-reducing (NR) 
conditions into wells of a 4-12% Bis-Tris gradient gel (Novex) together with Seeblue Plus2 pre-
stained protein standards (Life Technologies).  De-glycosylation of hIgM by PNGase F resulted in a 
decrease in the molecular weight (MW) of the IgM heavy chain (from ~62kDa to ~55kDa) and light 
chain (~25kDa to ~23kDa), and reductions in MW for the heavy chain with neuraminidase treatment 
(~62kDa to ~60kDa), which signify the removal of glycans from hIgM molecules. There appears to be 
no obvious differences in MW between α1-6-mannosidase-treated and non-treated hIgM.  
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Figure 3.7 Glycans do not mediate interactions between IgM and hFcμR. hFcμR-transfected cell 
were incubated with media supplemented with endoglycosidase-treated (green trace) and –non-treated 
(black trace) hIgM, or buffer only (grey trace) for 1hr on ice. Binding of hIgM to cells was detected 
using F(ab’)2-anti-human IgM-RPE. Data shown is representative of one of three repeat experiments. 
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3.3.4. Human IgM binds to lymphocytes expressing FcμR 
In humans, FcμR is predominantly expressed by adaptive immune cells including 
CD19
+
 B cells, CD4
+
 and CD8
+
 T cells, and CD56
+
CD3
-
 natural killer (NK) cells 
137
.  
Since hIgM was shown to bind to hFcμR-transfected cells, the ability of hIgM to 
bind lymphocyte subsets known to express FcμR was next investigated. Peripheral 
blood mononuclear cells (PBMCs) were isolated from healthy donors and labelled 
with markers to differentiate lymphocyte subsets (Figure 3.8). IgM binding to 
lymphocyte subsets was detected by labelling with exogenous hIgM and F(ab’)2-anti-
human IgM-RPE, whereas the levels of IgM on lymphocyte surfaces were 
determined by staining with F(ab’)2-anti-human IgM-RPE alone (Figure 3.9). There 
was clear binding of exogenous IgM to CD3
+
 T cells and CD56
+
CD3
-
 NK cells, 
whereas binding to CD19
+
 B cells was moderate. Endogenous surface levels of IgM 
were high for CD19
+
 B cells and CD56
+
CD3
-
 NK cells, but not CD3
+
 T cells, 
indicating differential binding of IgM between subsets expressing hFcμR in vivo. 
The presence of endogenous IgM on the surfaces of isolated lymphocytes was also 
confirmed by immunofluorescence microscopy (Figure 3.10). Together, these results 
show that IgM is present on the surfaces of isolated B cells and NK cells, which 
support previous findings 
140
. For B cells, the observed high levels of IgM on cell 
surfaces are contributed at least in part to cross-reactivity of the F(ab’)2-anti-human 
IgM-RPE with IgM
+ 
B cell receptors (BCR). 
Curiously, the monocytic cell population was also found to be positive for cell 
surface IgM (Figure 3.11C). Circulating monocytes were shown to retain IgM on 
their surface following purification (Figure 3.11C, grey trace), and were able to bind 
exogenous IgM (Figure 3.11C, aqua trace). These data suggest that monocytes 
express a hitherto unidentified cell surface receptor for hIgM, or could possibly 
suggest that hFcR is expressed on human monocytes, in conjunction with several 
reports of  FcR expression on murine monocytes 180, 234, 235.  
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Figure 3.8 Gating strategy for lymphocyte subsets. (A) Lymphocytes (shown as blue dots) were 
gated from human PBMCs by side (SSC) and forward (FSC) scatter profiles. Within the lymphocytes 
gate, B cells (CD19
+
CD3
-
; shown as green dots), T cells (CD3
+
CD19
-
; shown as pink dots). (B) and 
natural killer cells (CD56
+
CD3
-
; shown as orange dots) (C) were identified based on the surface 
expression of CD19, CD3 and CD56.  
 
 
 
 
Figure 3.9 Lymphocyte subsets known to express FcμR bind exogenous hIgM. FcμR is expressed 
on human B cells, T cells, and natural killer (NK) cells. To determine if exogenous hIgM could bind 
to these cell populations, PBMCs isolated from healthy donors were incubated with 15μg/ml hIgM at 
4˚C for 1hr. Cells were washed and labelled with anti-human CD3-APC, anti-human CD19-Brilliant 
Violet
™
 421, anti-human CD56-FITC and F(ab’)2-anti-human IgM-RPE prior to flow cytometry. 
Exogenous hIgM was shown to bind to CD3
+
CD19
-
 T cells (A), CD3
-
CD19
+
 B cells (B) and CD3
-
CD56
+
 NK cells (C), respectively shown as pink, green, and orange traces. In addition, endogenous 
IgM levels on cell surfaces were high for B cells and NK cells but not T cells (shown as grey traces). 
Data are representative of three repeats.  
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Figure 3.10 Human IgM is present on lymphocyte surfaces. PBMCs were cytospun onto slides and 
labelled with (A) F(ab’)2-anti-human IgM-RPE (shown as red) or with (B) anti-
CD4/CD8/CD19/CD56-FITC (shown as green) for 1hr at 4˚C and washed before cell surface levels of 
hIgM were visualised by immunofluorescence microscopy (20x and 40x magnification for left and 
right panels, respectively). Images were taken from the same field of view. Images quality was 
improved by adjusting the contrast and brightness of the images.  
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Figure 3.11 Exogenous human IgM binds to monocytes. (A) PBMC population was gated based on 
forward (FSC) and side scatter (SSC) profiles (shown as blue dots). (B) Gating strategy for 
monocytes. PBMCs were labelled with anti-human CD14-APC Cy7 and anti-human CD3-Brilliant 
Violet
™
 421 to differentiate monocytic cell populations (CD3
-
CD14
+
; shown as aqua dots). (C) 
Exogenous hIgM binding to monocytes. PBMCs were incubated with  media alone (grey trace) or 
media supplemented with 15μg/ml hIgM (aqua trace) at 4˚C for 1hr, prior to washing and labelling 
with F(ab’)2-anti-human IgM-RPE to detect IgM binding to gated monocytes by flow cytometry. Data 
are representative of three repeats. 
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3.3.5. DC-SIGN is a novel receptor for IgM-Fc 
As hIgM bound to monocytes, we hypothesised that monocytes expressed a cell 
surface receptor specific for hIgM. Although there has been controversy over the 
expression of FcµR on innate cells in mice 
179-181
, there is strong evidence to suggest 
that hFcµR is not expressed on innate cells 
137. Furthermore, hFcα/µR expression is 
restricted to human mesangial cells 
236
, follicular dendritic cells in germinal centres 
and pre-germinal B cells (IgD
+
CD38
+
) 
144
. Therefore, the identity of the hIgM-
binding receptor on monocyte surfaces was investigated.  
Dendritic cell-specific ICAM-3grabbing nonintegrin (DC-SIGN) is a C-type lectin 
membrane protein which is expressed by a subset of CD14
+
 cells in the periphery 
167, 
237
. As multimeric IgM is known to form highly valent interactions, it was 
hypothesised that the expression of DC-SIGN on CD14
+
 monocytes may account for 
the observed binding of hIgM. To test this hypothesis, the ability of human DC-
SIGN to bind CHO cell-derived hexameric IgM-Fc 
238
 was investigated by 
multichannel surface plasmon resonance (SPR). These experiments were performed 
in the laboratory of Dr Daniel Mitchell (University of Warwick). The binding of 
IgM-Fc to SIGNR1, the mouse orthologue of DC-SIGN 
166
, was also investigated by 
SPR. As shown in the sensogram in Figure 3.12, IgM-Fc bound DC-SIGN with 
nanomolar affinity (Kd ~0.26μM) and bound strongly to SIGNR1 (Kd ~2.2μM). 
Furthermore, the ability of Pentaglobin
®
 to bind to DC-SIGN and SIGNR1 was 
investigated to see if this binding could be duplicated with native Abs. Pentaglobin
®
 
is a licensed IVIG preparation which is enriched for polymeric immunoglobulins 
(12% IgM, 12% IgA and 76% IgG by weight) 
239
. Pentaglobin
®
 bound strongly to 
DC-SIGN but unlike IgM-Fc, no binding was observed with SIGNR1 (Figure 3.12). 
A possible explanation for this is that the expression of IgM-Fc in CHO cells may 
alter glycan composition of IgM or result in undetermined posttranslational 
modifications that could affect binding 
136
.  
The ability of hIgM to bind to native DC-SIGN was confirmed by flow cytometry 
experiments analysing hIgM to monocyte-derived immature dendritic cells (iDCs), 
which showed marginal binding of hIgM to iDCs (Figure 3.13). 
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Figure 3.12 Binding of IgM to DC-SIGN by multi-channel surface plasmon resonance. To 
determine if DC-SIGN is a receptor for IgM-Fc, recombinant human DC-SIGN or mouse SIGNR1 
were immobilised onto a sensor chip. Doubling dilutions (10μM-0.32μM) of IgM-Fc or Pentaglobin® 
were injected at flow time 0, and replaced with buffer at 300 sec. The sensograms depict the 
association and dissociation curves of IgM-Fc and Pentaglobin
® 
binding to DC-SIGN and SIGNR1, 
which include dissociation constants (Kd) values for IgM-Fc binding. Data are representative of 
duplicate experiments (performed in the laboratory of Dr Mitchell). 
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Figure 3.13 Dendritic cells bind human IgM. Immature dendritic cells (iDCs) were derived from 
autologous-sorted CD14
+
 blood monocytes by culture with granulocyte-macrophage colony 
stimulating factor (GM-CSF), IL-4 and tumor necrosis factor (TNF)-α for six days. iDCs and hIgM 
were investigated in the laboratory of Dr Britta Urban. Following culture, iDCs were incubated with 
media only (red trace) or media supplemented with hIgM (blue trace) for 1hr on ice. The binding of 
hIgM to gated iDCs was assessed by staining with F(ab’)2-anti-human IgM-RPE and subsequent flow 
cytometric analysis.  
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DC-SIGN is C-type lectin which possesses high affinity for high mannose structures 
136, 240
. As IgM is heavily mannosylated 
168
, it is possible that the interaction between 
DC-SIGN and IgM is mannose dependent. To test this theory, glycans were cleaved 
from human IgM and/or IVIG with PNGase F (Figure 3.14). Subsequently, the 
ability of de-glycosylated Abs to bind to DC-SIGN was assessed by ELISA (Figure 
3.15).  PNGase F treatment reduced the binding of hIgM and IVIG to DC-SIGN by 
~30% and 50%, respectively (Figure 3.15). This suggests that PNGase F susceptible 
glycans do contribute to the binding of IgM to DC-SIGN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
 
 
 
 
 
 
 
Figure 3.14 Removal of glycans from IgM by PNGase F treatment. Human IgM (50μg; Sigma-
Aldrich) and IVIG (50μg; GammaGard) were incubated overnight at 37˚C in the presence (+) or 
absence (-) of PNGase F in accordance with the manufacturer’s instructions (NEB). Following 
incubation, 5μg of each Ab preparation was run under reducing conditions on a 4-12% Bis-Tris 
gradient gel (Novex) with Seeblue Plus2 pre-stained protein standards (Life Technologies). 
 
 
 
Figure 3.15 DC-SIGN binds to glycans on IgM. The ability of PNGase cleaved hIgM and IVIG to 
bind DC-SIGN was assessed by ELISA. For this, 10μg/ml recombinant DC-SIGN was coated to 
microtitre wells (Nunc) in carbonate buffer (pH9) overnight at 4˚C. The wells were then washed and 
blocked with TSM (20mM Tris-HCl, 150mM NaCl, 2mM CaCl2, 2mM MgCl2, 5% BSA) buffer (pH 
7.4) for 2hr at room temperature (RT), prior to four washes with TSM and overnight incubation at 4˚C 
with 10μg/ml digested (+) or undigested (-) Abs in duplicate. After overnight incubation, wells were 
washed and incubated with anti-human IgM-alkaline-phosphatase (1:1000) for 2hr at RT, then 
developed with 100μl of the substrate p-nitrophenyl phosphate after further washing. Absorbance was 
measured at 405nm. Data are representative of the mean ±SEM of two independent repeats. 
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3.3.6. Modelling of IgM binding to hFcμR  
Molecular dynamic simulations were used to provide structural insights into how 
IgM engages hFcμR, which were generated in collaboration with the laboratory of Dr 
Daniel Czajkowsky (Shanghai Jiao Tong University, China). For this, a recently 
resolved homology-based structural model of hIgM 
135
 was used to model the 
interaction between hIgM and hFcμR. As there is no known structure for hFcμR, we 
searched for possible structural homologs using the Phyre2 Server 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index), as previously 
described 
199
. The server identified homologs for two regions of hFcμR. The first 
segment consists of residues Phe252 to Val272, which exhibited striking homology 
to the transmembrane region of the epiderminal growth factor receptor known as 
erbb1 
201
. Intriguingly, erbb1 is expressed on the cell surface as a dimer, mediated by 
its transmembrane region 
201, 241, suggesting that hFcμR may also exist as a dimer. 
The second segment (residues Val33 to Gly105) was found to be homologous to 
numerous Ig-like domains (Figure 3.16), including those for the IgM receptors pIgR 
and Fcα/μR 137, 203, 242-245. These receptors were shown to bind IgM via the 
complementarity determining region (CDR1-3) loops present in the Ig-like domain 
203. Owing to the sequence homologies between hFcμR and pIgR/ Fcα/μR, the CDR 
region of the Ig-like domains of hFcμR was investigated as the binding region for 
IgM. Further, interactions of IgM with a dimeric version of hFcμR were also 
evaluated (Figure 3.17), with adjacent monomers localised as in known for dimeric 
Ig-domain structures 
206
.  The finding that glycosylation was not involved in 
mediating interactions between hFcμR and IgM (Figure 3.7), and the likely 
involvement of two IgM domains (Cμ2/Cμ4 or Cμ3/Cμ4) (Figure 3.5) provide 
constraints on the potential binding sites of hFcμR. Moreover, as all known 
interactions between Abs and their receptors occur via the C-terminal end of Ig 
domains 
244, 246, these region were chosen to generate the model. The FcμR Ig-like 
domain was positioned so that its CDR loops completely covered the Cμ2/Cμ4 
interface, characteristic of type I engagement of Ab-receptor interactions 
244
.  
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Figure 3.16 Model of hFcμR. Molecular dynamic simulation of hFcμR (performed in the laboratory 
of Dr. Czajkowsky), represented as a monomer (A) and as a dimer (B), which contains a single Ig-like 
domain composed of three complementarity determining regions (CDR).  
 
 
 
 
Figure 3.17 Model of hFcμR-IgM interaction. Molecular dynamic simulations depicting the 
interaction between dimeric hFcμR (shown in magenta) and the heavy chain of IgM. The Cμ2, Cμ3 
and Cμ4 domains of IgM are shown as red, blue, and green ribbons, respectively.  
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Closer inspection of the interface between the monomeric hFcμR Ig-like domain and 
Cμ2/Cμ4 domains revealed several charged and hydrophobic residues that could play 
a significant role in mediating this interaction (Figure 3.18). In particular, there are 
two pairs of charged residues (Arg344 and His327 in IgM and Asp94 and Glu24 in 
hFcμR), and a pair of polar residues within hydrogen bonding distance from each 
other (Glu345 in IgM and Asn92 in hFcμR) that surround a hydrophobic pocket 
(consisting of Leu326 and Leu343 in IgM and Met91 in hFcμR) that could be 
important in mediating the interaction between Cμ4 and hFcμR. Additionally, the 
hydrophobic patch involving Val159 and Val324 in IgM and Met25 and Val27 in 
hFcμR, could be important for the simultaneous interaction between Cμ2 and hFcμR.  
Overall, consideration of the available structural information of these proteins indeed 
provides a physical means to explain the experimental results generated in this 
Chapter. Additional experimental data featured in Chapter 4 provides further insight 
into how IgM docks onto hFcμR. 
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Figure 3.18 Closer inspection of hFcμR-IgM interaction. The binding sites and key residues of two 
proteins are shown in stick representation. The colouring of hFcμR and the domains of IgM are as in 
Figure 3.17, and the hydrophobic, positively charged, and negatively charged residues are depicted as 
white, blue, and red sticks, respectively. 
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3.4. Discussion 
In this chapter, the biochemical nature of IgM binding to hFcμR was investigated. 
Several intriguing features were identified: (1) The Cμ4 domain of IgM mediates 
binding to FcμR, which does not involve glycans. (2) Heat-aggregated IgM ICs are 
able to bind FcμR. (3) FcμR is proposed from modelling with homologous proteins 
to form a dimer on cell surfaces. 
A panel of domain-swap IgM and IgA Abs 
120
 was used to determine regions vital for 
hFcμR binding. The Cμ4 domain of hIgM was identified as the domain which bound 
cell-surface hFcμR expressed on transfected cell lines, with a partial contribution 
made by the Cμ2 and/or Cμ3 domain. Although the Cμ2 and/or Cμ3 domain alone 
exhibited weak binding to hFcμR, the absence of these domains in domain-swap Abs 
containing the Cµ4 domain resulted in a reduction in binding when compared to 
pentameric IgM. One interpretation is that the Cμ2, Cµ3 and Cµ4 domains form a 
binding interface for hFcμR. Alternatively, the Cμ2 and Cµ3 domain may enable 
stabilisation of the Fc region. The Cμ3 and Cμ4 domains feature as ligands for other 
IgM receptors. For example, the binding of IgM to hFcα/µR was also shown to 
require contributions from both the Cμ3 and Cμ4 domains 247. Furthermore, the 
observation that the extracellular portion of pIgR (known as secretory component) 
blocked IgM binding to hFcα/µR also implicated these domains in governing IgM-
pIgR interactions 
247, 248
. Together, the findings reported here support and extend the 
previous discovery that the Fc5μ fragment of IgM governs interactions with hFcμR 
137
. 
The discovery of the Cµ4 domain of pentameric IgM as the ligand for hFcµR is 
particularly intriguing given that this domain is also the target of P. falciparum-
derived IgM-binding molecules PfEMP1, DBLMSP and DBLMSP2 
120, 146
. Whether 
non-specific binding of IgM by these molecules prohibits interactions between IgM 
and hFcµR remains to be determined (see Chapter 4). As FcµR has been implicated 
in modulating immune responses 
138
, preventing the binding of hIgM to this receptor 
could be crucial for the survival of the parasite in the host. This interesting question 
will be explored further in Chapter 4. 
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The Cµ3 and Cµ4 domains of IgM contain N-linked glycosylation sites at Asn-395, 
Asn-402, and Asn-563 which are predominantly occupied with complex glycans or 
oligomannose-type glycans 
168
. The removal of these glycans did not perturb hIgM 
binding to hFcμR, which differs from other FcRs which require Ig glycosylation for 
optimal binding 
169
. The fact that the single N-linked site in the Cμ4 domain is only 
~17% occupied could offer one explanation as to why endoglycosidase treatment of 
IgM did not impact on binding to hFcμR (Arnold 2005). As the glycosylation of IgM 
molecules is critical for permitting interactions with mannose-binding lectin (MBL), 
it is tempting to speculate that the IgM-hFcμR interaction evolved in a glycan-
independent manner to allow IgM-MBL-Ag immune complexes to bind hFcμR.  
An intriguing finding was that IgM-ICs are able to bind hFcμR expressed on 
transfected cells, as this could suggest that the receptor plays a role in priming 
immune responses. The formation of ICs through agglutination of pathogens by IgM 
is pivotal for immune responses against infection. Further, internalisation of ICs 
results in the removal of pathogens and antigen presentation to the adaptive immune 
system via MHC class I molecules. For example, murine B cells were shown to 
internalise Staphylococcus aureus-IgM-ICs in a Fcα/μR-dependent manner 143, and 
FcγRIIA and FcRn have been implicated on the internalisation and cross-
presentation of antigens on dendritic cells (DCs) 
249, 250
. The data reported here, in 
support of previous data which showed the role of FcμR in IgM internalisation 183, 
highlights the potential of the receptor to initiate cross-presentation of IgM-ICs on 
antigen presenting cells such as B cells. However, whether Ag-specific IgM-ICs can 
bind to and be internalised by hFcμR remains to be determined, especially as IgM is 
predicted to adopt a different confirmation upon antigen binding 
135
. Alternatively, 
hFcμR may function to bind and internalise non-specific IgM-ICs to promote their 
removal. In support of this hypothesis, experiments using knock-out mice (FcμR-/-) 
suggested that FcμR regulates IgM levels in the periphery 182 and IgM internalised 
via FcμR is shuttled to endosomes for degradation 183. Finally, the binding of IgM-
ICs by FcμR may function to initiate cross-linking of receptors, similar to that 
observed for CD22 and the BCR on murine B cells 
233
. This cross-linking was shown 
to trigger a negative feedback mechanism for B cell activation through CD22-
mediated BCR-signalling suppression. Curiously, FcμR was implicated in lowering 
the threshold of BCR signalling as B cell proliferation in response to anti-IgM 
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stimulation was reduced in FcμR-/- mice 138. Furthermore, cross-linking of FcμR 
enhanced survival of B cells in response to BCR cross-linking 
138
. It will therefore be 
of interest to further investigate significance of IgM-IC binding to hFcµR, especially 
in relation to how Ag-specific IgM-ICs may modulate B cell responses via FcµR and 
BCR cross-linking.  
Studies using knockout mice (FcμR-/-) have generated the majority of insight into the 
biological function of FcµR 
138, 180, 182
, or from studies which use mouse IgM to 
investigate the role of FcµR in humans 
140
. As a result of this, little is known about 
the interaction of hIgM to hFcµR. Moreover, there has been controversy on whether 
FcµR functions to inhibit apoptosis 
178, 210
 or to act as an IgM receptor 
137
. Here, we 
confirm that hFcµR is a receptor for hIgM and show that exogenous hIgM can bind 
to
 
lymphocytes known to express FcµR. Moreover, isolated B cells and NK cells 
were found to have high levels of cell-surface IgM, which were not so pronounced 
for T cells. This data supports a recent study which reported IgM on the surface of 
circulating NK cells 
140
. The high affinity of the IgM-FcµR interaction (Kd ~10.8nM) 
may offer one explanation for this observed effect, as hFcµR may be opsonised with 
IgM on circulating B cells and NK cells. Under this assumption, hFcµR expressed on 
T cells would not be occupied with IgM. The high surface levels of IgM and 
marginal binding of exogenous IgM to B cells suggests that FcµR is fully occupied 
on these cells. However, the expression of IgM
+ 
BCR may account for the observed 
high levels of IgM on B cell surfaces. Further work is required to clarify the 
persistence of IgM bound to FcµR on lymphocyte surfaces. Although B cells, T cells 
and NK cells bound exogenous hIgM, there was differential binding between the 
lymphocyte subsets. The reasons for this are still unclear, however the high surface 
levels of IgM on purified B cells and low surface levels on T cells, coupled with the 
ability of T cells to bind exogenous IgM, supports the hypothesis that T-B cell 
interactions can be formed via the interactions of FcµR on T cells with IgM
+ 
BCR or 
IgM-Ag complexes on B cells 
137
. 
Surprisingly, IgM was also observed to bind to monocytes. The presence of a 
receptor for IgM on the surface of human monocytes was suggested by an earlier 
study, determined by the ability of monocytes to form rosettes with sheep 
erythrocytes (SRBC) in the presence of anti-SRBC Abs of the IgM isotype 
251
. 
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However, a later study repeated these experiments and observed no rosette formation 
252
. The study concluded that human monocytes do not express Fcμ receptors and 
that the previous findings may have been contributed to contaminating IgG Abs in 
the IgM preparations 
252
.  However, the discussion over the expression of FcμR on 
monocytes remains controversial. Numerous studies have published conflicting data 
on the expression of hFcμR on human monocytes recently 137, 179, 180, 235, 242, and the 
debate remains unresolved. Therefore, there is a possibility that the observed binding 
of IgM to monocytes could be due to the expression of hFcμR. To resolve this issue, 
future studies should aim to clarify whether hFcμR is expressed on monocytic cell 
populations. 
The identification of DC-SIGN as a novel ligand for IgM could offer an alternative 
explanation as to how monocytes bind hIgM. However, expression of DC-SIGN on 
CD14
+
 cells which bind hIgM needs to be confirmed. Although a subset of 
monocytes express DC-SIGN 
167, 237
, given the observed high levels of IgM binding 
to monocytes, it seems unlikely that these cells contribute to the proportion of IgM 
binding observed here. Therefore, it is tempting to speculate that another unidentified 
receptor expressed on monocyte surfaces can also bind IgM. Despite the identity of 
this receptor being unknown, numerous candidate mannose-binding ligands are 
expressed on monocytes subsets, including mannose receptor (MR) and DC-SIGN 
253, 254
. MR is constitutively expressed by multiple monocyte-derived cell 
populations, such as immature monocyte-derived DCs and alternatively activated M2 
macrophages 
255, 256
. Moreover, the attenuation of ricin toxin-induced apoptosis of 
THP-1 monocytes by anti-MR Abs suggests expression of MR on monocytes 
surfaces 
254, 257
. Selectins (e.g. CD62e, CD621) which bind complex N-glycans via 
sialyl Lewix x (sLe
x
) motifs were also proposed as mannose ligands on monocytes 
254, 258
. The mannose-dependent binding of type I fimbriated E. coli  by Mac1 
(CD11b/CD18) 
259
, and the high affinity of CD11b
+
 monocytes for mannosylated 
glycopolymers 
260
, implicate Mac1 as a potential mannose-binding ligand expressed 
on monocytes 
254
. Repeating the aforementioned binding assays with glycan cleavage 
IgM would confirm whether the binding of IgM to monocytes is mediated via glycan 
receptors.  
89 
 
 
Whether the expression of DC-SIGN by monocytes can account for the observed 
IgM binding is still unknown. Nonetheless, IgM-Fc or IgM-enriched IVIG bound 
DC-SIGN and SIGNR1 with high-affinity. These data confirm DC-SIGN as a novel 
receptor for hIgM 
136
. The interaction of DC-SIGN with IgM was found to be 
dependent upon glycosylation of IgM 
136
. IgM glycosylation has previously been 
shown to significantly enhance receptor binding to another lectin receptor, namely 
CD22 on B cells 
261, 262
. Furthermore, the extent of IgM-glycosylation was shown to 
correlate with the binding of recombinant DC-SIGN to IgM
+ 
BCR follicular 
lymphoma B cells 
263
.  The cross-linking of IgM
+ 
BCR by recombinant DC-SIGN led 
to the induction of signalling in these malignant B cells, highlighting the potential 
importance of the interaction between IgM and DC-SIGN. However, in-depth 
knowledge of the functional consequence of IgM binding by DC-SIGN remains to be 
determined. Given the abundant expression of DC-SIGN on monocyte-derived 
dendritic cells 
167
, it is tempting to speculate that the binding and internalisation of 
IgM-ICs to the receptor could function to enhance immune responses through 
antigen presentation. Moreover, binding of IgM by DC-SIGN could govern clearance 
of IgM-opsonised apoptotic cells and production of anti-inflammatory IL-10 by 
dendritic cells 
264
.  It will be of interest to further investigate the IgM-DC-SIGN 
interaction.  
Molecular dynamic simulations proposed that hFcμR could exist as a dimer on cell 
surfaces, as its transmembrane region shared sequence homology with erbb1, which 
was previously shown to form dimers 
241
.  In support of dimer formation for this IgM 
receptor, Fcα/μR is known to form a stable homo-dimer on cell surfaces via ε-(γ-
glutamyl) lysine isopeptide bond formation between the ε-amino group of lysine 
residues and γ-carboxamide group of glutamic acid residues 144. Given the large 
molecular weight of IgM, it is tempting to speculate that dimerisation of FcμR could 
contribute to avidity interactions and account for its high affinity for IgM 
137
. 
However, whether FcμR exists as a dimer is still to be determined experimentally. 
Future studies could utilise two-colour quantum-dot tracking for the visualisation of 
dimer formation, as previously described 
241
. Here, we provide a structural insight 
into the possible interaction between hFcμR and the Fc portion of IgM based on 
experimental data. This topic will be further expanded in Chapter 4.  
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Chapter 4: Determining why P. falciparum 
merozoites express proteins which bind 
non-immune IgM 
4.1. Literature review 
4.1.1. MSP3 family 
The merozoite surface protein 3 (MSP3) multi-gene family encodes six MSP3-like 
proteins expressed on the merozoite surface; MSP 3 (MSP 3.1), MSP6 (MSP 3.2), 
H101 (MSP 3.3), DBLMSP (MSP 3.4), H103 (MSP 3.7) and DBLMSP2 (MSP 3.8) 
148
. MSP3-like family proteins are synthesised simultaneously in schizont-stage 
parasites, which undergo proteolytic cleavage in parasitophorous vacuoles during 
merozoite maturation 
265, 266
. The majority of the cleaved fragments are released into 
the culture supernatant upon schizont rupture, however a small proportion of 
fragments associate non-covalently to the merozoite surface by  mechanism(s) yet to 
be resolved 
265, 267
. 
Members of the MSP3 multi-gene family were grouped due to similarities in the 
organisation of their C-terminal regions compared to MSP3 (Figure 4.1) 
148
. 
Although the N-terminal regions of MSP3-like proteins were found to be highly 
polymorphic 
265, 268, 269
, the C-terminal regions shared sequence homologies  and are 
highly conserved among parasite isolates 
148
, implying that these proteins may play a 
role in parasite survival 
270
. The conservation of C-terminal sequences within the 
MSP3 multi-gene family contributed to the ability of Abs raised against one member 
of the family to cross-react with other members of the gene family 
148
. These cross-
reactive Abs promoted Ab-dependent cellular inhibition (ADCI) of parasite growth 
148, 271
.  Moreover, immune sera from individuals living in endemic regions also 
recognised the C-terminal domain of different members of the MSP3-gene family 
148, 
270
, and anti-MSP3 Abs have been shown to correlate with protection in field studies 
272-274
. These results highlight the importance of MSP3-like proteins in eliciting 
protective immunity against malaria.  
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4.1.2. DBLMSP and DBLMSP2 
Duffy-binding like (DBL) domains play a crucial role in  disease severity in malaria 
by mediating a number of  pathogenic mechanisms including erythrocyte invasion 
and cytoadhesion 
66, 275
. These cysteine-rich DBL domains are encoded by a variety 
of genes within the P. falciparum genome, including members of the erythrocyte-
binding ligand (EBL)  and var gene superfamilies 
110
.  
A recent study characterised the expression of DBL domains by two members of the 
MSP3 multi-gene family 
149
. Two closely-related members of the MSP3-family, 
DBLMSP and DBLMSP2, were found to contain a central DBL domain in addition 
to  a C-terminal secreted polymorphic antigen associated with merozoites (SPAM) 
domain 
147, 149
. Whereas the majority of the MSP3-gene family contain a single 
SPAM domain 
148, 266
, the presence of a single central DBL domain is unique to 
DBLMSP and DBLMSP2 (aa residue 143-443 and 161-457, respectively) 
147, 149
. 
DBL domains of DBLMSP and DBLMSP2 share 38% sequence identity and 62% 
similarity, whereas the SPAM domains share 30 and 53%, respectively 
147
. SPAM 
domains are composed of a glutamic acid-rich region and a leucine-zipper-like 
region, which are thought to form large oligomers that could extent to potentially 
allow for improved interactions with erythrocyte membrane proteins 
147, 276
. 
Recently, the SPAM domains of DBLMSP and DBLMSP2 were resolved as high 
molecular weight oligomers by size-exclusion chromatography, suggesting that the 
C-terminal domain of these proteins facilitates oligmerisation 
146
.  This intriguing 
feature will be explored more in Chapter 5.  
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Figure 4.1 Structure of the MSP3-like family proteins. The schematic diagram depicts the presence 
of SPAM domains common to all MSP3-like family members, whereas the DBL domain is exclusive 
to DBLMSP and DBLMSP2 adapted from 
147
. The numbers depict amino acid (aa) residues.  
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4.1.3. Structure of DBLMSP and DBLMSP2 
The three-dimensional structure of the DBL domain of DBLMSP2 was recently 
resolved by X-ray crystallography, which was subsequently used as a template to 
build a homology-based structure of the DBL domain of DBLMSP 
147
. DBLMSP2 
was found to contain a canonical DBL fold with an α-helical core composed of three 
subdomains which adopted a boomerang-like shape (Figure 4.2). Inter-chain 
disulphide linkages were found to stabilise DBLMSP2, and the disulphide bond 
architecture of DBLMSP and DBLMSP2 was proposed to be unique to that of the 
DBL proteins of the PfEMP1 and EBL family 
147
. Further, DBLMSP2 showed 
structural similarities with DBL domains from PfEMP1, including VAR2CSA 
DBL6e, DBL3X and PfEBA-175 F2 DBL 
147
. Although other DBL-containing 
proteins have been suggested to form dimers 
277
, the domain architecture and 
structure of DBLMSP2 did not satisfy the requirements for this kind of dimerisation 
147
. However, as the structure of the full-length protein has yet to be resolved, the 
oligomerisation status of DBLMSP and DBLMSP2 remains unknown.   
DBLMSP is expressed on merozoites surfaces in all schizonts, whereas DBLMSP2 is 
expressed on a very small subset (≤1%) of schizonts 151. However, numerous studies 
have confirmed the presence of DBLMSP and DBLMSP2 on merozoite surfaces 
147, 
149
. Due to the lack of GPI-anchor motifs or transmembrane domains, DBLMSP and 
DBLMSP2 are thought to associate with other proteins on the surface of merozoites 
147, 149
. Hodder et al. hypothesised that processing by the parasite serine protease 
PfSUB1 may account for incorporation of DBLMSP and DBLMSP2 onto the 
merozoite surface 
147
. In support of this, the N-terminus regions of these proteins 
contain potential PfSUB1 cleavage sites and saponin-processing revealed that two 
forms of the proteins exist 
147
, and the integration of MSP6 into the MSP1 complex 
was found to be dependent on PfSUB1 processing 
278, 279
. However, further research 
is required to elucidate the exact mechanism by which DBLMSP and DBLMSP2 
associate with the merozoite surface, and clarify their interaction with other 
merozoite surface proteins.  
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Figure 4.2 Structure of the DBL domains of DBLMSP and DBLMSP2 (A) Crystal structure of the 
DBL domain of DBLMSP2 domain (PDB accession code 3VUU). (B) Homology-based model of the 
DBL domain of DBLMSP was derived from the crystal structure of DBLMSP2. The structure of the 
DLB domain of DBLMSP2 was used as a template to build a model of the DBL of DBLMSP using 
the MODELLER program adapted from 
147
.  
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4.1.4. Vaccine candidate antigens 
The striking polymorphisms in dblmsp and dblmsp2, particularly within the dbl 
region, indicates that these genes are likely to be subject to immense immune 
selection pressure, presumably owing to their expression on the merozoite surface 
280
. This is supported by findings that full-length recombinant DBLMSP  elicit 
specific Abs which inhibited erythrocyte invasion by P. falciparum merozoites 
281
. 
These inhibitory Abs did not cross-react with the SPAM (C-terminal) domains of the 
other MSP3-family members, suggesting that they recognise regions outside of the 
SPAM domain of DBLMSP 
281
. However, the role of the SPAM domain in 
protection has been documented in numerous studies 
148, 271, 272
. Asymptomatic adults 
in endemic regions of Senegal exhibit high prevalence of Abs specific for the SPAM 
domain of DBLMSP 
270
, immune sera from individuals in India recognised both the 
DBL and SPAM domains of DBLMSP 
149
, and Abs against DBLMSP were isolated 
from sera of asymptomatic Thai adults 
281
. The generation of Abs specific for 
DBLMSP irrespective of parasite isolate or endemic area signifies the potential 
importance of this protein in P. falciparum malaria. Additional research is required 
to assess the relationship between anti-DBLMSP Ab titres and clinical protection 
from malaria on a global scale, to help clarify the importance of these proteins in 
immunity to malaria 
281
. Together, these data highlight the potential of DBLMSP and 
DBLMSP2 as attractive vaccine candidates. Understanding what role these proteins 
play in immunity to malaria could therefore help facilitate vaccine design. 
4.1.5. DBLMSP and DBLMSP2 bind human IgM 
Intriguingly, a recent study identified a previously unknown function of DBLMSP 
and DBLMSP2 whilst attempting to ascertain their immunoreactivity 
146
. Full-length 
recombinant DBLMSP and DBLMSP2 exhibited non-specific immunoreactivity to 
both immune sera and unexposed control sera, suggesting that these proteins bind 
non-immune immunoglobulins 
146
. Further analysis revealed that DBLMSP and 
DBLMSP2 bound non-immune human IgM, but not IgG, IgA, or IgE, and that this 
binding was human specific 
146
. The Cμ4 domain of hIgM was identified as the target 
for DBLMSP and DBLMSP2, and these proteins were able to bind hIgM irrespective 
of whether it was bound to antigen or not. Although the presence of the J-chain in 
hIgM molecules was not essential for binding, the lack of a J-chain reduced binding 
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of DBLMSP2. The DBL domains of DBLMSP and DBLMSP2 govern binding to 
IgM, which occurs at high avidity (Kd = 0.3 and 1.1 nM, respectively). No binding to 
IgM was observed for the SPAM domains.   
A variety of DBLMSP and DBLMSP2 DBL domains from different P. falciparum 
strains possess the IgM-binding phenotype, despite high levels of sequence 
polymorphisms 
146
. The ability of native DBLMSP to bind IgM was confirmed since 
wild-type, but not dblmsp-deficient merozoites, had IgM bound to their surfaces 
following culture with human serum or purified human IgM 
146
. These results 
identify DBLMSP and DBLMSP2 as novel IgM-binding P. falciparum proteins 
which are expressed on the surfaces of merozoites.  
4.1.6. Functions of DBLMSP and DBLMSP2 
Exactly why DBLMSP and DBLMSP2 variants bind non-immune hIgM remains 
unclear. To date, these proteins have been implicated in erythrocyte binding 
147, 149
 
and camouflaging critical epitopes from immune detection through the binding of 
non-immune IgM 
146
. 
Invasion of host erythrocytes is pivotal for P. falciparum replication and virulence. 
P. falciparum merozoites utilise numerous mechanisms to gain entry into host 
erythrocytes, including the expression of ligands which bind receptors on host cells 
282
. The EBL family of proteins expressed on merozoite surfaces are well-
characterised erythrocyte-binding ligands (EBL) which mediate erythrocyte invasion 
283
. Since DBL domains are common in members of the EBL family, the ability of 
DBLMSP and DBLMSP2 to bind erythrocytes was investigated 
147, 149
. COS-7 cells 
transfected with DBLMSP formed rosettes with uninfected erythrocytes, suggesting 
that DBLMSP may mediate merozoite attachment during erythrocyte invasion 
processes 
149
. Hodder et al. further characterised DBLMSP and DBLMSP2 as 
erythrocyte-binding proteins, and highlighted the role of the DBL domains in this 
interaction 
147
. They observed enhanced binding of recombinant DBL domain and 
full-length proteins in the presence of specific metal ions (Ca
2+
, Cu
2+
, Co
2+
, and 
Zn
2+
). This binding was not sensitive to trypsin and neuraminidase treatment of 
erythrocytes 
147
, contradicting earlier findings 
149
. As well as the expression of DBL 
domains, the erythrocyte-binding phenotype is a unique feature of the DBLMSP 
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proteins as other MSP3-family members do not bind erythrocytes 
147
.  However, 
subsequent analysis revealed that the addition of DBLMSP-specific Abs had a 
modest inhibitory effect on erythrocyte invasion, and the ablation of dblmsp gene in 
knock-out parasites had no effect on erythrocyte invasion 
146
. Therefore, although the 
DBLMSP proteins may help initiate interactions between merozoite and erythrocyte, 
their expression is not essential for invasion processes. More research is required to 
calrify the role of these proteins in erythrocyte invasion. 
Despite high levels of sequence polymorphism, IgM-binding is a conserved 
phenotype of DBLMSP variants 
146
. In total, ten representative DBL variants and six 
field isolates of DBLMSP, including the P. reichenowi ortholog for DBLMSP, and 
six representative DBL variants of DBLMSP2, were shown to bind IgM 
146
. 
Curiously, the DBL domains of DBLMSP from variants 7G8 and 028 did not bind 
IgM, despite sharing sequence homology with the DBL domains of their DBLMSP2 
counterparts 
146
. The residues mediating interactions between DBL domains and IgM 
have yet to be determined. However, conservation of the IgM-binding between 
variants suggests that this phenotype could play an important role in malaria 
146
. 
The DBL domains of DBLMSP and DBLMSP2 variants were found to be poorly 
immunogenic 
146
. One explanation for this poor immunoreactivity could be that IgM-
binding by DBLMSP and/or DBLMSP2 conceals critical epitopes from the host 
immune system, as previously described for the PfEMP1 variant VAR2CSA 
284
. 
Immunoreactivity of full-length DBLMSP and DBLMSP2 to immune IgG was 
reduced in a dose-dependent manner when complexed with non-immune IgM. This 
effect was observed for numerous DBLMSP variants, suggesting that the camouflage 
of immune epitopes from Abs through non-immune IgM binding is a strain-
transcending function 
146
. 
Whether DBLMSP and/or DBLMSP2 permit additional functional consequences is 
yet to be determined, and therefore forms the focus of this chapter. Since MSP3 is 
shed from the merozoite surface upon erythrocyte invasion 
265, 267
, and given the high 
affinity of the DBLMSP proteins for human IgM 
146
, it is tempting to speculate that 
the formation of immune complexes of DBLMSP with IgM in the periphery could 
function to block IgM binding to its cognate receptors.  
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4.2. Objectives 
To determine why P. falciparum merozoites express DBL domains which bind non-
immune human IgM.  The specific objectives were: 
I. To identify requirements for the interaction between DBLMSP/ DBLMSP2 
and human IgM 
II. To establish whether DBLMSP and/or DBLMSP2 function to block IgM 
binding to host receptors 
III. To determine if IgM-opsonised immune-cells are targets for DBLMSP and 
DBLMSP2, and the biological consequences of DBLMSPs binding 
IV. To investigate the structural requirements for DBLMSP and DBLMSP2 
interacting with IgM bound by FcμR 
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4.3. Results 
4.3.1. Malaria DBL domains bind the Cμ4 domain of human IgM 
DBLMSP and DBLMSP2 have been recently characterised to bind the Cµ4 domain 
of hIgM 
146
. Since this domain is also bound by hFcµR (see Chapter 3), we sought to 
confirm which domain of hIgM the malarial proteins bind. Initially, the ability of 
full-length recombinant DBLMSP and DBLMSP2 proteins 
146
 to bind hIgM was 
assessed. DBLMSP and DBLMSP2 bound strongly to IgM in ELISAs, whereas no 
binding was observed for the control protein Cd4-d3+4 (Figure 4.3A; left panel). 
Further, the individual DBL domains of DBLMSP and DBLMSP2 were shown to 
bind to hIgM (Figure 4.3A; right panel).  
A panel of domain-swap Abs generated in a previous analysis 
120
, and that were also 
used to characterise the interaction with VAR2CSA 
284
 were used to characterise the 
interaction of DBLMSP and DBLMSP2 with hIgM by ELISA. These experiments 
were performed by Professor Pleass (Liverpool School of Tropical Medicine). The 
Cμ4 domain was crucial for permitting DBLMSP and DBLMSP2 binding to domain-
swap Abs (Figure 4.3B). No binding was detected with the α1μ2μ3α3 domain-swap 
Abs lacking the Cμ4 domain (Figure 4.3B). The presence of the Cμ2 and Cμ3 
domains, in conjunction with the Cμ4 domain (α1μ2μ3μ4), enhanced binding of 
DBLMSP to the chimeric Abs, whereas the presence of these domains had less effect 
for DBLMSP2 binding (Figure 4.3B). These results confirm the ability of 
recombinant DBLMSP and DBLMSP2 to bind the Cμ4 domain (and partially via the 
Cμ2-Cμ3 domains) of hIgM. 
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Figure 4.3 DBLMSP and DBLMSP2 bind to the Cμ4 domain of hIgM. (A) An indirect ELISA 
was used to confirm binding of recombinant full-length biotinylated DBLMSP and DBLMSP2 to 
hIgM (left panel). Biotinylated Cd4-d3+4 control protein did not bind to hIgM (left panel). Further, 
individual DBL domains of DBLMSP and DBLMSP2 bound hIgM, whereas no binding was observed 
with individual SPAM domains (right panel). The mean ± SD are shown for three repeat experiments. 
Unpaired t test was used to test for statistical significance (p < 0.05). (B) A panel of domain-swap Abs 
were used in which domains of IgA (shown as α) were substituted with domains of IgM (shown as μ) 
120
. DBLMSP (right panel) and DBLMSP2 (left panel) bound to domain-swap Abs containing the Cμ4 
domain (α1α2μ4 and α1μ2μ3μ4). No binding was observed for domain-swap Abs containing the Cμ2 
and Cμ3 domains (α1μ2μ3α3). The mean ± SD are shown for two repeat experiments. 
 
 
 
 
 
A) 
B) 
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4.3.2. IgM glycosylation is not involved in DBLMSP and DBLMSP2 binding 
Malaria antigens are typically not complex glycoproteins as P. falciparum lacks the 
biosynthetic machinery required for complex glycan synthesis 
285
.  We therefore 
wondered if DBLMSP and DBLMSP2 could interact with the glycans found on 
hIgM.  For this, a range of endoglycosidases were used, including PNGase F, α1-6 
mannosidase, and neuraminidase (which cleave N-glycans, mannose residues, and 
sialic-acid terminating glycans, respectively), which have previously been used to 
remove glycans from IgM 
286, 287
. Endoglycosidase treatment had no significant 
effect on the binding of either DBLMSP or DBLMSP2 to hIgM (Figure 4.4). No 
binding of IgM was observed to the Cd4-d3+4 control. Together, these data suggest 
DBLMSP and DBLMSP2 bind hIgM in a glycan-independent manner. 
4.3.3. Malaria DBL domains that also bind the Cμ4 domain of IgM do not block 
the interaction of IgM with hFcμR 
Since the Cμ4 domain of IgM was also observed to be the target of hFcμR (see 
Chapter 3), we sought to investigate if these parasite proteins had evolved to block 
the interaction of IgM with hFcμR, as previously proposed 198. Human IgM was 
incubated with varying concentrations of DBLMSP or DBLMSP2 and binding to 
hFcμR-transfected cell lines investigated by flow cytometry (Figure 4.5A,B). 
Saturating concentrations of DBLMSP2 had no significant effect (p= 0.58) on the 
interaction of hIgM with hFcμR (Figure 4.5A, right panel). DBLMSP at best could 
only block ~30% of the binding of hIgM to the hFcμR-transfected cells (Figure 4.5A, 
left panel), however this effect was not significant (p= 0.09). 
 In addition, prior binding of hIgM to the hFcμR-transfected cells did not prevent the 
interaction of either DBLMSP or DBLMSP2 with hIgM bound to the cell surface via 
FcμR (Figure 4.5B; left panel). This data also suggests that DBLMSP binds hIgM 
more strongly than DBLMSP2, a finding that has consistently been observed 
146
. No 
binding of DBLMSP and DBLMSP2 to hFcμR was observed in the absence of hIgM 
(Figure 4.5B; right panel). 
 
102 
 
 
 
Figure 4.4 Endoglycosidase treatment of human IgM does not inhibit IgM binding to DBLMSP 
or DBLMSP2. Recombinant DBLMSP, DBLMSP2, and Cd4-d3+4 (10 μg/ml )were immobilised and 
incubated with varying concentrations of endoglycosidase-treated (non-filled markers; +) or non-
treated (filled markers; -) hIgM. Dunn’s multiple comparison tests revealed no statistical difference in 
binding of treated- or non-treated hIgM to DBLMSP or DBLMSP2. No binding was observed with 
Cd4-d3+4 control protein. Bars represent mean ± SD; n = 2.  
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Figure 4.5 DBLMSP and DBLMSP2 do not block the binding of human IgM to FcμR. (A) 
hFcμR-transfected cells were incubated with media supplemented with hIgM or media supplemented 
with hIgM preincubated with varying concentrations of DBLMSP or DBLMSP2 for 1hr on ice. Cells 
were washed and then labelled with F(ab’)2-anti-human IgM-RPE to detect IgM binding by flow 
cytometry. Percentage of hIgM on cell surfaces (GMFI) shows a trend for DBLMSP to block hIgM 
binding to hFcμR-transfected cells (albeit not significant), whereas no blocking was observed with 
DBLMSP2. The mean ± SD from three independent experiments is shown. Multiple t-tests were 
performed for the comparison of % IgM on cell surface (GMFI) values for hIgM preincubated with 
varying concentrations DBLMSP or DBLMSP2, and hIgM alone (0μg). Statistical significance was 
regarded as p < 0.05. (B) DBLMSP and DBLMSP2 engage hIgM bound to hFcμR-transfected cells. 
Normalised biotinylated DBLMSP or DBLMSP2 were incubated with hIgM-opsonised hFcμR-
transfected cels on ice prior to flow cytometry analysis. In the overlay shown (left panel), binding of 
DBLMSP (blue trace) and DBLMSP2 (pink trace) to gated GFP
+ 
cells was detected using anti-biotin-
APC. Background binding detected with anti-biotin-APC in the absence of biotinylated proteins (grey 
trace). No binding of either DBLMSP or DBLMSP2 to hFcR-transfected cells was observed in the 
absence of hIgM (right panel). The results shown are representative of three independent experiments.  
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4.3.4. DBLMSP and DBLMSP2 interact with IgM bound to DC-SIGN 
To test if DBLMSP and DBLMSP2 could interact with IgM bound to other known 
IgM receptors 
136
, the interaction of DBLMSP and DBLMSP2 with soluble 
recombinant human DC-SIGN tetramers by multichannel surface plasmon resonance 
analysis (MC-SPR) was investigated in the laboratory of Dr Daniel Mitchell 
(University of Warwick). The sensorgrams show that DBLMSP2 can still bind hIgM 
after hIgM has first engaged DC-SIGN (Figure 4.6). The high affinity for the 
interaction of DBLMSP2 for DC-SIGN-bound hIgM (Kd= 96nM) is approximately 
of the same order as those observed for the binding of DBLMSP and DBLMSP2 to 
IgM (Kd= 0.3nM and 1.1nM, respectively), as shown previously 
146
. Given the 
multimeric nature of IgM, DC-SIGN and the two parasite proteins studied, these 
measurements reflect overall binding avidity and are not easily comparable with 
other monomeric protein interactions. The physiological concentration of IgM in 
human serum is around 1-2mg/ml (1-2μM), at least three orders of magnitude higher 
than the measured binding constants, implying that DBLMSP2 complexed to IgM 
would be rapidly and irreversibly bound by DC-SIGN and/or the FcμR. 
 
 
 
 
 
105 
 
 
 
 
Figure 4.6 DBLMSP2 interact with IgM bound to DC-SIGN. Multi-channel surface plasmon 
resonance was conducted in the laboratory of Dr Daniel Mitchell (University of Warwick). 
Association and dissociation curves of DBLMSP2 binding to IgM bound to recombinant human DC-
SIGN immobilised on a sensor chip. Human IgM was injected at doubling dilutions from 10M to 
0.32M into flow at time 0, and replaced with buffer at 300 sec. DBLMSP2 was injected at doubling 
dilutions from 10μM to 0.32μM into flow at time 900, and replaced with buffer at 1300 sec. Data are 
representative of duplicate experiments. Similar results were observed for DBLMSP (data not shown). 
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4.3.5. DBLMSP and DBLMSP2 bind lymphocyte subsets that express hFcμR 
As the hFcμR-transfected cell lines may not accurately reflect the expression of 
hFcμR in vivo, we next investigated the interaction of DBLMSP and DBLMSP2 with 
lymphocyte subsets previously shown to express hFcμR 137, 140. 
Whether IgM
+
 gated lymphocytes were also positive for DBLMSP and DBLMSP2 
binding was first determined. For this, lymphocytes were first gated into IgM 
negative and positive populations, based on the use of controls (e.g. no detecting 
Ab). Three cell populations were observed (Figure 4.7); lymphocytes with no cell 
surface IgM (IgM
-
), IgM positive lymphocytes (IgM
+
), and highly positive 
lymphocytes (IgM
++
). We hypothesised that cells with high levels of IgM on their 
surface are likely to be B cells expressing IgM
+ 
BCR. Importantly, all of the cells 
that bound DBLMSP and DBLMSP2 were also positive for cell surface IgM (Figure 
4.7; overlays). In fact, binding of these proteins to lymphocytes appeared to correlate 
with the levels of surface IgM, as IgM
++
 lymphocytes exhibited the highest 
proportion of binding (Figure 4.7A). Moreover, there were significant differences in 
the binding of DBLMSP and DBLMSP2 to IgM positive (
+
 and 
++
) lymphocytes 
when compared to IgM negative (
-
) lymphocytes (Figure 4.7B; p <0.01). Thus, the 
binding of DBLMSP and DBLMSP2 to lymphocytes appears to be dependent on the 
presence of surface IgM.  
We next determined the subsets of lymphocytes that bound DBLMSP and 
DBLMSP2 (Figure 4.8). Both DBLMSP and DBLMSP2 bound to T cells (CD4
+
 and 
CD8
+
), CD19
+ 
B cells and CD56
+
 NK cells, although binding of DBLMSP was 
always stronger. Interestingly, the great majority (>60% between at least three 
independent donors) of circulating peripheral CD19
+
 B cells bound both DBLMSP 
and DBLMSP2, whereas only ~10-40% of circulating T lymphocytes and NK cells 
bound either protein (Figure 4.8 & 4.9).  This supports the finding that lymphocytes 
with high levels of surface IgM (IgM
++
) bound the highest proportion of DBLMSP 
and DBLMSP2, suggesting that these proteins may also engage the IgM
+ 
BCR, 
although this has yet to be determined. 
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Figure 4.7 DBLMSP and DBLMSP2 bind to IgM-positive lymphocytes. Freshly isolated PBMCs 
were incubated with normalised amounts of biotinylated DBLMSP or DBLMSP2, washed and then 
incubated with anti-biotin-APC and F(ab’)2 goat anti-human IgM-RPE prior to flow cytometry 
analysis. (A) Lymphocytes were gated (blue dots), and further gated into IgM
-
 (magenta gate), IgM
+
 
(green gate), and IgM
++ 
(purple gate) populations. Gates were set using negative controls (no detecting 
Ab).  Binding of DBLMSP (blue trace) and DBLMSP2 (pink trace) to these populations are shown as 
traces. No binding was observed with the Cd4-d3+4 control protein (grey trace). (B) There was 
significant difference in binding of DBLMSP (left panel) and DBLMSP2 (right panel) to gated IgM
-
, 
IgM
+
, and IgM
++
 lymphocytes (as in A), as determined by multiple unpaired t-tests.  The mean± SD of 
two repeats are shown.  
 
A) 
B) 
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Figure 4.8 DBLMSP and DBLMSP2 bound to human lymphocytes. Freshly isolated PBMCs were 
incubated with normalised amounts of biotinylated DBLMSP, DBLMSP2 or Cd4-d3+4, and then with 
anti-biotin-APC along with the appropriate FITC-labelled mAbs specific for CD4, CD8, CD19, or 
CD56. Subsets of lymphocytes were gated and analyzed for binding of biotinylated DBLMSP (blue 
trace) and DBLMSP2 (pink trace). Percentages of gated lymphocytes positive for DBLMSP (middle 
panel) or DBLMSP2 (lower panel) binding are shown. Gates were set using the Cd4-d3+4 control 
(upper panel).  Data is representative of one of three repeat experiments. 
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Figure 4.9 Quartile plots of variation in DBLMSP and DBLMSP2 binding to gated lymphocytes. 
Percentage of gated lymphocytes positive for DBLMSP or DBLMSP2 (n=3) are shown.  Values are 
depicted as upper quartile, median and lower quartile (boxes) with minimum and maximum ranges.  
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Figure 4.10 Individual domains of DBLMSP do not bind to lymphocytes. DBLMSP proteins are 
composed of Duffy-binding like (DBL) and secreted polymorphic antigen merozoite (SPAM) 
domains. To investigate which domain of the DBLMSP proteins mediated interactions with 
lymphocytes, normalised amounts of biotinylated DBL and SPAM domains were incubated with 
freshly isolated PBMCs and sequentially labelled with anti-biotin-APC and FITC-labelled Abs 
specific for human CD4, CD8, CD19, and CD56. The binding of DBL and SPAM domains of 
DBLMSP (shown as blue trace) and DBLMSP2 (shown as pink trace) to gated lymphocytes were 
assessed by flow cytometry. Neither DBL nor SPAM domains alone could bind to lymphocytes. Data 
are representative of one of three repeat experiments. 
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Although there was considerable variation in binding between donors, gated 
lymphocytes from all donors bound DBLMSP and DBLMSP2 but not the Cd4-d3+4 
control (Figure 4.7 & 4.8). Intriguingly, individual DBL or SPAM domains of 
DBLMSP and DBLMSP2 expressed in isolation were unable to bind IgM
+
 
lymphocytes (Figure 4.10). The fact that the DBL domains alone were unable to 
engage IgM
+
 lymphocytes supports the role of the SPAM domain in oligomerisation.  
Oligomerisation of the DBL domains in the full-length proteins may facilitate avidity 
interactions allowing DBLMSP/ DBLMSP2 to bind to IgM on lymphocyte surfaces.  
There was also consistent binding of hIgM to CD14
+
 monocytes (Figure 4.11A), and 
of the DBLMSP proteins to the monocytic cell population (Figure 4.11B), although 
this binding is likely to be mediated via an alternative IgM binding receptor as the 
debate regarding the expression of hFcµR by monocytes remains controversial 
137, 179, 
180, 235, 288
.  
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Figure 4.11 DBLMSP and DBLMSP2 bind to monocytic cells (A) Individual CD14
+ 
monocytes 
stained with anti-human CD14-APC Cy7 were gated (shown by blue dots, left panel). Binding of 
exogenous hIgM (black trace) to or cell surface levels of hIgM on cell surfaces (dotted trace) on gated 
CD14
+
 monocytes were detected using F(ab’)2-anti-human IgM-RPE (right panel). (B) To investigate 
whether DBLMSP proteins bind to monocytic cells, monocytic cell population was gated based on 
forward (FSC) and side (SSC) scatter profiles of PBMCs (shown by blue dots, left panel). Binding of 
normalised biotinylated DBLMSP (blue trace) or DBLMSP2 (pink trace) to monocytic cells was 
detected using anti-biotin-APC (right panel). Data are representative of three repeat experiments.  
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4.3.6. DBLMSP and DBLMSP2 per se do not induce proliferation or apoptosis of 
human lymphocytes 
Recent studies have suggested that chronic P. falciparum exposure induces immune 
dysfunction among B and T cell responses that may explain why immunity to 
malaria is slow to develop 
289
. Immune dysfunction may include non-specific 
proliferation 
290
 and/or increased apoptosis 
291
 of immune cells. Since human 
lymphocytes, and B cells in particular, were shown to bind DBLMSP and DBLMSP2 
we hypothesised that DBLMSP and DBLMSP2 may induce lymphocytes to 
proliferate or to undergo programmed cell death by apoptosis. Neither recombinant 
DBLMSP nor DBLMSP2 per se had any observable proliferative or apoptotic 
inducing functionality when co-cultured in the presence of human PBMCs (Figure 
4.12 & 4.13, respectively). Similar results were obtained if DBLMSP or DBLMSP2 
were complexed with IgM or coated directly to the surface of culture wells prior to 
incubation to with PBMCs to facilitate cross-linking of surface receptors (see 
appendix III; Figure A1). 
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Figure 4.12 DBLMSP and DBLMSP2 do not induce cellular proliferation of lymphocytes. 
Purified CellTrace
™
 Violet-labelled PBMCs from malaria-naive individuals were co-cultured with 
varying concentrations of his-tagged DBLMSP (pink trace) or media only (grey trace). CellTrace
™
 
Violet dilution of gated lymphocytes was examined five days post-incubation by flow cytometry. 
DBLMSP did not induce proliferation of gated CD4
+ 
(upper panel), CD8
+ 
(middle panel), or CD19
+
 
(lower panel) lymphocytes but was induced by the positive control, PHA (black trace). Similar results 
were observed with DBLMSP2 and Cd4-d3+4 control (data omitted for clarity). Data are 
representative of one of four repeat experiments.  
 
 
 
 
 
CD4+ 
CD8+ 
CD19+ 
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Figure 4.13 DBLMSP and DBLMSP2 do not induce apoptosis of lymphocytes. PBMCs were co-
cultured with 50μg/ml his-tagged DBLMSP, DBLMSP2, or Cd4-d3+4 control for 24hr and analyzed 
for apoptosis by Annexin V and 7-AAD staining on gated lymphocyte populations. Apoptosis of 
lymphocytes are calculates as percentage of Annexin V
+
7-AAD
-
 (early apoptosis), Annexin V
+
7-
AAD
+
 (late apoptosis), or Annexin V
-
7AAD
+ 
(dead) cells. Dot plots from one of three independent 
experiments are shown. 
 
 
 
116 
 
 
4.3.7. DBLMSP per se do not inhibit proliferation of human lymphocytes 
FcμR has been previously implicated in enhanced B cell survival and proliferation 
following BCR cross-linking 
138, 292
. Since the malaria proteins did not seem to 
initiate proliferation or apoptosis of PBMCs, it remained to be determined whether 
the binding of the malaria proteins to lymphocytes could function to inhibit cellular 
proliferation. For this, DBLMSP was preincubated with phytohaemagglutinin (PHA) 
or the TLR-9 agonist CpG ODN 2006 (CpG) for the induction of cellular 
proliferation of T cells and B cells, respectively, and then co-cultured in the presence 
of PBMCs.  Preliminary data showed inhibition of cellular proliferation of 
CD4
+
/CD8
+
 T cells and CD19
+
 B cells with saturating concentrations of DBLMSP 
but not Cd4-d3+4 (Figure 4.14). However, repeat experiment using two additional 
donors and further titrations of the recombinant proteins revealed a dose-dependent 
but protein non-specific inhibitory effect, owing to the inhibition observed at 
saturating concentrations of DBLMSP and Cd4-d3+4 (Figure 4.15).  
Similar results were observed when DBLMSP was complexed to hIgM (Figure 4.16; 
upper panels). To our surprise, high concentrations of hIgM were also shown to 
inhibit the proliferation of CD4
+
/CD8
+
 T cells and CD19
+
 B cells (Figure 4.16; 
middle panels). The specificity of IgM-mediated inhibition was confirmed in 
subsequent experiments, as proliferation of T cells and B cells was inhibited in a 
dose-dependent manner with cells co-cultured with high concentrations of hIgM but 
not BSA (see Chapter 6). 
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Figure 4.14 Saturating concentrations of DBLMSP appeared to inhibit proliferation in one 
donor. To investigate whether DBLMSP functions to inhibit cellular proliferation of T cells and/or B 
cells, varying concentrations of his-tagged DBLMSP or control protein Cd4-d3+4 were incubated 
with 5μg/ml PHA or 1μg/ml CpG for 30 min at 4˚C. CellTrace™ Violet-labelled PBMCs were then 
cultured for 5 days in media alone (grey filled trace) or with PHA (5μg/ml), CpG (1μg/ml), or 
PHA/DBLMSP, PHA/Cd4-d3+4, CpG/DBLMSP, and CpG/Cd4-d3+4 mixtures.   Cellular 
proliferation of gated lymphocytes was investigated by flow cytometry. Saturating concentrations 
(500μg/ml) of DBLMSP (pink trace; upper panel) resulted in the inhibition of PHA-induced 
proliferation of CD4
+
 and CD8
+
 T cells, whereas slight inhibition was observed with Cd4-d3+4 (green 
trace; upper panel). Additionally, slight inhibition of CpG-induced proliferation of CD19
+
 B cells by 
DBLMSP was observed at saturating concentrations (pink trace; upper panel). These effects were not 
observed at a lower concentration (50μg/ml), indicating that inhibition of cellular proliferation by 
DBLMSP was dose-dependent for this donor (n=1).  
 
 
 
 
 
 
118 
 
 
 
 
 
Figure 4.15 Inhibitory effect of DBLMSP is non-specific. To further investigate the ability of 
DBLMSP to inhibit cellular proliferation, the inhibition assay described above was repeated in 
another two donors and the concentrations of DBLMSP and Cd4-d3+4 his-tag proteins were further 
titrated. In these experiments, inhibition of PHA-induced proliferation of CD4
+ 
and CD8
+
 T cells, and 
CpG-induced proliferation of CD19
+
 B cells was observed for DBLMSP and Cd4-d3+4 at saturating 
concentrations (500μg/ml; top panels). This effect was dose-dependent, but not protein-specific, as the 
inhibitory effect decreased with decreasing protein concentrations (250μg/ml and 50μg/ml; middle 
and lower panels, respectively). Data are representative of two repeat experiments.   
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Figure 4.16 IgM/DBLMSP immune complexes inhibit cellular proliferation at saturating 
concentrations. Saturating concentrations of the IgM/DBLMSP complex (pink trace; upper panel), 
when co-cultured with PHA or CpG (5μg/ml and 1μg/ml, respectively), induce inhibition in gated 
lymphocytes. Co-culture of IgM with stimulants also initiated inhibition of cellular proliferation 
(purple trace; middle panel). IgM alone did not induce proliferation (aqua trace; lower panels). 
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4.3.8. Immunoglobulins bind stimulants 
A striking finding was that hIgM inhibited cellular proliferation of stimulated 
lymphocytes (Figure 4.16). IgM molecules are heavily mannosylated, and the ability 
of oligomannose residues of hIgM to bind lectins, such as mannose-binding lectin 
(MBL), has been well characterised 
168, 293
. Therefore, a possible explanation for the 
observed inhibition of proliferation by hIgM could be that IgM binds directly to 
PHA, and subsequently prevents their interaction with cellular receptors. 
To test this hypothesis, the ability of human immunoglobulins (Ig) to bind various 
stimulants, including PHA, CpG, lipopolysaccharide (LPS) and pokeweed mitogen 
(PWM), was assessed by ELISA. As seen in Figure 4.17, a variety of stimulants 
bound human Igs. There was significant binding of PWM to human IgM, IgG, and 
IgA, with two-fold binding of IgM to PHA compared to IgG. IgM also bound PHA 
and LPS significantly. For hIgA, significant binding was observed with PHA and 
CpG. There was no significant binding of IgG to PHA, CpG, and LPS, when 
compared to the control (PBS) (Figure 4.17).   These results show that PHA, LPS 
and PWM bind hIgM, which may account for the results observed in Figure 4.16. 
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Figure 4.17 Immunoglobulins bind various stimulants by ELISA. The binding of coated 
stimulants (10μg/ml) to different Ig isotypes (10μg/ml) was detected using mouse anti-human Ig-HRP 
Abs specific for each Ig isotype. The mean ± SD for three replicates are shown (n=3). Significant 
differences were determined using a paired t-test, in which binding of Igs to stimulants was compared 
to binding to PBS: *p <0.05, ** p <0.01, and *** p <0.001. 
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4.3.9. IgM exists in complex with DBLMSP/DBLMSP2 and other unidentified 
parasite molecules 
One possible explanation for the lack of an observed effect of recombinant DBLMSP 
and DBLMSP2 per se may be that these proteins associate with other merozoite 
surface proteins during culture or in vivo that were not available in the functional 
assays with the recombinant proteins investigated here. For example, it is known that 
MSP3, MSP6, and MSP7 associate non-covalently with MSP1
294
. 
Therefore, IgM was immunoprecipitated from culture supernatants isolated from 
long-term P. falciparum ITGvar1 and ITGvar13 parasite cultures, or from negative 
controls without parasite, and their reactivity with DBLMSP-specific Abs (Figure 
4.18A; left panel) or Malawian (malaria) immune sera (Figure 4.18A; right panel) 
was determined. A ~100kDa band corresponding to native DBLMSP could be 
detected with an anti-DBLMSP polyclonal Ab in the parasite cultures but not in the 
negative control (Figure 4.18A; left panel, boxed) consistent with previous 
observations 
149, 281
. Immune sera from Malawians recognised additional parasite 
antigens that are also found in complex with IgM (Figure 4.18A; right panel). These 
data were also extended to pull-down experiments with 3D7 parasites from which 
these DBLMSP proteins were originally cloned (Figure 4.18B).  Bands were 
observed at ~250kDa, 100kDa, 53kDa and 25kDa for IgM pull-downs from ITGvar1 
and ITGvar13 cultures (Figure 4.18A; right panel), and ~250kDa, 140kDa, 100kDa, 
80kDa, and 36kDa for IgM pull-downs from 3D7 culture (Figure 4.18B; right panel), 
which were not detected using non-immune sera. In these experiments, the detecting 
Ab appeared to cross-react with numerous other proteins present in the pull-down 
solution, including the heavy and light chains of IgM (Figure 4.18A; left panel). 
However, we identify suspected parasite proteins as bands that appeared for the 
parasite pull-down samples but not for the negative control. 
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Figure 4.18 Additional parasite proteins are present in the IgM-DBLMSP complex. P. 
falciparum strains ITGvar1, ITGvar13, and 3D7 were cultured in the presence of 10% human AB 
serum (Sigma-Aldrich). IgM was immunoprecipitated from culture supernatant using anti-human 
IgM-agarose beads and washed three times in PBS. Non-reducing and reducing buffer was added to 
the beads, which were boiled for 5 min prior to being run on a 4-12% Bis-Tris gel. Following transfer 
to nitrocellulose membrane by Western blotting, membranes were blocked, washed extensively and 
incubated with rabbit anti-DBLMSP/2-mAbs or with sera for 3hr at RT. After extensive washing, 
parasite proteins in immunoprecipitations were detected using anti-rabbit IgG-peroxidase (1:1000; 
Sigma-Aldrich) or anti-human IgG-AP (1:2000; Sigma-Aldrich). Parasite proteins (shown as *) were 
regarded as bands present for the parasite strains that were absent from the negative control (-). The 
anti-rabbit IgG (whole molecule) cross-reacts with hIgM (arrow = IgM heavy chain, @ = light chain), 
detecting Ab was only absorbed against human IgG not IgM. However, this provided a good internal 
control for protein loading. Negative controls cultures (-) were incubated as for ITGvar1, ITGvar13, 
and 3D7 but without parasites. Suspected bands for DBLMSP/2 are boxed. 
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Alongside the IgM-immunoprecipitations, we investigated whether the presence of 
these additional parasite proteins within hIgM-DBLMSP complex blocked 
interactions of hIgM to hFcμR. IgM from parasite culture supernatants was still able 
to bind hFcμR-transfected cell, suggesting that the presence of additional parasite 
proteins within the complex does not affect its interactions with hFcμR (Figure 4.19). 
Although these molecules remain to be identified, it does suggest that future 
experiments to determine the function of DBLMSP and/ or DBLMSP2 need to be 
undertaken with native material rather than with recombinant proteins alone, as the 
unidentified parasite proteins within complexes could initiate immunomodulatory 
effects such as the proliferation or apoptosis of lymphocytes. 
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Figure 4.19 Parasite culture pull-down IgM can bind FcμR. Immunoblots were performed on P. 
falciparum 3D7 and ITGvar13 parasite culture supernatants to confirm presence of IgM. For this, 5μl 
culture supernatant was blotted onto nitrocellulose paper and allowed to dry, then blocked with 
PBST/5% milk powder for 1hr at RT. Following extensive washing, IgM was detected using mouse 
anti-human IgM-AP (1:5000 dilution).After confirming the presence of IgM in culture supernatants, 
50μl of culture supernatant (predicted to contain 5μg hIgM) from each strain was incubated with 
hFcμR-transfected cells for 1hr at 4˚C, washed labelled with F(ab’)2-anti-human IgM-RPE and 
analysed by flow cytometry. Binding of IgM isolated from 3D7 (aqua trace; left panel) or ITGvar13 
(yellow trace; right panel) parasite cultures, or human IgM alone (5μg; black trace) are shown as 
overlays (n=2). 
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4.3.10. Molecular dynamic simulation of the IgM/FcμR/DBLMSP interaction 
A working atomic model of the IgM/DBL interaction was recently characterised 
100, 
135
. Based on this structure, we investigated whether a physically plausible model of 
the IgM/FcμR/DBLMSP interaction could be produced that might provide insight 
into the results generated in this chapter.  
A homology model of DBLMSP was generated using the known structures of 
members of the DBL family 
196, 295
, for which there is a high sequence similarity. 
This was used to build the IgM/FcμR/DBLMSP, alongside the previous model for 
IgM 
135
 and hFcμR (Chapter 3). 
The binding of two DBLMSP proteins (maximally) to a single IgM monomer (within 
the pentameric or hexameric complex) severely restricts the potential binding sites on 
IgM for the FcμR. Furthermore, the fact that glycans are not required for this 
interaction and the likely involvement of two IgM domains (Cμ2/Cμ4 or Cμ3/Cμ4) 
(shown in Chapter 3) also provides constraints on these binding sites. Inspection of 
the IgM/DBLMSP model showed that the interface of Cμ3/Cμ4 is completely buried 
by the DBLMSP domains (Figure 4.20A). The N-linked glycosylation sites were 
positioned away from the predicted DBLMSP binding site, potentially explaining the 
findings that glycosylation of IgM did not affect DBLMSP binding (Figure 4.4).  
As the FcμR interaction with IgM does not completely prevent DBLMSP interaction 
with IgM (Figure 4.5), we thus reasoned that FcμR contacts the Cμ2/Cμ4 interface 
(Figure 4.20B), similar to a type I engagement of Ab-receptor interactions 
244
. In this 
orientation, CDR loops of the FcμR Ig-like domain completely cover the Cμ2/Cμ4 
interface, resulting in a partial occlusion of one of the DBLMSP domains (Figure 
4.20B & Figure 4.21). Such an occlusion is not extensive (involving only 5% of the 
residues in the DBLMSP and 16% in the FcμR Ig-like domain), and so would be 
expected to only perturb, but not completely prevent, the simultaneous association of 
DBLMSP and FcμR with IgM, as was observed experimentally (Figure 4.5). A 
similar association of dimeric FcμR with this Cμ2/Cμ4 interface also shows partial 
overlap with the DBLMSP (34% of the residues in the DBLMSP and 16% the FcμR 
Ig-like domain)(Figure 4.20C & Figure 4.21).  
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Figure 4.20 (A) Model of the interaction between IgM-Fc and two DBLMSP proteins, shows 
DBLMSP (shown in teal) can engage IgM-Fc principally via the Cμ4 domain (shown in green), and 
partially via the Cμ3 domain (shown in blue). N-linked glycans sites are depicted as van der Waals 
spheres (shown in orange), which are positioned outside of the IgM-DBLMSP binding site. The box 
depicts the predicted binding site of hFcμR. The interaction between the DBL domain of DBLMSP 
(shown in teal) and IgM-Fc (as in A) is also shown, in which hFcμR (shown in magenta) is depicted as 
monomer (B) or as a dimer (C). Note that in this orientation, there are residues within the Ig-like 
domains of hFcμR which occlude the DBLMSP proteins (shown as salmon spheres). The model 
suggests that DBLMSP proteins are able to engage IgM bound to hFcμR as a monomer or dimer, 
which occurs outside the glycosylated regions of IgM-Fc.  
 
A) 
B) 
C) 
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Together with the structural data presented in Chapter 3, we show here that is it 
physically viable for IgM-DBLMSP complexes to interact with hFcμR. This supports 
the experimental findings that the binding of DBLMSP and DBLMSP2 to IgM does 
not completely block subsequent interactions with the receptor. 
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4.4. Discussion 
DBLMSP and DBLMSP2 are two newly characterised P. falciparum-encoded 
proteins which avidly bind non-immune hIgM via their DBL domains, in order to 
mask immunogenic antigens on merozoite surfaces from humoral immune 
recognition 
146
. However, whether these proteins perform additional functions is 
unknown. In this chapter, we show that DBLMSP and DBLMSP2 bind the same 
domain of hIgM as recognised by hFcμR, but do not completely block interactions 
between hIgM and hFcμR. In fact, full-length DBLMSP and DBLMSP2 were able to 
engage IgM
+
 lymphocytes, but did not cause any biological consequences per se. 
This was possibly owing to the fact that additional parasite proteins are present in the 
DBLMSP-IgM complex. 
In order to investigate why P. falciparum express IgM-binding proteins on merozoite 
surfaces, we first sought to confirm how these proteins recognise hIgM. The 
expression of the individual DBL and SPAM domains of DBLMSP and DBLMSP2 
revealed that the DBL domain governs interactions with hIgM. A panel of domain-
swap Abs 
120
 confirmed  the Cμ4 domain of hIgM as the target of DBLMSP and 
DBLMSP2, as previously described 
146
. In addition to the Cμ4 domain, the presence 
of the Cμ3 domain in domain-swap Abs significantly enhanced binding of DBLMSP 
and marginally enhanced binding of DBLMSP2 to IgM. Numerous PfEMP1 variants 
bind non-immune IgM via their DBL domains 
118, 120
, which also recognise the Cμ4 
domain of hIgM 
120
. This, together with the data presented here, highlights the 
potential importance of DBL domains in P. falciparum malaria and suggests that P. 
falciparum-encoded proteins utilise a conserved mechanism to bind non-immune 
hIgM. It will be of interest to explore the sequences of P. falciparum proteins which 
bind non-immune hIgM to see whether there are conserved sequences which govern 
this interaction. As the binding of non-immune hIgM by both PfEMP1 and DBLMSP 
variants has been implicated in the shielding of immunogenic epitopes from humoral 
immune responses 
146, 284
, the development of strain-transcending Abs which inhibit 
non-immune IgM-binding could be implicated in vaccine design to enhance vaccine 
efficacy.  
Given that DBLMSP and DBLMSP2 recognise the same domain of hIgM as hFcμR 
(see Chapter 3), we hypothesised that these proteins may have evolved to block 
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interaction of hIgM with hFcμR. To investigate this, the ability of hIgM preincubated 
with full-length recombinant DBLMSP proteins to hFcμR-transfected cells was 
assessed by flow cytometry. DBLMSP partially (~15-30%) inhibited hIgM binding 
to hFcμR, whereas DBLMSP2 had no effect on binding, suggesting that these 
malaria proteins bind to the same domain but not the same residues of IgM as 
hFcμR. Although not significant, the blocking effect could have implications in 
malaria immunity since hFcμR has previously been shown to enhance B cell survival 
and Ab responses 
137, 138, 182
. However, the effect of this partial blocking needs to be 
determined in vivo. In addition, as this effect was only observed at saturating 
concentrations, quantification of soluble DBLMSP in the periphery is required.  
Despite the observed inhibition, the majority of hIgM still bound to hFcμR 
suggesting that the function of these proteins is not to block IgM-hFcμR interactions.  
As the binding of DBLMSP to hIgM did not significantly inhibit subsequent 
interactions with hFcμR, we next investigated whether these proteins utilised cell-
surface IgM to bind to host cells. DBLMSP and DBLMSP2 bound to hIgM on 
hFcμR-transfected cells, whereas DBLMSP was found to consistently bind better to 
than DBLMSP2, possibly reflecting the difference in their affinity for IgM 
146
 or 
could signify that the proteins serve different biological functions during malaria 
infections. Similar results were observed for lymphocytes known to express hFcμR 
137
. Due to the high affinity interaction between hIgM and hFcμR, the majority of 
purified lymphocytes are opsonised in hIgM. We therefore investigated if DBLMSP 
and DBLMSP2 could interact with hIgM bound to immune cells, and found that 
these proteins were only able to bind to IgM
+
 lymphocytes. Strikingly, the majority 
of CD19
+
 B cells bound both DBLMSP and DBLMSP2, whereas less binding 
observed for CD4
+
/CD8
+
 T cells and CD56
+
 NK cells. One explanation for the high 
proportion of binding to CD19
+
 B cells includes the binding of DBLMSP to IgM
+ 
BCR as well hFcμR. DBLMSP and DBLMSP2 also bound to the monocytic cell 
population, previously shown to bind hIgM (Chapter 3). However, the identity of the 
subsets binding these proteins remains unidentified, as does the receptor to which 
they bind. We also observed considerable variation in DBLMSP binding between 
donors, most likely owing to differential expression of hFcμR and/or surface levels 
of hIgM on lymphocytes. To confirm this, additional experiments should investigate 
whether the binding of DBLMSP to lymphocytes correlates with hFcμR expression. 
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In addition, lymphocyte subsets which bind these malarial proteins should be 
identified as disturbances in B cell homeostasis has been reported in P. falciparum 
infections 
296, 297
. Regardless of donor variation, lymphocytes isolated from each 
donor bound recombinant full-length DBLMSP and DBLMSP2 but not the control 
protein, signifying the specificity of this interaction.  To our knowledge, this is the 
first report of the conserved binding of malaria proteins binding directly to B cells, T 
cells, and NK cells. 
Despite the fact that the DBL domains of DBLMSP and DBLMSP2 govern binding 
to hIgM 
146
, these domains alone were insufficient to permit binding to IgM
+ 
immune 
cells that express hFcμR. As the SPAM domain has been implicated in 
oligomerisation of DBLMSP and DBLMSP2 
146
, as well as in MSP3 
276
, it is possible 
that monomers of DBL domains do not generate sufficient avidity to interact with 
hIgM on hFcμR. This supports previous data which showed the affinities of 
DBLMSP and DBLMSP2 for IgM were decreased ~200- to 550- fold in the absence 
of the SPAM domain 
146
. The requirement of oligomerisation for receptor binding 
has also been proposed for other DBL-containing proteins such as EBA-175 and 
PvDBP 
147
. Therefore, it is possible that oligomerisation of DBLMSP and DBLMSP2 
is a prerequisite for ligand recognition.  Hodder et al. hypothesised that dimerisation 
via the SPAM fragments would orientate two DBL domains in a parallel fashion; 
however the presence of a flexible linker region between the DBL and SPAM 
fragments could permit variations in DBL orientation 
147
. Resolving the crystal 
structure of full length DBLMSP and/or DBLMSP2 will help clarify how the SPAM 
domain could permit oligomerisation of these proteins.  
In addition to hFcμR, DBLMSP and DBLMSP2 also interacted with hIgM bound to 
DC-SIGN. Since our previous research identified glycan residues on hIgM as the 
ligands for DC-SIGN 
136
, we wished to determine if DBLMSP and DBLMSP2 
utilised glycans for hIgM binding. The removal of glycans did not block the binding 
of these proteins to hIgM, but rather marginally enhanced binding, possibly owing to 
the fact that the glycans are confined to the non-Ag binding face of hIgM due to its 
barrel-like structure 
169
. The removal of glycans could therefore facilitate interactions 
between the DBLMSP proteins and the Cμ4 domain that were previously restricted 
due to steric hindrance. Together this data suggests that DBLMSP engage hIgM via 
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residues outside of the glycosylation regions, which may help to characterise how 
these proteins are able to interact with IgM bound to receptors such as hFcμR or DC-
SIGN.  As interactions between blood stage Plasmodium parasites and dendritic cells 
(DCs) are pivotal for priming adaptive immune responses against malaria 
298
, and 
since DBLMSP and DBLMSP2 do not bind the glycans recognised by DC-SIGN, it 
is tempting to speculate that these proteins may have evolved to permit interactions 
of merozoites with DCs. Since these malaria proteins do not appear to be involved in 
erythrocyte invasion, it may be more likely that they have evolved to interact with 
other cell types. This area requires further research to determine whether these 
proteins can bind to hIgM on DC cell surfaces, and what the consequence of this 
binding may be. 
Immune dysregulation is characteristic of P. falciparum infections 
123
. Since a high 
proportion of CD19
+
 B cells bound DBLMSP and DBLMSP2, we hypothesised that 
binding of these proteins to hFcμR and/or IgM+ BCR could induce cross-linking of 
receptors resulting in downstream effector functions, such as proliferation or 
apoptosis. This hypothesis supports previous findings that hFcμR initiates signalling 
pathways through conserved tyrosine and serine residues in its cytoplasmic tail 
137, 
140
. Although DBLMSP and DBLMSP2 bound to IgM
+ 
lymphocytes, the proteins did 
not induce proliferation or apoptosis of CD19
+
 B cells, CD4
+
/CD8
+
 T cells, nor 
monocytic cell populations. However, P. falciparum culture pull-downs revealed that 
additional parasite proteins were also complexed to hIgM, possibly explaining why 
the use of recombinant DBLMSP and DBLMSP2 alone did not generate any 
functional effects per se in these experiments.  
The finding that numerous parasite proteins immunoprecipitated with hIgM supports 
the hypothesis that merozoite surface proteins are able to form complexes 
294
. 
Parasite proteins of ~250kDa, 100kDa, 53kDa, and 25kDa from ITGvar1 and 
ITGvar13 long-term cultures, and ~250kDa, 140kDa, 100kDa, 80kDa, and 36kDa 
from 3D7 long-term cultures, were isolated using IgM pull-downs.  The observed 
band at ~100kDa was predicted to be the DBLMSP proteins, since it was of the 
correct corresponding MW, and anti-DBLMSP Abs identified a band of similar MW 
(Figure 4.18A; right panel). Although the identity of the additional proteins remain to 
be determined, immunoprecipitations using anti-MSP142 Abs captured proteins of 
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similar MW and identified them as two putative RAP proteins (~110 and 22kDa) and 
RhopH3 (~50kDa) by mass spectrometry 
294
. As RhopH3 and RAP proteins have 
been implicated in parasite invasion of RBCs 
294, 299
, future research should aim to 
identify the additional parasite proteins by mass spectrometry, and investigate 
whether these proteins exist in complex with or can bind directly to IgM. 
Another reason why the binding of recombinant DBLMSP to lymphocytes produced 
no functional effects could be owing to the use of non-native forms of the proteins. 
Hodder et al. identified two forms of DBLMSP and DBLMSP2; a mature form of 
corresponding MW to the full-length proteins (~75 and 100kDa, respectively), and a 
~25kDa shorter protease-cleaved processed form 
147
. The mature form was found in 
the culture supernatant of saponin-treated 3D7-infected erythrocytes, supporting the 
hypothesis that these proteins are present in the periphery, whereas the processed 
form was confined to the cell pellet 
147
. They speculated that the unprocessed forms 
which are not incorporated into the merozoite membrane may act as immuno-decoys 
in the periphery to generate inappropriate immune responses 
147
. However, 
confirmation is required to confirm the presence of the mature or processed forms of 
DBLMSP in the periphery, and determine whether they form complexes with hIgM.  
It will be of interest to repeat the functional assays with the processed form of 
DBLMSP and DBLMSP2 to see whether similar results are obtained. 
Experiments investigating whether DBLMSP initiated inhibition of proliferation in 
lymphocytes produced some unexpected results. Inhibition of cellular proliferation 
was observed at saturating concentration with DBLMSP and the control protein Cd4-
d3+4, and thus was attributed to a protein-loading effect. When investigating whether 
DBLMSP needed to be complexed to hIgM to initiate inhibition, high concentrations 
of IgM-DBLMSP complexes were observed to promote inhibition, as did saturating 
concentrations of hIgM. IgM is heavily mannosylated, and the ability of the 
oligomannose residues of hIgM to bind lectins such as mannose-binding lectin 
(MBL) has been well characterised 
168, 293
. Therefore, an explanation for the observed 
inhibitory effect could be that IgM directly binds to the stimulants and thus prevents 
their interaction with cellular receptors. In support of this hypothesis, we observed 
significant binding of hIgM not only to PHA but also to PWM and LPS, but 
interestingly not CpG. LPS is an integral structural component of the outer 
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membrane of Gram negative bacteria, and potently induces innate immune responses 
through interactions with several host proteins 
300
. Therefore, it is conceivable to 
speculate that the binding of hIgM to LPS is specific (e.g. Fab-mediated) and results 
from immunity to previous bacterial infections. This explanation cannot be extended 
for the binding of hIgM to PWM and PHA, since these are lectins found in plants.  It 
is tempting to propose that IgM binds to PHA and PWM in a glycan-dependent 
manner. Repeating these experiments with endoglycosidase-treated IgM could help 
clarify the role of glycans in mediating binding of stimulants to IgM. These results 
are significant as they suggest that binding of stimulants by Igs should be considered 
for functional assay design.  
Finally, the atomic model of the IgM/FcμR/DBLMSP interaction provided a physical 
means to explain the experimental data generated in this chapter. This model was 
built using the DBL domains of DBLMSP, which predicted maximal binding of two 
DBL domains to a single IgM monomer. As the oligomerisation status of full-length 
DBLMSP and/or DBLMSP2 is unknown, solving the crystal structure of these 
proteins will clarify how oligomerisation may influence the binding of DBL domains 
to pentameric IgM. Moreover, since IgM was found to immunoprecipitate from 
parasite cultures with numerous malaria proteins, the modelling should be updated 
once the identity of these additional malaria proteins is revealed to investigate how 
these proteins exist within the IgM/FcμR/DBLMSP. Future studies could adopt this 
model to investigate whether other IgM-binding malaria proteins can engage IgM on 
hFcμR, such as PfEMP1. 
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Chapter 5: Production of recombinant DBLMSP 
and DBLMSP2 
5.1. Literature review 
5.1.1. Role of the SPAM domain in oligomerisation 
The expression of a SPAM domain is a key feature of the MSP3 gene family 
148
. 
McColl et al. initially designated the polymorphic antigen MSP3 as the “secreted 
polymorphic antigen associated with merozoite” (SPAM) 266. Analysis of the 
sequence encoding MSP3 revealed alanine heptad repeats in the N-terminus and a 
conserved glutamic acid-rich C-terminus featuring a leucine zipper-like sequence 
266
. 
This C-terminal was shown to be conserved in more than 100 P. falciparum field 
isolates from different geographical locations 
301
.  Further analysis revealed that 
additional merozoite surface proteins shared similarities in the structural organisation 
of their C-terminal regions 
148
. These proteins were grouped to form the MSP3-like 
gene family, which include MSP3 (MSP3.1), MSP6 (MSP3.2), H101 (MSP3.3), 
DBLMSP (MSP3.4), H103 (MSP3.7) and DBLMSP2 (MSP 3.8) 
148
.  The highly 
conserved C-terminus of the MSP3-gene family members was subsequently 
designated as the SPAM domain 
148
. Common features of the SPAM domain of 
MSP3-like family members include: 
 Glutamic acid-rich region 148 
 Leucine zipper-like sequence 147, 148 
 No GPI anchor 147, 266 
 
Relatively little is known about the function of the SPAM domain. The C-terminal 
regions of the MSP3-like family members elicit cross-reactive Abs capable of 
generating Ab-dependent cellular inhibition (ADCI) of parasite growth, highlighting 
their potential as vaccine candidates 
148
. MSP3 has also been shown to form highly 
elongated oligomers via its C-terminal region 
276, 302
. It was hypothesised that 
oligomer formation of MSP3-like proteins may permit long-distance interactions 
with erythrocyte receptors 
147, 276
. In support of this, transmission electron 
microscopy and immuno-staining revealed that MSP3 formed self-assembled 
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filamentous structures on merozoite surfaces that associated with erythrocyte 
membranes 
302
.  Furthermore, MSP3 oligomerisation was recently proposed to confer 
a protective role for the parasite by binding to, and potential detoxifying, free haem 
in the periphery 
302
.  Intriguingly, a peptide region outside  the SPAM domain of 
MSP3 (192-196 aa; YILGM) may also mediate oligomer formation 
302
. Whether this 
region is a feature of the other MSP3-family members remains to be determined. 
5.1.2. SPAM domain of DBLMSP and DBLMSP2 
DBLMSP and DBLMSP2 feature a single SPAM domain in their C-termini 
147, 149
. 
Due to the similarities with the C-terminal region of MSP3, these SPAM domains 
were predicted to mediate oligomerisation of these  DBLMSP proteins 
147
. A recent 
study which characterised DBLMSP and DBLMSP2 as IgM-binding proteins 
confirmed the ability of these proteins to form high molecular weight oligomers 
146
.  
Individual DBL fragments were eluted as a single monodispersed peak by size 
exclusion chromatography, signifying monomer formation. In contrast, the C-
terminal region of DBLMSP and DBLMSP2 composed of the SPAM and coiled-coil 
domains (SPAM fragment) exhibited a polydispersed elution prolife, consistent with 
tetramer and higher order complex formation 
146
. Furthermore, full-length DBLMSP 
and DBLMSP2 proteins exhibited similar elution profiles to the individual SPAM 
fragments, suggesting that these also form higher-order oligomers via their C-
terminus 
146
. Curiously, the absence of the SPAM fragment in recombinant proteins 
reduced the binding affinity of DBLMSPs for IgM. Full length DBLMSP and 
DBLMSP2 interacted with IgM with very high equilibrium binding constants (Kd = 
0.3 and 1.1 nM, respectively), thought to reflect the overall binding avidity due to the 
multimeric nature of both IgM and DBLMSPs 
146
. However, monomeric DBL 
fragments of DBLMSP and DBLMSP2 bound IgM at 60nM and 600nM, 
respectively, signifying a 200- to 550-fold reduction in binding. As the SPAM 
fragment does not directly bind IgM, these weaker binding constants were proposed 
to result from a reduction in overall avidity since the DBL fragments could no longer 
oligomerise via the SPAM fragments. These data show the important role that the 
SPAM fragments play, not only in the oligomerisation of DBLMSP and DBLMSP2, 
but also how they enhance the binding of these proteins to IgM. 
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In Chapter 4, the function of the SPAM fragment in oligomerisation was supported 
by the findings that the DBL fragments alone were insufficient to mediate binding to 
IgM
+
 lymphocytes. This signifies that the SPAM fragments are essential for this 
interaction, and therefore play an important role in mediating binding of malarial 
proteins to host receptors. It will be of interest to further characterise the role of the 
SPAM fragment in DBLMSP and DBLMSP2, as it may be possible to harvest its 
oligomerisation function for therapeutic advantage. For example, hexa-Fc is an 
oligomeric Fc-scaffold which was recently developed to enhance binding of IgG to 
low-affinity receptors, such as the human neonatal FcR, through avidity interactions 
136
. Fc-fusions are well-established as therapeutics 
303
, and the hexa-Fc was proposed 
as a template Fc-fusion molecule which could be further engineered to create novel 
drugs and vaccines 
136
. As the C-terminal region of the MSP3-like protein family has 
been implicated in generating cross-reactive Abs 
148, 271
, and has been shown to be 
immunogenic 
148, 270
, the incorporation of target malarial antigens (e.g. RTS,S/AS01, 
Basingin) onto the SPAM domains of DBLMSP and/or DBLMSP2 could produce 
highly immunogenic chimeric malarial antigens which could be used in vaccine 
design to prime immune responses. Alternatively, SPAM domains alone may be 
sufficient for the induction of immunity.  By gaining further understanding of the 
SPAM domains of DBLMSP and DBLMSP2, future studies can harvest the potential 
of these fragments to generate highly efficient malaria vaccines. Whether the SPAM 
domain of DBLMSP and/or DBLMSP2 could also serve as a multimeric scaffold for 
drug and vaccine development is an exciting question.    
In addition to therapeutics, recombinant DBLMSP and DBLMSP2 proteins could be 
utilised for other applications. Owing to their high affinity for hIgM, these proteins 
could be coupled to agarose beads to be used for IgM purification. In support of this, 
the well-characterised IgM-binding protein MBL is frequently used for IgM 
purification 
168
, although it has the disadvantage of not being able to purify all glyco-
variants of IgM. This chapter aims to explore the oligomerisation status of DBLMSP 
and DBLMSP2 further, to ascertain how the SPAM domain may function to facilitate 
receptor binding. 
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5.2. Objectives 
This chapter aims to determine the role of SPAM fragments in DBLMSP and 
DBLMSP2. The specific objectives include: 
I. Produce full-length and DBL knock-out DBLMSP and DBLMSP2 
recombinant proteins 
II. Investigate the role of SPAM fragments in oligomerisation using recombinant 
DBL knock out proteins 
III. Explore the possibility of a novel IgM purification method using recombinant 
DBLMSP-coated agarose beads 
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5.3. Results 
5.3.1. Gene synthesis and mammalian expression vector construction 
It has been proposed that the linker region of DBLMSP and DBLMSP2 plays a role 
in the flexibility of oligomers 
147
. We therefore decided to create recombinant 
DBLMSP and DBLMSP2 proteins that lack the DBL domain (C = control) to further 
investigate the role of the SPAM domain in oligomerisation. Although individual 
SPAM domains had been looked at previously 
146
, these proteins (constructs) did not 
contain the flexible linker region which may influence the conformation and/or 
function of the proteins 
147
.  
The genes for variants of the DBLMSP and DBLMSP2 proteins from the P. 
falciparum 3D7 strain (PF10_0348 and PF10_0355, respectively) were synthesised 
by Life Technologies, with the addition of two c-myc tags, a 6-histidine tag and a 
kozak sequence at the N-terminus to initiate translation.  
Four new constructs were made (Life Technologies) using the mammalian 
expression vector pcDNA 3.1(+):  DBLMSP-FL (DBL + SPAM domains); 
DBLMSP-C (SPAM only); DBLMSP2-FL (DBL + SPAM domains); DBLMSP2-C 
(SPAM only) (see Appendix II for vector maps and sequences). The coding regions 
including the c-myc and histidine tags were flanked by BamHI and XhoI restriction 
enzyme sites. Potential N-linked glycosylation sequons were mutated in these 
chemically synthesised genes to prevent inappropriate glycosylation of Plasmodium 
proteins, and these genes also codon-optimised for mammalian expression.  
Restriction enzyme digests revealed bands that corresponded in predicted size to the 
four new constructs (Figure 5.1). Sequencing confirmed the correct insertion of 
DBLMSP-FL, DBLMSP-C, DBLMSP2-FL, and DBLMSP2-C into the mammalian 
expression vector pcDNA 3.1(+).  
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Figure 5.1 Diagnostic digest of mammalian expression vectors containing DBLMSP domains (A) 
Domain structures of DBLMSP and DBLMSP2 full-length and control (SPAM only) genes from the 
3D7 P. falciparum clone. (B) Restriction enzyme digests confirmed the presence of inserts coding for 
the DBLMSP (left panel) and DBLMSP2 (right panel) synthesised genes. The predicted size of the 
inserts are 2199bp and 1374bp for DBLMSP-FL and –C respectively, and 2373bp and 1542bp for 
DBLMSP2-FL and –C respectively. Lanes left to right: M – 1kb plus marker (NEB), FL – full-length 
insert, C – SPAM-only control. pUC19 DNA (Life Technologies) was used as a positive control. 
Bands observed at >2kb correspond to full-length (FL) inserts and bands between 1-1.5kb correspond 
to SPAM-only (C) inserts released by double digest (BamHI/ XhoI). The plasmid vectors are 
designated as pcDNA 3.1(+)DBLMSP-FL or –C, and pcDNA 3.1(+)DBLMSP2-FL or –C.  All 
constructs were analysed by Sanger sequencing (Source Bioscience) and the nucleotide sequences are 
shown in Appendix II.  
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5.3.2. Expression of pcDNA 3.1(+)-DBLMSP vectors in mammalian cells 
Mammalian expression systems were employed for the transient expression of 
recombinant DBLMSP proteins, as this approach has been shown to be successful 
146
. 
All four constructs were amplified by DNA maxiprep (Qiagen), resequenced, and 
transfected into Chinese Hamster Ovary (CHO-K1) cells using the FuGENE
®
 6 
transfection reagent (see section 2.2.2 for details). As DBLMSP and DBLMSP2 
proteins are expressed in a soluble form 
146
, culture supernatant was harvested after 
two weeks and tested for the presence of recombinant proteins. A pilot protein 
expression trial, using ELISA and immunoblotting in which anti-his Abs were used 
to detect the 6x histidine tag, revealed the lack of soluble recombinant DBLMSP-FL, 
DBLMSP-C, DBLMSP2-FL or DBLMSP2-C in culture media taken off the 
transfected CHO-K1 cells (Figure 5.2). 
The failure to detect protein in the pilot trial was thought to be due to insufficient 
yield. To resolve this issue, transfected CHO-K1 cells were expanded and seeded to 
select for high-expressing cell colonies. As shown in Figure 5.3, no protein 
expression was observed in any of the screened transfected CHO-K1 cell clones (n= 
20). Next, we sought to investigate whether an expanded polyclonal transfected cell 
culture contained detectable levels of recombinant proteins. For this, a c-myc column 
was used to purify proteins via the c-myc tags (Figure 5.4A).  A peak was observed 
at fractions A6-A10 for DBLMSP-FL (~170 mAU) and smaller peaks at fractions 
A4-A7 and A2-A6 for DBLMSP2-FL and DBLMSP2-C (~15 and ~17 mAU, 
respectively). The chromatogram revealed that there was no protein produced for 
DBLMSP-C, and therefore this sample was not used in subsequent analysis. To 
confirm the identity of these eluted proteins, 20μl of each fraction was resolved 
under reducing conditions by SDS-PAGE. The predicted MW of DBLMSP-FL, 
DBLMSP-C, DBLMSP2-FL and DBLMSP2-C were 84kDa, 52kDa, 91kDa and 
59kDa, respectively, as derived from the amino acid sequences submitted to 
ExPASY (http://web.expasy.org/compute_pi/). No bands were resolved by 
Coomassie staining for DBLMSP2-FL or –C, indicating that the protein quantities 
were too low to be detected by gel electrophoresis (Figure 5.4B). 
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Figure 5.2 Pilot expression of DBLMSP and DBLMSP2 in CHO-K1 mammalian cells. (A) The 
expression of recombinant protein and its ability to bind hIgM was tested by ELISA. 10μg/ml human 
IgM was coated to microtitre wells (Nunc) in carbonate buffer (pH9.6) overnight at 4˚C. The wells 
were washed and blocked with PBST/ 5% milk powder for 1hr at RT, washed four times with PBST 
and incubated for 2hr at RT with 100μl of culture supernatant, or 10μg/ml recombinant his-tag 
DBLMSP2 (kindly provided by Dr. Cecile Crosnier, Sanger Institute) as a positive control, in 
duplicate. Wells were washed and incubated with anti-his-HRP (1:2000) for 1hr at RT, washed again 
then developed with 100μl of the TMB substrate (Sigma-Aldrich). Absorbance was measured at 
450nm. The mean ± SD of duplicate reads is shown.  (B) Immunoblots of culture supernatant from 
transfected CHO-K1 cells. 5μl of culture supernatants were blotted onto nitrocellulose membrane and 
allowed to dry for 30 min. The presence of protein was detected using anti-his-HRP (1:5000). 
DBLMSP-H and media were used as positive and negative controls, respectively.  
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Figure 5.3 Screening transfected CHO-K1 cell clones for expression of DBLMSP and 
DBLMSP2. 20 cell colonies each of transfected CHO-K1 cells were seeded for DBLMSP-FL, 
DBLMSP-C, DBLMSP2-FL, and DBLMSP2-C. As similar results were observed for all colonies, 
only three from each cell line (#1-3) are shown for clarity. (A) The expression of recombinant protein 
and its ability to bind hIgM was tested by ELISA. 10μg/ml human IgM was coated in duplicate on 
microtitre wells (Nunc) in carbonate buffer (pH9.6) overnight at 4˚C. The wells were washed and 
blocked with PBST/ 5% milk powder for 1hr at RT, prior to washing with PBST and incubated for 2hr 
at RT with 100μl of culture supernatant, or 10μg/ml recombinant his-tag DBLMSP as a positive 
control. Wells were washed and incubated with anti-his-HRP (1:2000; Sigma-Aldrich) for 1hr at RT, 
washed and developed. Absorbance was measured at 450nm. The mean ± SD of duplicate reads is 
shown. (B) Immunoblots of culture supernatant from transfected CHO-K1 cells, which were 
developed using anti-his-HRP (1:5000). Recombinant his-tagged DBLMSP2 and media were used as 
positive and negative controls, respectively. 
145 
 
 
 
 
 
 
Figure 5.4 Small-scale purification of recombinant DBLMSP and DBLMSP2. (A) FPLC 
chromatogram showing the affinity purification of recombinant proteins (labelled) from 200ml 
polyclonal tissue culture supernatant using an anti-c-myc column. The blue line corresponds to eluted 
protein as determined by UV absorbance (OD 280nm) shown on the y-axis. The green line shows a 
linear increase in volume of 0.1M glycine (pH2) elution buffer. Fractions are shown in red on the x-
axis. (B) Following elution, 20μl of fractions corresponding to peaks on chromatograms were 
separated under reducing conditions by SDS-PAGE and stained with Coomassie Brilliant Blue R-250 
(left panel) or transferred to nitrocellulose by Western blotting (right panel). Nitrocellulose 
membranes were blocked with PBST/5% milk powder for 1hr, washed extensively and incubated with 
anti-his-HRP (1:5000; Sigma-Aldrich) for 3hr at RT. Blots were developed to detect for the presence 
of his-tagged recombinant proteins. 
A) 
B) 
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Bands were detected at ~54kDa for DBLMSP-FL (fractions A9-A10) (Figure 5.4B), 
which did not match the predicted MW of this recombinant protein. To confirm the 
identity of these proteins, Western blots were performed with anti-his-HRP to detect 
for recombinant proteins. No bands were detected for any of the proteins, indicating 
that the ~54kDa bands identified by Coomassie staining were not DBLMSP-FL, and 
the identity of these proteins is unknown. 
Due to the lack of protein in the culture supernatants, transfected polyclonal CHO-
K1 cells were expanded in attempts to increase the quantity of recombinant protein in 
culture supernatants. For this, 1L of transfected CHO-K1 cell culture was cultured at 
37˚C for 21 days under selection prior to purification and/or protein expression trials. 
An ELISA confirmed the lack of protein expression (Figure 5.5). Therefore, despite 
numerous expression trials, no recombinant protein production was observed using 
the pcDNA 3.1(+)-DBLMSP vectors.  
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Figure 5.5 Large-scale purification of recombinant DBLMSP and DBLMSP2. The expression of 
recombinant protein and its ability to bind hIgM was tested by ELISA. For this, 5μg/ml or 1μg/ml 
human IgM was coated on microtitre wells (Nunc) in carbonate buffer (pH9.6) overnight at 4˚C. The 
wells were washed and blocked with PBST/ 5% milk powder for 1hr at RT, washed four times with 
PBST and incubated for 2hr at RT with 100μl of culture supernatant, or 10μg/ml DBLMSP-H as a 
positive control, in duplicate. Wells were washed and incubated with anti-his-HRP (1:2000) for 1hr at 
RT, washed again and then developed. Absorbance was measured at 450nm. The mean± SD of 
duplicate reads is shown. 
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5.3.3. Subcloning of DBLMSP fragments into a pFUSE mammalian expression 
vector 
As there was no detectable expression of recombinant proteins using the pcDNA 
3.1(+)-DBLMSP vectors, we decided to sub-clone DBLMSP-FL, DBLMSP-C, 
DBLMSP2-FL, and DBLMSP2-C DNA fragments into another mammalian 
expression vector. The pFUSE-hIgG1-Fc2 vector (InvivoGen) has previously been 
shown to produce high yields of recombinant proteins 
185
, and was therefore selected 
for sub-cloning. This vector features a IL-2 signal sequence at the 5’ end of the 
cloned insert, which enhances the secretion of novel recombinant proteins 
304
. 
As the pFUSE-hIgG1-Fc2 vector encodes for Fcγ–fusion proteins, which are 
unsuitable for use with lymphocytes owing to potential cross-reactivity with FcγRs, 
we designed a parking vector that lacks the Fcγ tag referred to as pFUSE- MCS (see 
Appendix II for vector map). To make this new vector, the hIgG1-Fc2 Fcγ insert was 
excised by restriction enzyme digestion (EcoRI/NheI) and replaced by a run of 
restriction sites, to create a multiple cloning site region only (pFUSE-MCS, 
synthesised by Eurofins). To isolate the DBLMSP-FL, DBLMSP-C, DBLMSP2-FL, 
and DBLMSP2-C inserts, restriction enzyme digests (BamHI/ XhoI) on the pcDNA 
3.1(+)-DBLMSP vectors were performed (Figure 5.6). 
The genes encoding DBLMSP-FL, DBLMSP-C, DBLMSP2-FL, and DBLMSP2-C 
were then subcloned into the pFUSE-MCS vector using the restriction enzyme sites 
BamHI and XhoI (Figure 5.7). All new constructs were confirmed by sequence 
analysis (Appendix II). Following unsuccessful miniprep screenings for all 
constructs, the same ligation mixture was retransformed into dam
-
/dcm
-
 competent E. 
coli cells (C2925, New England Biolabs) to improve transformation efficiency. 
Although we did not assess the methylation status of the inserts, dam
-
/dcm
-
 
competent E. coli cells are known to be more accepting of foreign DNA. 
Transformation efficiencies for pFUSE-MCS-DBLMSP2-FL and –C were 
significantly lower than those for pFUSE-MCS-DBLMSP-FL and –C, as more than 
75 minipreps were screened for each prior to the identification of vectors containing 
correct inserts (confirmed by restriction enzyme digestion and sequencing), whereas 
only  less than 10 minipreps were screened for the pFUSE-MCS-DBLMSP vectors.  
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Figure 5.6 Restriction enzyme digestion of DNA fragments from pcDNA 3.1(+)-DBLMSP 
vectors. DNA fragments were excised from the pcDNA 3.1(+) vectors by digestion with BamHI/ 
XhoI restriction enzymes. 5μl of each digest was run on a 1% agarose gel. The predicted size of the 
inserts are 2199bp and 1374bp for DBLMSP-FL and –C respectively, and 2373bp and 1542bp for 
DBLMSP2-FL and –C respectively. Bands were observed at >2kb and at ~1.5kb, corresponding to 
full-length (FL) and SPAM-only (C) DBLMSP and DBLMSP2, respectively.   
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Figure 5.7 Generation of pFUSE-MCS-DBLMSP mammalian expression vectors. Diagnostic 
digestions of miniprep DNA of pFUSE-MCS-DBLMSP vectors to confirm the presence of inserts 
coding DBLMSP-FL and –C, and DBLMSP2-FL and –C. The predicted size of the inserts are 2199bp 
and 1374bp for DBLMSP-FL and –C respectively, and 2373bp and 1542bp for DBLMSP2-FL and –C 
respectively. Bands at ~3kb correspond to the pFUSE-MCS vector backbone released by double 
digestion with BamHI/ XhoI. The number of miniprep DNAs screened before identification of a 
positive vector is shown in white (#), and each lane represents individual clones. Bands at >2kb and 
~1.5kb correspond to the FL- and C-DBLMSP fragments. Sequencing confirmed the generation of 
pFUSE-MCS-DBLMSP mammalian expression vectors (see Appendix II). The subcloning 
experiments were performed by Dr Pat Blundell. 
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5.3.4. Expression of pFUSE-MCS-DBLMSP vectors in mammalian cells 
After confirming that all cloned inserts were correct, the pFUSE-MCS vectors were 
amplified and transfected into CHO-K1 cells (see section 2.2.2). After 21 days under 
selection, the polyclonal transfected cell culture media was harvested and filter 
sterilised. Production of recombinant DBLMSP-FL and DBLMSP-C in culture 
supernatants was tested by SDS-PAGE and Western blotting with anti-histidine and 
anti-c-myc Abs, respectively (Figure 5.8). Despite numerous transfections, CHO-K1 
cells transformed with the pFUSE-MCS-DBLMSP2 vectors failed to grow. No 
protein was detected for either DBLMSP-FL or –C, as no bands were observed at the 
predicted MW for recombinant DBLMSP-FL and -C (~84kDa and 52kDa, 
respectively). Non-specific bands were observed at ~55kDa and ~78kDa for the anti-
histidine Western blots, and ~38kDa for the anti-c-myc Western blot, in all samples 
tested. The presence of these bands for the negative control signifies that the 
detecting Abs may be cross-reacting with unidentified proteins present in the culture 
supernatants. 
As protein production was unsuccessful in CHO-K1 cells, we next decided to 
transfect HEK293T mammalian cells as these cells have previously been shown to 
produce recombinant DBLMSPs 
146
. Protein expression trials of polyclonal 
transfected cell culture media revealed that transfected HEK293T cells did not 
secrete any recombinant protein (Figure 5.9). As there was no positive control 
available for the capture ELISA in Figure 5.9 (e.g. a protein containing both a c-myc 
and 6x histidine tag), an IgM-binding ELISA was used to confirm that the negative 
results in Figure 5.9 were due to lack of protein rather than a failure of the c-myc 
mAb to capture the recombinant proteins. However, no expression of the 
recombinant proteins was observed (Figure 5.10).   
Finally, whether the lack of protein expression was due to insoluble protein 
production was investigated. To confirm this, transfected HEK293T cells were lysed 
then probed for the presence of recombinant protein using Abs to detect the 6x 
histidine tag. As shown in Figure 5.11, there were no obvious differences between 
the control (HEK293T) and transfected HEK293T cells observed by Coomassie 
staining or Western blotting.  
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Figure 5.8 Protein expression trials of the pFUSE-MCS-DBLMSP vectors. The culture 
supernatant of CHO-K1 cells transfected with pFUSE-MCS-DBLMSP-FL and pFUSE-MCS-
DBLMSP-C were harvested following 21 days under selection. The presence of secreted recombinant 
DBLMSP-FL and DBLMSP-C was investigated following gel electrophoresis by Coomassie Brilliant 
Blue R250 staining (A) and Western blotting (B) with anti-his-AP (left panel) and anti-c-myc-AP 
(right panel) Abs. 
 
 
 
 
 
 
 
 
 
 
A) B) 
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Figure 5.9 Protein expression trials of the pFUSE-MCS-DBLMSP vectors in HEK293T cells. (A) 
A capture ELISA was used to screen for soluble recombinant DBLMSP protein production in 
transfected cell culture supernatants. For this, 10μg/ml anti-c-myc mAb was coated in duplicate onto 
wells of a microtitre plate (Nunc). Following overnight incubation in carbonate bicarbonate buffer 
(pH9.6), the wells were washed three times and blocked for 1hr in PBST/5% milk powder. After three 
more washes, 100μl of transfected cell culture supernatants were added to each well and incubated for 
3hr at RT, then extensively washed. To detect the presence of recombinant protein, anti-his-AP 
(1:5000) was added to wells for 3hr and then washed and developed. As a positive control, 10μg/ml of 
the recombinant his-tagged DBLMSP (DBLMSP-H) (kindly provided by Dr Cecile Crosnier, Sanger 
Institute) was also coated. The mean± SD of duplicate reads is shown. (B) Immunoblot analysis of 
transfected cell culture supernatant. 5μl of each culture supernatant was blotted onto nitrocellulose 
membrane and allowed to dry for 30 min. The membrane was blocked in PBST/5% milk powder for 
1hr, washed extensively and incubated with anti-his-AP Abs in PBST (1:5000).  
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Figure 5.10 IgM-binding ELISA to detect recombinant protein production in HEK293T cells. 
(A) A capture ELISA was used to screen for soluble recombinant DBLMSP protein production in 
transfected cell culture supernatants. 10μg/ml hIgM (Sigma-Aldrich) was coated in duplicate onto 
wells of a microtitre plate (Nunc) and incubated overnight in carbonate bicarbonate buffer (pH9.6). 
The wells were then washed three times and blocked for 1hr in PBST/5% milk powder. After three 
more washes, 100μl of transfected cell culture supernatants were added to the wells and incubated for 
3hr at RT, then extensively washed. To detect the presence of recombinant protein, anti-his-AP 
(1:5000) was added to the wells for 3hr, washed and developed. As a positive control, 10μg/ml 
recombinant his-tagged DBLMSP (DBLMSP-H) (kindly provided by Dr Cecile Crosnier, Sanger 
Institute) was also coated. The mean± SD of duplicate reads is shown. 
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Figure 5.11 Lysis of pFUSE-MCS-DBLMSP-transfected HEK293T cells. To determine whether 
recombinant protein was trapped intracellularly, HEK293T cells transfected with pFUSE-MCS-
DBLMSP-FL or -C, and pFUSE-MCS-DBLMSP2-FL or –C, or HEK293T cells alone were lysed. For 
this, cells (1x 10
6
) were harvested, washed and pelleted by centrifugation. Cells were then 
resuspended in 300μl of 1x NuPAGE reducing buffer (Life Technologies), and boiled for 5 min at 
95˚C. 20μl of this mixture was loaded into the wells of 4-12% Bis-Tris gels and proteins were 
separated by electrophoresis. Gels were either stained with Coomassie Brilliant Blue R250 (left panel) 
or transferred to a nitrocellulose membrane by Western blotting (right panel). The presence of 
recombinant protein on the membrane was detected using anti-his-AP (1:5000).  
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5.3.5. Subcloning of DBLMSP into pRSET bacterial expression vector 
Since numerous expression trials were unsuccessful in mammalian cells, we decided 
to sub-clone the DBLMSP inserts into a bacterial expression vector. The commercial 
expression vector pRSET EmGFP (Life Technologies) was selected for use as it 
contained compatible restriction enzyme sites to the DBLMSP inserts. To prepare the 
vector for sub-cloning, the GFP gene was removed by double digestion with BamHI/ 
XhoI. The linearised vector was then dephosphorylated and inactivated to prevent re-
ligation, and purified by gel elution (Figure 5.12).   
The linear pRSET vector was ligated with BamHI/XhoI digested DBLMSP-FL, 
DBLMSP-C, DBLMSP2-FL, and DBLMSP2-C inserts at a 1:3 ratio. The resulting 
cloning vectors are referred to as pRSET-DBLMSP-FL, pRSET-DBLMSP-C, 
pRSET-DBLMSP2-FL, and pRSET-DBLMSP2-FL. Five microliters of each ligation 
mix was transformed into TOP10 competent E. coli cells (see section 2.1.7). Despite 
numerous attempts, transformation efficiencies were very low, as only pRSET-
DBLMSP-C was successful (Figure 5.13). To resolve this issue, the same ligation 
mix was transformed into dam
-/
dcm
-
 competent bacteria (C2925). Positive clones for 
pRSET-DBLMSP-FL, pRSET-DBLMSP2-FL, and pRSET-DBLMSP2-FL were 
identified by restriction enzyme digestion and sequence analysis (Figure 5.14).  
5.3.6. Expression of pRSET-DBLMSP vectors in BL21Star (DE3) E. coli  
After confirming the presence of the cloned inserts by sequencing, the pRSET-
DBLMSP vectors were amplified and transformed into BL21Star (DE3) E. coli cells 
using the heat-shock technique (section 2.1.7). Following transformation, small 
protein expression trials were initiated. For this, starter cultures of transformed cells 
were grown to mid-log phase (OD600= 0.3-0.4) prior to initiating transcription with 
1mM IPTG, as previously described 
147
.  
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Figure 5.12 Digestion and linearisation of the pRSET EmGFP bacterial expression vector. The 
pRSET vector was double digested with BamHI/ XhoI restriction enzymes to release the green 
fluorescence protein (GFP) gene, shown as the lower band at ~738 bp. The upper band at ~2862 bp is 
the linearised pRSET vector backbone. 
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Figure 5.13 Transformation of TOP10 competent E. coli with pRSET-DBLMSP-C bacterial 
expression vector. pRSET-DBLMSP-C was transformed into TOP10 E. coli cells and incubated 
overnight at 37˚C on LB-ampicillin plates. Bacterial colonies were screened for the presence of the 
DBLMSP-C insert by restriction enzyme digestion (BamHI/XhoI) and agarose gel electrophoresis. 
Positive colonies were amplified and sent for sequencing. Colonies with the correct sequence are 
shown as # in lane 1.  The subcloning experiments were performed by Dr Pat Blundell. 
 
  
 
Figure 5.14 Generation of pRSET-DBLMSP mammalian expression vectors in dam
-
/dcm
-
 
competent E. coli cells. Ligation mixes were transformed into dam-/dcm- cells following failed 
transformation into TOP10 E. coli. Colonies were screened for the presence of DBLMSP inserts in 
pRSET-DBLMSP vectors by restriction enzyme digestion (BamHI/XhoI) and agarose gel 
electrophoresis. Positive colonies were amplified and sent for sequencing. Colonies with the correct 
sequence are shown as #, and correspond to lanes 1, 3, and 1 for DBLMSP-FL, DBLMSP2-FL, and 
DBLMSP-C, respectively.  The subcloning experiments were performed by Dr Pat Blundell. 
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Initial protein expression trials focussed on DBLMSP-FL and –C, as the growth of E. 
coli transformed with pSRET-DBLMSP2-FL and pSRET-DBLMSP2-C. As the 
recombinant proteins were predicted to form insoluble inclusion bodies, the cells 
were lysed by sonication and boiling in reducing buffer. The expression of 
recombinant protein was determined by Coomassie Brilliant Blue staining and 
Western blotting (Figure 5.15), which showed no obvious differences between the 
non-induced and induced samples for either pRSET-DBLMSP-FL or pRSET-
DBLMSP-C. Furthermore, striking similarities were observed between DBLMSP-FL 
and DBLMSP-C (Figure 5.15, left panels). Bands of ~30kDa were observed in lane 2 
for the non-induced and induced samples of DBLMSP-C (Figure 5.15B, left panel), 
which do not correspond to the predicted MW of DBLMSP-C (52kDa). This is most 
likely due to cross-reactivity of the detecting Ab, as previously observed in Figure 
5.11.    
Subsequent protein trials were performed with pRSET-DBLMSP-FL/-C and pRSET-
DBLMSP2-FL/C vectors. In these experiments, the BL21Star (DE3) E. coli were 
also transformed with the pRSET-EmGFP original vector (see Appendix II for map) 
to investigate whether the GFP tag could be expressed, which has a predicted MW of 
27kDa 
305
. Expression of the GFP tag would indicate that the vector is sufficient for 
protein production, therefore confirming that the issues with recombinant protein 
expression are specific for the DBLMSP genes. In addition, protein expression was 
initiated with 1mM IPTG (1mM), which was incubated with cells for a longer period 
(6hr), to assess whether this had an effect on expression. As shown in Figure 5.16, 
there was expression of the GFP tag (lane A, highlighted with a black box) at 
~30kDa but no expression of recombinant DBLMSP-FL/C or DBLMSP2-FL/C. 
Together, these results indicate that bacterial expression of recombinant DBLMSP 
proteins was unsuccessful. 
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Figure 5.15 Small-scale protein production in BL21Star (DE3) E. coli. pRSET-DBLMSP-FL and 
pRSET-DBLMSP-C transformed E. coli were grown to mid-log phase (OD600 = 0.3-0.4). 1mM IPTG 
was used to initiate protein expression. Induced and non-induced cells were incubated for 3hr at 37˚C 
in a shaking incubator, and pelleted by centrifugation. The cells were resuspended in 40μl of 1x 
NuPAGE reducing buffer (Life Technologies), and boiled for 5 min at 95˚C. 5μl of this mixture was 
loaded into the wells of 4-12% Bis-Tris gels and visualised by Coomassie Brilliant Blue R250 staining 
(left panels) or Western blotting (right panels) with anti-his-AP Abs (1:5000). A total of five 
transformations were screened for each protein (lanes 1-5; non-induced and induced). No expression 
of recombinant DBLMSP-FL (A) or DBLMSP-C (B) was observed.  
 
A) 
B) 
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Figure 5.16 Protein expression trials of transformed BL21Star (DE3) E. coli. pRSET-EmGFP and 
pRSET-DBLMSP vectors transformed into E. coli  were grown to mid-log phase (0D600 = 0.3-0.4), 
prior to the addition of 1mM IPTG. Induced and non-induced bacteria were incubated for 6hr at 37˚C 
in a shaking incubator, and pelleted by centrifugation. The cells were resuspended in 40μl of 1x 
NuPAGE reducing buffer (Life Technologies), and boiled for 5 min at 95˚C. 5μl of this mixture was 
loaded into the wells of 4-12% Bis-Tris gels and visualised by Coomassie Brilliant Blue R250 
staining. Lanes are as follows: A- pRSET-EmGFP; B- pRSET-DBLMSP-FL; C- pRSET-DBLMSP-
C; D- pRSET-DBLMSP2-FL; E - pRSET-DBLMSP2-C. Expression of the GFP tag (~ 30kDa) is 
highlighted with a black box. Owing to the poor resolution of proteins from non-induced samples by 
Coomassie staining, a larger volume (>5μl) of mixture should be loaded onto gels in future expression 
trials. 
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5.3.7. Synthesis of the DBL fragments of DBLMSP and DBLMSP2 and sub-
cloning into pRSET bacterial expression vector 
The DBL domain of DBLMSP2 has been successfully cloned using bacterial 
expression systems 
147
. Owing to the extreme difficulty in production of the 
DBLMSP2 proteins, we investigated whether the presence of the SPAM domain was 
inhibiting the expression of recombinant DBLMSP and DBLMSP2. For this, 
bacterial expression vectors containing genes encoding only the DBL domains of 
DBLMSP and DBLMSP2 from the 3D7 P. falciparum strain were designed. The 
DBL domains were synthesised and cloned into the pFUSE-MCS parking vector 
(Eurofins, see Appendix II for plasmid maps and sequences), digested with 
restriction enzymes to confirm correct insertion (Figure 5.17A), and checked by 
sequencing. The inserts were subcloned into the pRSET vector, which was linearised 
and dephosphorylated. The resulting vectors are referred to as pRSET-DBLMSP-
DBL and pRSET-DBLMSP2-DBL, which were confirmed by sequencing (Figure 
5.17B). 
5.3.8. Expression of pRSET-DBL vectors in BL21Star (DE3) E. coli  
The pRSET-DBLMSP/2-DBL vectors transformed into BL21Star (DE3) E. coli. 
Starter bacterial cultures were grown to mid-log phase, then grown for a further 6hr 
at 37˚C in a shaking incubator, in the presence or absence of 1mM IPTG. Protein 
expression was determined by Coomassie Brilliant Blue R250 staining and Western 
blotting. Western blot analysis revealed expression of the GFP tag (~30kDa) but not 
of the recombinant DBLMSP-DBL or DBLMSP2-DBL (Figure 5.18, right panel). 
No obvious differences were observed by Coomassie staining (Figure 5.18, left 
panel).  These results indicate that bacterial expression of the DBL domains was 
unsuccessful.   
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Figure 5.17 (A) Digestion and linearisation of the pRSET EmGFP bacterial expression vector. 
The pFUSE-MCS-DBLMSP/2-DBL vectors were double digested with BamHI/ XhoI restriction 
enzymes to release the genes encoding the DBL domains of DBLMSP and DBLMSP2, shown above 
as the lower band at ~800 and ~830bp, respectively. The upper band at >3000bp is the linearised 
pFUSE-MCS vector backbone. (B) Generation of the pRSET-DBLMSP-DBL and pRSET-
DBLMSP2-DBL vectors. DBL inserts were subcloned into the pRSET vector linearised with 
BamHI/XhoI. The resulting pRSET-DBLMSP/2-DBL vectors were transformed into TOP10 E. coli 
cells and incubated overnight at 37˚C on LB-ampicillin plates. Bacterial colonies were screened for 
the presence of the DBL inserts by restriction enzyme digestion (BamHI/XhoI) and agarose gel 
electrophoresis. The upper bands represents the linearise pRSET vector (>3000bp) and the lower 
bands represent the DBLMSP/2-DBL inserts. Positive colonies were amplified and checked by 
sequencing. Colonies with the correct sequence are shown as #. The subcloning experiments were 
performed by Dr Pat Blundell. 
B) 
A) 
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Figure 5.18 Expression of recombinant DBL domains of DBLMSP and DBLMSP2. pRSET-
EmGFP and pRSET-DBLMSP/2-DBL vectors transformed E. coli were grown to mid-log phase 
(OD600= 0.3-0.4), prior to the addition of 1mM IPTG. Induced (+) and non-induced (-) cells were 
incubated for 6hr at 37˚C in a shaking incubator, and pelleted by centrifugation. The cells were 
resuspended in 40μl of 1x NuPAGE reducing buffer (Life Technologies), and boiled for 5 min at 
95˚C. 5μl of this mixture was loaded into the wells of 4-12% Bis-Tris gels and visualised by 
Coomassie Brilliant Blue R250 staining (left panel) or Western blotting using anti-his-AP (1:5000) 
(right panel). The Western blot reveals expression of the GFP tag (~30kDa) but not of the 
recombinant his-tagged DBL domains of DBLMSP and DBLMSP2.  
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5.3.9.  Analysis of possible explanations for failed protein expression 
The recurrent failure to produce recombinant protein via mammalian and bacterial 
systems led us to investigate possible explanations for this lack of protein expression. 
In the mammalian expression systems, our genes in two different plasmids (pcDNA 
3.1(+) and pFUSE-MCS), and in two different cell lines (CHO-K1 and HEK293T) 
could not generate recombinant protein. There are several factors which can 
influence protein expression in mammalian systems, including the presence of the 
Kozak consensus sequence 
306
, signal peptide sequences 
304
, and fusion partners 
307, 
308
. The Kozak sequence (A/GxxATGG) was identified as the optimal sequence for 
initiation by eukaryotic ribosomes 
306, 309
. Reanalysis of the synthesised gene 
sequences revealed that the Kozak sequence used here (ACCATGA; Appendix II) 
contained an adenine (A) at position-6 rather than a guanine (G; A/GxxATGG), 
possibly as a result of codon-optimisation. Base substitutions in the positions 
surrounding the ATG initiation codon can modulate its function 
306
, therefore, the 
substitution of an A for a G at position-6 could affect the efficiency of translation, 
potentially offering one explanation for the lack of recombinant protein expression 
observed.  
Sakamoto et al. offered an alternative explanation by suggesting the possibility of 
RNA polymerase spillage at AT-rich areas in plasmodium genes, which may induce 
potential frameshifts during the transcription stage 
281
. They identified three regions 
of adenine-repeat sequence areas of the dblmsp gene at positions 701-707bp, 1363-
1370bp and 1871-1875/ 1901-1909bp, which were subject to site-directed 
mutagenesis during plasmid construction 
281
. Using the assumptions described 
previously for the identification of adenine-repeat areas 
281
, we characterised six 
adenine-repeat regions (≥7 adenines) in the gene encoding DBLMSP2 (PF10_0355), 
as shown in Figure 5.19.  However, analysis of the cloned inserts showed that these 
areas had been removed by codon-optimisation (see Appendix II). Sequence analysis 
revealed that the overall A-T content for the cloning inserts used in this chapter were 
~46% (Table 5.1), thus this does not offer an explanation as to why DBLMSP2 was 
more difficult to produce.  
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Figure 5.19 Schematic diagram of the adenine-repeat regions of DBLMSP2. Six vertical lines 
show the adenine-rich sites of the dblmsp2 gene; 10 consecutive adenines (305-314bp); 7 consecutive 
adenines (918-924bp); 7 consecutive adenines (1085-1091bp); 7 consecutive adenines (1191-1197bp); 
8 consecutive adenines (1342-1349bp) and 7 consecutive adenines (1404-1410bp). These regions 
were removed from the cloned inserts used in this chapter by codon-optimisation.  
 
 
 
 
 
Table 5.1 Analysis of the A-T content of genes encoding DBLMSP and DBLMSP2. Counts of 
adenine (A) or thymine (T) base pairs were taken from the cloned inserts between the BamHI/ XhoI 
restriction enzyme sites. Percentage of A+T and G+C were calculated using the equation: (A+T or 
G+C counts/ total bp) x 100.  
 
Genes Base pairing 
Counts  
(total bp) 
Percentage of total 
bp (%) 
DBLMSP-FL 
A+T 1013 (2187) 46.3 
C+G 1174 (2187) 53.7 
DBLMSP2-FL 
A+T 1090 (2373) 45.9 
C+G 1283 (2373) 54.1 
DBLMSP-C 
A+T 646 (1374) 47 
C+G 728 (1374) 53 
DBLMSP2- C 
A+T 712 (1542) 46.2 
C+G 830 (1542) 53.8 
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Another factor contributing to the successful expression of recombinant proteins in 
mammalian cells is the use of a fusion partner. Fusion proteins have long been 
adopted for enhancing expression and solubility of recombinant proteins, in 
particular in prokaryotic expression systems which lack folding and chaperone 
machinery 
308
. In mammalian systems, Fc regions of Abs and human serum albumin 
have been shown to enhance expression levels 
308, 310
. Therefore, the difference in 
successful protein expression using the pFUSE-hIgG1-Fc2 and pFUSE-MCS could 
be due to the presence of the Fcγ-fusion partner in the former vector. However, this 
remains to be determined. 
Expression of the genes encoding DBLMSP fragments in the bacterial expression 
vector was also unsuccessful. Initially, we hypothesised that the removal of the 
fluorescent protein sequence (209-928bp) from the pRSET-EmGFP may have 
cleaved the ribosome binding site (RBS), which would affect initiation of 
transcription. However, further analysis revealed the RBS to be upstream of the 
6xhis tag at base pair position 76-81 (Life Technologies, personal communication).  
As the genes were codon-optimised for mammalian expression, the failed expression 
of recombinant DBLMSP proteins in contrast to the GFP tag could be due to 
suboptimal codon selection. 
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5.4. Discussion 
The SPAM domain of MSP3-family proteins has been implicated in allowing the 
formation of oligomers 
276
. Since the SPAM domains of DBLMSP and DBLMSP2 
were shown to oligomerise 
146
, we sought to clarify whether DBLMSP and 
DBLMSP2 proteins lacking DBL domains (C= control, SPAM only) could also form 
high molecular weight oligomers, to clarify the potential involvement of regions 
outside of the SPAM domains in oligomerisation of these proteins. 
To achieve this, we tried to produce full-length and SPAM-only recombinant 
DBLMSP and DBLMSP2 proteins. Mammalian expression systems were initially 
used, as this system was adopted by Crosnier et al. to generate recombinant 
DBLMSP and DBLMSP2 
146
. However, protein expression trials using the pcDNA 
3.1(+)-DBLMSP vectors were unsuccessful. To determine whether this issue was 
due to vector selection, inserts were subcloned into the pFUSE-hIgG1-Fc2 vector 
which has previously been shown to produce high yields of protein 
185
. Furthermore, 
expression of the DBL domains only had been successful using this vector (Shona 
Moore, personal communication). Despite numerous expression trials using two 
mammalian cell lines (CHO-K1 and HEK293T), we were unable to generate 
recombinant protein using this vector. Protein trials with cell lysate indicated that the 
lack of expression in HEK293T cells was not due to issues with protein secretion. 
These results were somewhat confounding, especially as the DBL domains were 
generated using identical methods. However, an adapted version of the pFUSE-
hIgG1-Fc2 vector was used here (pFUSE-MCS) in which the sequence encoding the 
Fcγ tag was removed. This could contribute to the efficiency of protein expression, 
as Fcγ tags have been shown to dramatically increase the expression of recombinant 
proteins 
308
.  Intriguingly, a review of the previously published data on DBLMSP 
and/or DBLMSP2 protein expression showed that the majority of studies omitted the 
native plasmodium signal peptide in cloning procedures 
147, 149, 281
. Whether the 
native signal peptide can affect protein expression in mammalian/ bacterial systems 
remains to be determined. Therefore, future protein expression trials could be 
repeated following cleavage of the native signal peptide from the dblmsp genes to 
clarify its role in protein expression. 
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Due to the failed expression in mammalian systems, we next sought to investigate 
whether these proteins could be produced via bacterial expression systems, similar to 
those used by Hodder et al. However, we were unable to express full-length, SPAM 
only, or DBL-only domains of DBLMSP and DBLMSP2 
147
. The expression of the 
GFP tag in bacteria was successful, suggesting that the issues with protein expression 
were governed by the inserts rather than the cloning vector. As discussed in section 
5.3.9, the most likely explanation for the failed protein expression in bacterial 
systems was codon-optimisation for mammalian cells, and therefore subsequent 
experiments should be repeated with genes codon-optimised for bacterial systems or 
use a commercial E. coli strain that contains rare tRNAs such as Rosetta.  
The production of DBLMSP2 was significantly more problematic compared to 
DBLMSP, as both mammalian and bacterial cells transfected with vectors containing 
DBLMSP2 were either slow growing or completely failed to grow. This observation 
was also confirmed for the DBL domain of DBLMSP2 produced by expression in the 
pFUSE-hIgG1-Fc2 vector (Shona Moore, personal communication). Sequence 
analysis of the dblmsp2 gene revealed that codon-optimisation had removed 
numerous AT-rich regions which may have cause RNA polymerase spillage. 
Therefore, the stunted growth of the DBLMSP2-containing constructs in both 
mammalian and bacterial cells suggests that this gene is toxic to cells. Possible 
methods to resolve this issue include the use of lower incubation temperatures (25-
30˚C) or repeating transformations with E. coli strains or vectors which exert tighter 
transcriptional control over the gene of interest.  
Only one laboratory has been successful in expressing full-length DBLMSP and 
DBLMSP2 to date 
146
. This success may have been due to the use of a more 
sophisticated cloning vector, the identity of which is currently unknown, or the use of 
bioreactors for large-scale protein production 
311
. In addition, this study utilises the 
mouse variable K light chain leader sequence and a rat Cd4 domain 3 and 4 tag 
(Cd4-d3+4), both of which have been implicated in enhanced protein production 
188-
190
. There is plenty of scope for building on the protein production techniques used in 
this chapter. For example, subcloning inserts into expression vectors previously 
shown to generate recombinant DBLMSP proteins, improving signal peptide 
sequences or fusion partners, or the upscale of protein production through the use of 
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bioreactors. Unfortunately, limitations in time and resources prevented us from 
pursing these potential avenues. 
The aim of this chapter was to determine the role of the SPAM domain in 
oligomerisation via the production of recombinant SPAM-only proteins. However, 
the present data indicates that full-length and SPAM-only recombinant DBLMSP 
and DBLMSP2 cannot be produced by the methods mentioned above. In addition to 
optimizing protein expression techniques, future studies could perform mRNA 
analysis to resolve whether the lack of protein expression was due to issues in the 
transcription or translation of the cloned inserts.  
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Chapter 6: Investigating the function of hFcμR 
6.1. Literature review 
6.1.1. Function of FcμR 
The biological consequences of IgM binding to hFcμR remain unclear. However, 
genetically altered mice lacking FcμR (FcμR-/-) have provided an insight into the 
function of this receptor. FcμR-deficiencies in mice resulted in significantly elevated 
serum IgM levels 
138
, altered differentiation of B cells 
292
, and increased production 
of autoAbs with age 
312
. Furthermore, FcμR-/- B cells were sensitive to apoptosis 
induced by B cell receptor (BCR) activation, suggesting that FcµR mediates 
enhanced B cell survival and proliferation following BCR cross-linking 
138, 292
. The 
effect of FcμR on immune responses has also been investigated using knockout mice 
models, which revealed that FcμR ablation resulted in reduced Ab responses to 
thymus independent (TI) and thymus dependent (TD) antigens 
138
. In addition, 
reduced Ab responses were accompanied by reduced germinal centre formation in 
FcμR-deficient mice immunised with TD antigen 138. Together, the data implicates 
murine FcμR in generation of immune responses, IgM homeostasis, and in the 
negative regulation of autoimmunity. 
6.1.2. Expression of human FcμR 
Although insights have been made into the function of FcµR in mice, differential 
expression of the receptor in mice and human poses the question whether the 
receptor serves a different function(s) in humans. In mice, FcμR is expressed on B 
cells but not T cells, dendritic cells and macrophages, whereas human FcμR is 
expressed on adaptive immune cells including B cells, T cells and at low densities on 
NK cells 
137
. The finding that overnight incubation of PBMCs in serum-free media 
enhanced the expression of hFcμR indicates that exogenous levels of IgM may 
influence the expression of the receptor 
137
. T cells were particularly susceptible to 
enhancement, and the effect was more prominent for tonsillar and splenic 
lymphocytes compared to blood lymphocytes 
137
.   
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Cellular activation was shown to influence FcμR expression. B cell stimulants PMA 
and anti-μ mAb promoted a ~2.2-fold increase in cell-surface hFcμR expression after 
24hr, whereas PMA or anti-CD3 mAb treatment of T cells reduced the expression of 
hFcμR by ~90% after 24-72hr 137. Murakami et al. supported these findings and 
concluded that interleukin (IL)-2 induced downregulated hFcμR expression on T 
cells and NK cells in a dynamic and reversible process 
140
. Furthermore, they found 
hFcμR expression on CD4+ T cells was downregulated through TCR activation, 
which supported the observation of lower receptor expression on effector and 
memory T cells when compared to naive T cells 
140
. However, this study used mouse 
IgM as a ligand for hFcμR owing to its increased binding ability 140. Therefore, these 
results should be viewed with caution as mouse IgM could induce alternative effector 
mechanisms, possibly owing to structural and biochemical differences between 
mouse and human IgM. Future studies should therefore focus on using human IgM to 
resolve the function of hFcμR. The expression of hFcμR in chronic lymphocytic 
leukaemia (CLL) cells was dramatically down-regulated within 24hr following 
culture with the toll-like receptor (TLR)-7 agonist imiquimod and the TLR9 agonist 
CpG-ODN 
183
. The contrasting effect of stimulation on hFcμR expression between B 
cells and T cells could be due to the receptor performing differential functions on 
these cells. 
An intriguing finding was that hFcμR expression was selectively overexpressed on 
malignant B cells in CLL disease 
178
. CLL is a malignancy of IgM
+ 
IgD
+
 mature B 
cells which are poly-reactive and are resistant to Fas-mediated apoptosis, although 
the mechanisms governing this resistance are unknown 
313, 314
. The mechanisms 
involved in CLL ontogeny are unclear, however Ag-stimulation has been proposed 
as a key pathway for CLL cell expansion 
315
. Given that BCR stimulation was found 
to increase the expression of hFcμR on CLL cells 137, 177, and the finding that BCR 
signalling influences hFcμR expression 137, the overexpression of hFcμR in CLL may 
be indicative of prolonged BCR activation 
183
. However, this remains to be 
determined. In addition to enhanced expression, serum titres of soluble FcμR 
(~40kDa) were also elevated in CLL patients, which strongly correlated with blood 
lymphocyte counts 
313
.  Healthy donors did not exhibit increased serum titres of 
soluble FcμR, which identified a soluble form of FcμR encoded by a FCMR splice 
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variant. CLL B cells and non-CLL B cells, but not T cells, secrete ~40kDa soluble 
FcμR 313. The significance of soluble FcμR in CLL disease remains unknown. 
6.1.3. Function of human FcμR 
The overexpression of hFcμR in CLL cells was initially associated with resistance to 
Fas-induced apoptosis, as determined by gene ontology analysis 
178
. Subsequent 
studies investigated the role of hFcμR in protection for apoptosis, and revealed that 
isolated FcμR cDNA is identical to that of the previously described human Fas 
apoptotic inhibitory molecule 3 (FAIM3). Hitoshi et al. identified FAIM3 as a potent 
inhibitor of Fas/CD95-induced apoptotic signalling within activated T cells using a 
retroviral cDNA library-based functional assay 
316
. In contrast, Kubagawa et al. 
dismissed hFcμR role in the inhibition of Fas-induced signalling as inhibition of 
apoptosis was only observed when anti-Fas IgM (and not IgG) Abs were used 
137, 312
. 
Despite the controversy over the role of FcμR as an anti-apoptotic receptor, 
numerous studies have since discounted the role of hFcμR as an anti-apoptotic 
receptor 
137, 140, 312, 317
. 
The finding that serum levels of IgM are significantly raised in FcμR-/- mice implies a 
role for the FcμR in IgM homeostasis 138. Peritoneal B1 cell populations are 
considered a major source of IgM 
318
. However, as these populations were not 
expanded in FcμR-deficient mice, the elevated IgM levels are unlikely to be a 
consequence of increased IgM production.  Further, the expression of FcμR on B cell 
surfaces inversely correlated with serum levels of IgM. Intriguingly, serum IgM 
levels were unaltered in pIgR- and  Fcα/μR-deficient mice, signifying FcμR as the 
sole receptor modulating the homeostasis of IgM 
138
. Administered exogenous 
monoclonal IgM exhibited a similar half life in WT and FcμR-/-   mice, indicating that 
FcμR is not involved in maintaining the half-life of IgM in mice 138. Alternatively, 
the similar half-life may be owing to the down modulation of FcμR expression on B 
cells, as FcμR expression is sensitive to exogenous IgM levels 137. These similarities 
in half-life may indicate that FcμR is not involved in IgM clearance under steady-
state conditions, although it is feasible that the ligation of IgM-immune complexes to 
FcμR during immune responses could lead to their catabolism 138.  
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Figure 6.1 Schematic diagram depicting FcμR-mediated endocytosis of human IgM. The cross-
linking of FcμR by IgM induces rapid internalisation of FcμR-bound IgM. Within 60 min of 
internalisation, IgM is shuttled to lysosomes (represented as blue vesicle) via the endocytic pathway 
for degradation by hydrolytic enzymes (represented in navy blue) adapted from 
183. Since FcμR 
expression was dramatically down-regulated by TLR activation, it was hypothesised that FcμR may 
function to shuttle IgM-opsonised immune complexes to lysosomes where TLR activation may ensue 
183
.   
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Further studies are required to evaluate the role of IgM and FcμR during in vivo 
immune responses. 
Initial studies reported that HeLa cells expressing mouse and human FcμR 
internalised microbeads coupled with mouse IgM, suggesting human FcμR may also 
serve as an endocytosis receptor for IgM-opsonised antigens by B cells 
175
. The 
cross-linking of hFcμR on CLL cells by IgM results in the rapid internalisation of 
IgM, which occurred within 1 minute 
183
. Following internalisation, IgM is shuttled 
through the endocytic pathway to lysosomes, whereby IgM is proposed to be 
degraded 
183
, as depicted in Figure 6.1. Inhibition of clathrin-dependent endocytosis 
by phenylarsine oxide (PAO) decreased IgM internalisation by more than half, 
signifying that IgM internalisation by CLL cells is partially mediated by a clathrin-
dependent mechanism 
183
. In the absence of IgM, basal FcμR recycling and 
degradation from the plasma membrane is slow. Therefore, it is thought that FcμR 
does not recycle from membrane to the trans-golgi network (TGN) without ligation 
of natural ligand 
183
. A panel of FcμR deletion mutants revealed that internalisation is 
controlled by a YXXφ motif 183. Together, these results identify hFcμR as an 
endocytotic receptor for hIgM on B cells. 
Despite these insights into the effector functions of FcμR, there are still gaps in the 
current knowledge regarding the role of human FcμR. For example, it is not known 
how cellular activation or immune complex formation can affect the internalisation 
of IgM via hFcμR, or what characteristics of IgM are required for internalisation. 
This chapter confirmed the role of hFcμR as an endocytic receptor for IgM, and 
investigated what additional factors contribute to this mechanism. 
 
6.2. Objectives 
This chapter presents experiments that were done with the aim of determining the 
function of FcμR in humans. The specific objectives were: 
I. Investigate whether FcμR functions as an endocytic receptor for IgM 
II. Determine the requirements for  FcμR-mediated internalisation of IgM 
III. Characterise the expression of hFcμR on lymphocyte subsets 
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6.3. Results 
6.3.1. Human FcμR mediates endocytosis of IgM into FcR expressing cell lines 
The role for FcμR in the internalisation of IgM molecules has been highlighted 
previously 
183
. As this previous study focused on human FcR overexpressed on 
CLL cells, the ability of human FcμR to function as an endocytic receptor for IgM 
was investigated here by flow cytometry. 
The internalisation of IgM by FcR was assessed by flow cytometry as previously 
described with minor modifications 
183. Briefly, hFcμR-transfected cell lines were 
opsonised with hIgM and washed prior to incubation at 37
º
C to induce receptor 
internalisation. IgM internalisation into untransfected BW5147 T cell lines was also 
investigated, and the values of which were subtracted from the data obtained for the 
hFcμR-transfected cell lines. As shown in Figure 6.2, there was marked 
internalisation of IgM within 5 min of incubation at 37
º
C, with ~50% reduction of 
IgM levels on cell surfaces. Cell surface IgM was further internalised until ~30% of 
IgM remained on the surfaces following 1hr at 37
º
C (Figure 6.2). This data suggests 
that upon ligand binding, hFcμR rapidly internalises bound IgM. Similarities in 
internalisation dynamics between purified human IgM (Sigma-Aldrich) and human 
serum suggests that additional serum components are not necessary to mediate IgM 
internalisation (Figure 6.2B; p= 0.746). 
To determine if IgM-immune complexes were also internalised by hFcμR, hFcμR-
transfected cell lines were opsonised with heat-aggregated IgM prior to incubation at 
37
º
C.  Intriguingly, IgM-immune complexes (ICs) exhibited significantly enhanced 
binding and internalisation by hFcμR when compared to untreated IgM molecules 
(Figure 6.3 & Table 6.1), most likely owing to receptor cross-linking. The enhanced 
internalised of IgM-ICs suggests that hFcμR may play a role in the internalisation 
and presentation of immune complexes during immune responses.  
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Figure 6.2 Human FcμR mediates endocytosis of IgM. (A) Human FcμR-transfected cell lines were 
incubated with media alone (grey filled trace) or media supplemented with 15μg/ml purified hIgM 
(left panel) or 10% human serum (right panel) for 1hr at 4
º
C, followed by extensive washing at 4
º
C to 
remove unbound IgM. Subsequently, the cells were either left at 4
º
C (black filled trace) or incubated 
at 37
º
C for the indicated times. Internalisation was halted with the addition of ice-cold media and 
immediate incubation on ice for 10min. Cells were then washed and labelled with F(ab’)2-anti-human 
IgM-RPE for 1hr on ice to detect the presence of IgM bound to the cell surface, and analyzed by flow 
cytometry.  IgM mean intensity fluorescence (MFI) shown for indicated time points are representative 
of five independent experiments. (B) IgM cell surface levels (geometric MFI) assessed in (A) and 
normalised to time 0. The mean ± SD from five independent experiments is shown. Mann-Whitney 
test was used for the comparison of % IgM on cell surface (GMFI) values for human IgM and human 
serum. Statistically significance was regarded as p < 0.05. 
 
 
 
 
B) 
A) 
p= 0.746 
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Figure 6.3 FcμR-mediated internalisation of IgM immune-complexes. (A) hFcμR-transfected cell 
lines were incubated with media alone (grey filled trace) or media supplemented with 15μg/ml heat-
aggregated hIgM (IgM-IC) or hIgM for 1hr at 4
º
C, prior to incubation either at 4
º
C (black filled trace) 
or at 37
ºC for the indicated times. Cells were then washed, labelled with F(ab’)2-anti-human IgM-RPE 
for 1hr on ice, and analyzed by flow cytometry. Data shown are representative of three repeat 
experiments. (B) IgM cell surface levels (GMFI) indicate enhanced binding of IgM-IC to hFcμR-
transfected cell lines followed by rapid internalisation of IgM-IC.  The mean ± SD from three 
independent experiments is shown. 
 
 
Table 6.1 The P values for the difference in internalisation of no IgM, human IgM, or IgM-IC. 
Mann-Whitney tests for the comparison of IgM on cell surface (GMFI) values for no IgM, human 
IgM and IgM-IC. Significant results are shown as red (p < 0.05). 
 
P value Human IgM IgM-IC 
No IgM 0.002 0.002 
Human IgM  0.026 
 
A) 
B) 
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To confirm the role of hFcμR as an endocytosis receptor for IgM, we next attempted 
to monitor internalisation of FcμR. First, the expression of hFcμR on cell surfaces 
was assessed.  FcμR was found to be strongly expressed on hFcμR-transfected cell 
lines (Figure 6.4A), which was shown to co-localise with hIgM binding (Figure 
6.4B). No expression of hFcμR was observed on untransfected cell lines (Appendix 
III; Figure A2). Next, internalisation of FcμR was tracked using a commercially 
available anti-hFcμR mAb (Abnova). As shown in Figure 6.5, cell surface levels of 
hFcμR decrease upon incubation at 37ºC, supporting basal levels of internalisation of 
this receptor. However upon IgM binding, internalisation of FcμR was dramatically 
increased (Figure 6.5), FcμR levels were reduced ~50% within 1hr in the presence of 
exogenous IgM, compared to a ~25% reduction in the absence of exogenous IgM. 
This data supports the role of hFcμR as an endocytic receptor for IgM. 
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Figure 6.4 IgM binding co-localises with the expression of FcμR on cell surfaces. (A) hFcμR-
transfected cell lines were incubated with media in the presence (blue trace) or absence (grey trace) of 
1μg mouse anti-hFcμR mAb (Abnova) for 1hr at 4ºC, followed by extensive washing in ice-cold 
media and labelling with anti-mouse IgG-APC for 1hr at 4
º
C. Labelled cells were analyzed by flow 
cytometry. (B) IgM co-localises with hFcμR expression on cell surfaces.  For this, hFcμR-transfected 
cells were incubated in the presence or absence of 15μg/ml hIgM (shown as black or grey dots, 
respectively) prior to labelling with anti-hFcμR mAb, anti-mouse IgG-APC, and F(ab’)2-anti-human 
IgM-RPE. Co-localisation of hIgM and hFcμR on cell surfaces was then assessed by flow cytometry 
(n=2). 
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Figure 6.5 FcμR is internalised upon IgM binding. hFcμR-transfected cells were labelled with anti-
hFcμR mAb (1μg), washed, then incubated in the presence or absence of 15μg/ml hIgM (shown as 
black squares or white dots, respectively) for 1hr at 4
º
C. Internalisation assays were then performed as 
above. Following internalisation, cells were washed, labelled with anti-mouse IgG-APC and analysed 
by flow cytometry. Background values were removed from FcμR cell surface levels (GMFI) values, 
which were then normalised to time 0 for both samples. The mean ± SD of two experiments is shown.  
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6.3.2. Human IgM is internalised into human lymphocytes 
Since hIgM was internalised by hFcμR-transfected cells, IgM internalisation into 
lymphocyte subsets known to express FcμR was next investigated. For this, PBMCs 
were labelled with markers to differentiate B cells, T cells and NK cells (Figure 6.6). 
Surface levels of IgM on gated lymphocyte surfaces was detected by staining with 
F(ab’)2-anti-human IgM-RPE in the presence or absence of IgM (Figure 6.7). As 
lymphocytes were found to be purified with IgM on their cell surfaces (see Chapter 
3), internalisation of endogenous surface IgM was detected with the addition of the 
anti-human IgM-RPE Ab only (no IgM). 
As lymphocytes express a multitude of receptors, the binding of additional 
components in human serum (e.g. complement, lectins) to receptors expressed on 
lymphocyte surface could affect the internalisation of IgM. To determine if 
additional serum components affected internalisation, some assays were performed 
using both purified hIgM (Sigma-Aldrich) and human serum as a source of IgM. 
There was no significant difference in IgM internalisation between two IgM sources 
(Appendix III; Figure A3), and therefore human serum was used for subsequent 
internalisation assays.  
We then investigated IgM internalisation on lymphocyte subsets. As shown in Figure 
6.7, exogenous IgM was internalised into B cells, CD4
+
 and CD8
+ 
T cells, and NK 
cells following incubation at 37
º
C. For T cells, CD8
+
 subsets were shown to 
internalise IgM better than CD4
+
, with ~75% reduction in cell surface levels of IgM 
in CD8
+
 T cells within 5 min at  37
º
C compared to ~60% reduction in CD4
+
 T cells 
(Figure 6.7). In the absence of exogenous IgM, incubation at 37
º
C still initiates a 
reduction of cell surface IgM, albeit at a slower rate (~20% and ~18% vs. ~75% and 
60% reductions after 5 min for CD8
+
 and CD4
+
 cells, respectively). In NK cells, 
surface levels of IgM were reduced by ~85% within 5 min in cells incubated with 
human serum and ~25% in cells incubated with media alone (Figure 6.7). However, 
these values were highly variable between donors as reflected by the high error bars 
(Figure 6.7). B cells exhibit high levels of IgM on cell surfaces upon purification, 
likely owing to the expression of IgM
+
 BCR, which resulted in difficulty 
differentiating between IgM bound to FcμR and IgM+ BCRs. Despite this, there was 
a noticeable reduction in cell surface IgM levels upon incubation in cells incubated 
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Figure 6.6 Gating strategy for lymphocyte subsets expressing hFcμR. PBMCs were washed and 
labelled with 1uM LIVE/DEAD
® 
Aqua Dead Cell stain in PBS at 4
º
C for 30 min. Cells were washed 
and incubated with anti-human CD3-Brilliant Violet
™
 421, anti-human CD56-Alexa Fluor 700, anti-
human CD8-PerCp, and anti-human CD4-FITC for 1hr at 4
º
C. To differentiate B cells, LIVE/DEAD 
stained PBMCs were incubated with anti-human CD3-Brilliant Violet
™
 421 and anti-human CD19-
FITC. Labelled cells were washed extensively and analyzed by flow cytometry. Lymphocytes were 
gated from the PBMC population based on side (SSC) and forward (FSC) profiles, which was further 
gated into live cells based on LIVE/DEAD
®
 and FSC staining. Live cell population was further gated 
into B cells (CD3
-
CD19
+
), T cell (CD3
+
CD56
-
) and NK cell (CD3
-
CD56
+
) populations, and the T cell 
population was divided into CD4
+
 (CD3
+
CD4
+
) and CD8
+
 (CD3
+
CD8
+
) T cell subsets.  
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Figure 6.7 Internalisation of IgM on lymphocyte subsets.  PBMCs were washed and incubated 
with media alone or supplemented with human serum for 1hr at 4
º
C. Cells were extensively washed 
and incubated at 37
º
C for the indicated times to induce receptor internalisation, then washed 
extensively to remove unbound IgM. Cells were labelled with lymphocyte markers (see Figure 6.6) 
and analysed by flow cytometry. Surface levels of IgM on gated lymphocytes levels (geometric MFI) 
is represented assessed was assessed and normalised to time 0. The mean ± SD of four independent 
repeats is shown. 
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with human serum compared to those incubated with media alone (Figure 6.7). 
Together, these results suggest that exogenous IgM is rapidly internalised into B 
cells, T cells, and NK cells upon binding to hFcμR. 
6.3.3. IgM sialylation and internalisation 
The μ chain of IgM contains five N-linked glycosylation sites (see Figure 1.6), which 
are predominantly occupied by complex glycans terminating in sialic acid or 
galactose, or oligomannose glycans 
168
. In Chapter 3, we showed that de-
glycosylation of IgM did not affect its binding to hFcμR. However, a recent study 
depicted a role for sialylated N-linked glycans in the internalisation of human IgM by 
T cells 
286
. The authors of this paper hypothesised that hFcμR could bind sialylated 
IgM and mediate its internalisation.  
To clarify the role of glycans in IgM internalisation by hFcμR, N-linked glycans 
were initially removed from human IgM using PNGase F and neuraminidase (Figure 
6.8). De-glycosylation of IgM by PNGase F resulted in a decrease in MW of the IgM 
heavy chain (from ~62kDa to ~55kDa) and light chain (~25kDa to ~23kDa), and 
reductions in MW for the heavy chain with neuraminidase treatment (~62kDa to 
~60kDa), which signify the removal of glycans from IgM. Next, the ability of hFcμR 
to internalise de-glycosylated IgM was investigated by flow cytometry (Figure 6.9). 
De-glycosylation of IgM had no effect on its internalisation by hFcμR-transfected 
cells (Figure 6.9; p= 0.746), demonstrating that PNGase F or neuraminidase 
susceptible glycan(s), such as the N-linked or sialic acid-terminating glycans, do not 
contribute to the internalisation of IgM by hFcμR, while also supporting our previous 
observations that deglycosylated IgM can still bind human FcR. 
In addition to FcμR, human lymphocytes express numerous ligands which have been 
shown to bind glycans, including lectins such as CD62L or CD33 (Siglec-3) 
319, 320
. 
Moreover, the lectin CD22 (Siglec-2) on B cells binds α2,6-linked sialic acid 
residues of soluble IgM, resulting in the induction of negative feedback for B cell 
activation 
233
. However, it is not known whether CD22 can mediate internalisation of 
IgM. To rule out the involvement of glycans and/or the possible involvement of  
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Figure 6.8 Endoglycosidase digestion of human IgM. Human IgM (50μg; Sigma-Aldrich) was 
digested in the presence (+) or absence (-) of 10μl (5,000 units) of PNGase F or neuraminidase 
according to manufacturer’s instructions (NEB). After overnight incubation at 37˚C, 5μg of each Ab 
preparation was run under reducing (R) or non-reducing (NR) conditions into wells of a 4-12% Bis-
Tris gradient gel (Novex).  
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Figure 6.9 Effect of de-glycosylation on FcμR-mediated IgM internalisation. hFcμR-transfected 
cell lines were incubated with media supplemented with endoglycosidase-treated 
(Neuraminidase+/PNGase F+) and non-treated (Neuraminidase-/PNGase F-) hIgM (15μg/ml) for 1hr 
on ice. Internalisation assays were performed as described previously. IgM cell surface levels (GMFI) 
were normalised to time 0 for both samples. The mean ± SD of two independent repeats is shown. 
Mann-Whitney test was performed for the comparison of % IgM on cell surface (GMFI) values for 
endoglycosidase-treated (Neuraminidase+/ PNGase F+) and non-treated (Neuraminidase-/PNGase F-) 
hIgM. Statistical significance was regarded as p < 0.05. 
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CD22 in IgM internalisation by lymphocytes, we repeated the internalisation assays 
with the de-glycosylated IgM.  
As shown in Figure 6.10, de-glycosylated IgM is still internalised by T cells (CD4
+ 
and CD8
+
) and B cells. Indeed there was a trend to increased uptake of hIgM when 
the glycans were removed (Figure 6.10). This effect was observed within 5 min at 
37˚C for T cells and was more prominent for B cells following 30 min at 37˚C 
(Figure 6.10; PNGase+). However, there was no significant difference in the 
internalisation of de-glycosylated IgM compared to normal IgM by lymphocytes 
(Table 6.2). Together, these results demonstrate that PNGase F or neuraminidase 
susceptible glycan(s) do not contribute to the binding or internalization of hIgM by 
hFcμR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
 
 
 
Figure 6.10 Effect of de-glycosylation on IgM internalisation by lymphocytes. PBMCs were 
washed and incubated with media supplemented with endoglycosidase-treated 
(Neuraminidase+/PNGase F+) and –non-treated (Neuraminidase-/PNGase F-) hIgM (15μg/ml) for 1hr 
on ice, prior to internalisation assays. Levels of IgM on lymphocyte surfaces were determined by flow 
cytometry using Abs specific for CD3, CD4, CD8, CD19, and hIgM. IgM cell surface levels (GMFI) 
were normalised to time 0 for both samples. The mean ± SD of three repeats is shown. 
 
 
 
Table 6.2 The P values for the affect of glycosylation on IgM internalisation by lymphocytes. 
Mann-Whitney tests were performed for the comparison of % IgM on cell surface (GMFI) values 
(Neuraminidase+/PNGase F+) for endoglycosidase-treated and –non-treated (Neuraminidase-/PNGase 
F-) human IgM samples. Statistically significance was regarded as p < 0.05 (shown in red).  
 
P value CD3+CD4+ CD3+CD8+ CD3-CD19+ 
Neuraminidase- IgM 
vs. neuraminidase+ IgM 
0.1587 0.3333 0.8968 
PNGase F- vs. PNGase F+ 0.2381 0.2381 0.1587 
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6.3.4. Cellular activation affects IgM internalisation 
IgM is the first Ab to be produced during humoral immune responses. The 
recognition and agglutination of pathogens by IgM is pivotal for primary responses 
against invading pathogens, and the ability of IgM to activate complement is 
important for priming adaptive immune responses 
155, 156
. Fc receptors for IgM have 
also been implicated in priming adaptive immune responses, as Fcα/μR was shown to 
mediate endocytosis of IgM-coated Staphylococcus aureus into splenic B cells 
143
. 
Given the importance of IgM in immunity, and the findings that IgM-immune 
complexes were internalised via FcμR, the effect of cellular activation on IgM 
internalisation was determined.  
A panel of different stimulants were used to activate lymphocytes (see Figure 6.6 for 
gating strategy). These stimulants were initially titrated to determine the optimum 
concentration to induce cellular proliferation of lymphocytes (see Chapter 2). B cells 
were stimulated with CpG and LPS. T cells were stimulated with PHA and anti-CD3 
mAb. In addition, anti-μ mAb was used to investigate the effects of cross-linking 
IgM on hFcμR for both B cells and T cells (and/or IgM+ BCR on B cells), and anti-
human IgA+IgG+IgM Abs were used for the cross-linking of surface Igs. To mimic 
activation in vivo, the assay was conducted in 10% human serum. The presence of 
stimulants in IgM internalisation assays resulted in marginally decreased levels of 
cell surface IgM on B cells when compared to the unstimulated controls (Figure 
6.11A). The effects of CpG, LPS, and anti-human IgA+IgG+IgM on IgM 
internalisation were observed following 30 min at 37˚C, whereby there were further 
decreases in levels of surface IgM (Figure 6.11A). However, anti-human IgM Fc5μ 
fragment-specific Abs appeared to affect the internalisation of IgM following 15 min 
at 37˚C, and appeared to have a more pronounced affect on internalisation (~65% 
reduction in surface IgM levels).  For T cells, anti-human IgM Fc5μ fragment specific 
Abs appeared to have no effect on the internalisation of IgM (Figure 6.11B). There 
was a slight increase in IgM internalisation with anti-human IgA+IgG+IgM 
stimulation, notable following 10 min at 37˚C. Curiously, stimulation of T cells with 
both PHA and anti-CD3-mAb resulted in increased levels of surface IgM; however 
the effect was more striking in PHA-stimulated T cells. As the effect of cellular 
activation on IgM internalisation was only assessed for one donor, the data presented 
here should be viewed as preliminary.  
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Figure 6.11 Cellular activation affects IgM internalisation by lymphocytes. PBMCs (2 x 10
5
) 
isolated from a healthy donor were washed and incubated with media supplemented with 10% human 
serum for 1hr at 4˚C. Cells were washed extensively to remove unbound IgM and incubated with 
media supplemented with PHA (5μg/ml), CpG (1μg/ml), LPS (10μg/ml), anti-CD3-mAb (1:3000), 
anti-human IgM Fc5μ fragment specific (hIgM) Abs (2μg/ml), anti-human IgA+IgG+IgM (Igs) Abs 
(2μg/ml) for 5 min on ice prior to incubation at 37˚C for the indicated times. Following incubation, 
cells were washed three times and stained with anti-CD3-APC and anti-CD19-Brilliant Violet
™
-421 
Abs for 1hr at 4˚C. Levels of IgM on cell surface of B cells (A) and T cells (B) were analysed by flow 
cytometry, and normalised to time 0. Data are from one donor.  
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Figure 6.12 PHA induces externalisation of human IgM on gated T cells. PBMCs were incubated 
with 10% human serum for 1hr at 4
°
C. Cells were then washed twice and resuspended in medium. 
PHA (1μg/ml) was added to cells immediately prior to incubation at 37°C for the indicated times. 
Following internalisation, cells were washed twice to remove unbound IgM. Subsequently, cells were 
labelled with F(ab’)2-anti-human IgM-RPE and anti-CD3-APC. IgM levels on cell surfaces were 
determined by the geometric mean fluorescence intensity of RPE (n= 3). Mann-Whitney test was done 
for the comparison of IgM on cell surface (GMFI) values for human serum and PHA + human serum 
samples. Statistical significance was regarded as p < 0.05, and are shown as red. 
 
 
 
 
 
 
 
 
 
 
 
 
 
193 
 
 
Given the striking observation that PHA induced increased levels of IgM on T cell 
surfaces (Figure 6.11B), we repeated the internalisation assay to confirm whether this 
effect could be reproduced with additional donors. The incubation periods were also 
extended in these experiments to investigate whether the levels of surface IgM 
returned to baseline. 
As shown in Figure 6.12, PHA activation of T cells resulted in the dramatic increase 
of IgM surface levels after 15 min at physiological temperature (p= 0.0087). Levels 
of IgM were seen to plateau following 60 min, but failed to reach basal levels within 
5hr (300 min) at physiological temperature as IgM levels remained ~2-fold higher 
than those at time 0.  This data reveals a hitherto unknown effect of PHA on T cells; 
the induction of raised surface IgM levels on activated T cells.  
6.3.5. IgM inhibits lymphocyte proliferation 
In Chapter 4, IgM was shown to inhibit proliferation in T cells stimulated with PHA. 
To further investigate this intriguing feature, we repeated the inhibition of 
proliferation assays previously performed with varying concentrations of human 
IgM, utilizing PHA and CpG to induce proliferation of T cells and B cells, 
respectively. In these assays, matching concentrations of bovine serum albumin 
(BSA) were used to confirm the specificity of this inhibitory affect.  
As shown in Figure 6.13, incubations of PBMCs with hIgM or BSA alone did not 
induce proliferation of T cells or B cells. However, hIgM was observed to strongly 
inhibit both PHA- and CpG-induced proliferation of T cells and B cells respectively 
(Figure 6.13). There were significant decreases in proliferation of CD4
+
 and CD8
+
 T 
cells (p= 0.0278 and p= 0.0469, respectively) in cells incubated in the presence of 
hIgM and PHA, when compared to incubation with PHA alone (Figure 6.13; top 
panel). No significant inhibition of CD4
+
 and CD8
+
 T cell proliferation was observed 
with similar concentrations of BSA (p= 0.2128 and p= 0.4632, respectively). 
Furthermore, there was a highly significant decrease in B cell proliferation in the 
presence of CpG and hIgM but not BSA (p= 0.0050 and p= 0.2689, respectively), 
suggesting that the inhibitory effect is specific for hIgM.  
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Figure 6.13 IgM inhibits T cell and B cell proliferation.  Varying concentrations of IgM or BSA 
were incubated with 5μg/ml PHA or 1μg/ml CpG for 30 min at 4˚C, prior to 5 day incubation with 
CellTrace
™
 Violet-labelled PBMCs at 37˚C. The ability of IgM or BSA (50μg/ml) to inhibit 
proliferation of gated lymphocytes was investigated by flow cytometry. Data are represented as mean 
± SD of two independent experiments. Multiple unpaired t-tests were used to determine significant 
differences in cellular proliferation (% proliferating cells) between samples. Significance was 
determined as; * = p < 0.05, ** = p <0.01, n.s. = not significant.  
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Lower concentrations of hIgM (but not BSA) also inhibited lymphocyte 
proliferation, albeit at a reduced rate, signifying that the inhibition is also titratable 
(Appendix III; Figure A4). Together these results show that hIgM can potently 
inhibit T cell and B cell proliferative responses.  
6.3.6. Expression of human FcμR on lymphocytes 
Finally, we sought to characterise the expression of FcμR on lymphocyte subsets by 
flow cytometry. For this, lymphocytes were gated on the forward versus side scatter 
profile. NK cells were defined as CD3
-
CD56
+
 and T cells as CD3
+
CD56
-
. T cells 
were further gated into CD4
+
 (CD3
+
CD4
+
) and CD8
+
 (CD3
+
CD8
+
) populations 
(Figure 6.6). B cell subsets were gated as follows: mature B cells were identified as 
CD19
+
CD10
-
 cells, which were further gated into naive B cells (CD19
+
CD10
-
CD21
+
CD27
-
), resting memory B cells (CD19
+
CD10
-
CD21
+
CD27
+
), atypical 
memory B cells (CD19
+
CD10
-
CD21
-
CD27
-
),  and activated memory B cells 
(CD19
+
CD10
-
CD21
-
CD27
+
) (Figure 6.14). Plasmablasts were gated as 
CD19
+
CD27
+
CD38
+
 cells (Figure 6.14). 
Cell-surface hFcμR expression was investigated using a commercially available 
receptor-specific mAb (anti-hFcμR; Abnova). In normal adult blood samples, hFcμR 
was expressed on CD4
+
 and CD8
+
 T cells and CD56
+
 NK cells (Figure 6.15).The 
expression of hFcμR on isolated T cells was relatively low, with ~10% of the total 
CD4
+
 T cell population staining positive for hFcμR and ~5% of the total CD8+ T cell 
population (Figure 6.15). NK cells were found to contain two populations of cells; 
those expressing low levels (10-15%) and those expressing high levels (~80-95%) of 
cell surface hFcμR (Figure 6.15). For blood B cells, cell surface levels of hFcμR 
were found to follow the hierarchy: naive < resting memory < activated memory B 
cells < and atypical memory B cells < plasmablasts (Figure 6.16). Expression of 
hFcμR on atypical memory B cells and plasmablasts was split into distinct 
populations with low and high levels of hFcμR (Figure 6.16), similar to that observed 
for NK cells (Figure 6.15). However, the high levels of surface hFcμR on 
plasmablasts may be contributed to the small total cell counts, which may skew the 
geometric mean intensity fluorescence (GMFI) values. 
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Figure 6.14 Gating strategy for B cell panel. Freshly isolated PBMCs were washed and labelled with 
1uM LIVE/DEAD
® 
Aqua Dead Cell stain in PBS at 4
º
C for 30 min. Cells were washed and incubated 
with anti-human CD19-PE-CF594, anti-human CD10-PE, anti-human CD38-Alexa Fluor
® 
700, anti-
human CD27-APC-Cy7 and anti-human CD21-Brilliant Violet
™
 421 for 1hr at 4
º
C. Labelled cells 
were washed extensively and analyzed by flow cytometry. Lymphocytes were gated from the PBMC 
population based on side (SSC) and forward (FSC) profiles, which was further gated into live CD19
+
 
B cells based on LIVE/DEAD
®
 and anti-human CD19 staining. Plasmablasts (PB) were gated as 
CD19
+
CD27
+
CD38
+
 cells. Mature B cells (MB) were identified as CD19
+
CD10
-
 cells, which were 
further gated into naive B cells (CD19
+
CD10
-
CD21
+
CD27
-
), resting memory B cells (RM; 
CD19
+
CD10
-
CD21
+
CD27
+
), atypical memory B cells (ATM; CD19
+
CD10
-
CD21
-
CD27
-
),  and 
activated memory B cells (ATM; CD19
+
CD10
-
CD21
-
CD27
+
).  
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Figure 6.15 FcμR expression on T cells and NK cells. Freshly isolated PBMCs were washed and 
labelled with 1uM LIVE/DEAD
® 
Aqua Dead Cell stain in PBS at 4
º
C for 30 min. Following extensive 
washing, cells were incubated with media in the presence or absence of 1μg mouse anti-hFcμR mAb at 
4
º
C for 1hr. Cells were then washed three times and labelled with anti-mouse IgG-APC to detect the 
expression of hFcμR. Subsequently, PBMCs were labelled with the T/NK cell Ab panel (see Chapter 
2) and analysed by flow cytometry. Lymphocyte subsets were gated as above and the expression of 
hFcμR was assessed as % cells positive for hFcμR (background removed). Averages are shown for 
eight independent donors, error bars indicate SEM. 
 
 
Figure 6.16 FcμR expression on B cell subsets.  PBMCs labelled with 1μg mouse anti-hFcμR mAb 
(Abnova) at 4
º
C for 1hr, washed three times and labelled with anti-mouse IgG-APC. Subsequently, 
PBMCs were labelled with B cell panel Abs and analysed by flow cytometry. B cell subsets were 
gated as in Figure 6.14, and the expression of hFcμR was assessed as % cells positive for hFcμR 
(minus background). Averages are shown for nine independent donors, error bars indicate SEM.  
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Previous studies hypothesised that hFcμR expression is sensitive to exogenous levels 
of IgM, as hFcμR levels were significantly raised on mononuclear cell surfaces 
following overnight culture in serum-free conditions 
137
. We sought to investigate 
whether these results could be duplicated using the commercially available anti-
hFcμR mAb.  Overnight culture of PBMCs in serum-free medium resulted in no 
significant increase expression of hFcμR on naive and activated memory B cells (p= 
0.60 and p= 0.76, respectively) (Figure 6.17). The expression of hFcμR was reduced 
on atypical memory B cells and on resting memory B cells and levels on plasmablast 
remain relatively constant (Figure 6.17). Together, these results indicate that 
exogenous IgM concentrations had no significant effect on the expression of hFcμR 
on PBMCs.  
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Figure 6.17 Comparing FcμR expression on freshly isolated vs. serum-starved B cell subsets. 
Levels of hFcμR on B cell surfaces was investigated on freshly isolated PBMCs (shown as fresh) or 
PBMCs cultured in serum-free media overnight (shown as overnight), in order to investigate whether 
FcμR expression is sensitive to exogenous IgM concentrations. Averages are shown for nine 
independent donors, error bars indicate SEM. Statistical analysis was done by multiple t-tests using 
the Graphpad Prism 6 software, whereby p values less than 0.05 were regarded as significant. 
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6.4. Discussion 
In this chapter, possible effector function(s) of hFcμR were investigated. We 
identified several key findings: (1) hFcμR is an endocytosis receptor for IgM. (2) 
Glycosylation does not influence IgM internalisation by hFcμR or by PBMCs (3) 
Cellular activation affects IgM internalisation by lymphocytes. (4) hFcμR is 
expressed on a variety of lymphocyte subsets, including B cells, T cells and NK 
cells.  
FcμR has been implicated in IgM homeostasis 137, 138, and one study showed receptor 
cross-linking promoted the rapid internalisation of IgM and FcμR 183. Here, we 
confirm that hFcμR mediates the endocytosis of both pentameric IgM and IgM 
immune-complexes, and that hFcμR is also internalised upon ligand binding. This 
supports the hypothesis that IgM is degraded upon internalisation and shuttling to 
lysosomes 
183
, however future studies could expand these findings by tracking the 
internalisation dynamics of IgM by confocal microscopy. 
To our knowledge, this is the first report of human IgM-immune complexes (IC) 
being internalised by hFcμR. However, HeLa cells expressing hFcμR were 
previously shown to  internalise mouse IgM-conjugated microbeads 
175
. IgM Abs are 
the first to be produced during immune responses, and are pivotal for pathogen 
opsonisation and complement activation 
156
. Therefore, internalisation of IgM-IC by 
hFcμR could be implicated in the primary stages of adaptive immune responses, 
through bridging immune complexes with adaptive immune cells. Whether hFcμR 
can indeed mediate the internalisation and cross-presentation of IgM-coated 
pathogens and/ or IgM-Ag complexes, and what effect this could have on immune 
responses, remains to be determined. Given that FcμR has been implicated in 
enhancing B cell proliferation and survival following BCR cross-linking in mice 
138
, 
it will be of interest to see whether specific IgM-Ag can influence B cell proliferation 
or signalling as a result of BCR and/ or hFcμR cross-linking. Recently, the ability 
hFcμR to internalise IgM was utilised in cancer immunotherapy 321. Vire et al. used 
the IgM-Fc (Fcμ) as a scaffold to deliver cytotoxic drugs to CLL cells 
overexpressing hFcμR 321. The internalisation of these Fcμ-drug candidates resulted 
in selective toxicity of CLL cells 
321
, highlighting the potential use of hFcμR in 
therapeutic design. 
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IgM internalisation was sensitive to the activation status of lymphocytes. The 
preliminary data presented here revealed that activation resulted in increased IgM 
internalisation by B cells. B cells are antigen presenting cells which prime T cell 
responses through the presentation of foreign antigens via MHC molecules 
322
. 
Therefore, it is tempting to speculate that increased internalisation following 
activation may function to endocytose foreign antigens bound to IgM and mediate 
their cross-presentation. However, this remains to be resolved. Curiously, activation 
of T cells with PHA and anti-CD3 Abs promoted externalisation of IgM following 
initial internalisation. It is still unknown whether this effect was due to the direct 
externalisation of IgM-FcμR complexes, or whether cellular activation promotes the 
upregulation of a hitherto unidentified IgM
+ 
receptor on T cells. Since no exogenous 
IgM was available during the internalisation assays, it is likely that the externalised 
IgM comes from within the cell. In support of this, Vire et al. showed that hFcμR 
accumulates in the trans-golgi network (TGN), and hypothesised that the TGN serves 
as an intracellular storage site for hFcμR so that the receptor can be released quickly 
under certain circumstances, such as cellular activation 
321
. As both PHA and anti-
CD3 mAbs were able to generate externalisation of IgM by T cells, it is tempting to 
speculate that this mechanism is important in governing T cell immunity. For 
example, the upregulation of IgM on activated T cell surfaces could promote cell-cell 
interactions between cells expressing hFcμR, as previously suggested 100, 137. 
Evaluating the internalisation dynamics of hFcμR alongside IgM could be one way 
of deciphering the role of the receptor in IgM internalisation and externalisation 
following cellular activation. 
De-glycosylation of IgM molecules had no effect on its internalisation by hFcμR-
transfected cell lines, T cells (CD4
+
 and CD8
+
) or B cells. This contradicted an 
earlier study that demonstrated that the FcμR mediated internalisation was dependent 
on sialylation of IgM 
286
. The findings presented here, as well as previous findings 
183
, suggest that IgM is rapidly internalised by hFcμR. As Colucci et al. investigated 
internalisation of desialylated IgM at 72 hr, it is possible that an alternative receptor 
is mediating the sialic-acid-dependent internalisation of IgM by T cells 
286
. 
Numerous glycan receptors are expressed on human T cells, including CD62L (L-
selectin) and members of the glycan-binding galectin family 
323
. The galectin family 
appear to have the greatest potential as the receptor mediating the internalisation of 
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sialylated IgM, as galectins are essentially expressed on all adaptive immune cells 
and have been implicated in the fine-tuning of T cell signalling and activation 
323
. 
Further, galectin 9 has been shown to bind to the heavy chain of serum IgM 
324
. The 
use of anti-galectin Abs to block interactions between IgM and galectins during 
internalisation assays could help clarify the role of galectins in IgM internalisation by 
T cells. 
Another interesting feature reported here was that IgM inhibited activation of both B 
cells and T cells. Similar results were described for T cells previously, whereby the 
sialic acid-dependent internalisation of IgM contributed to augmentation of T cell 
inhibition 
286
. However, we discounted the role for sialic-acid in mediating the 
internalisation of IgM by hFcμR. One possible explanation for the T cell inhibition 
could be that IgM directly binds to PHA (see Chapter 4), and thus prevents its 
interaction with cell surface receptors to initiate T cell activation.  Alternatively, the 
binding of IgM to galectins on T cell surfaces could potentially mediate the 
inhibitory effect 
323
. Galectins are also expressed on B cells and have been implicated 
in the inhibition of B cell proliferation 
325, 326
. Likewise, the binding of IgM to the 
inhibitory glycan receptor CD22 could be responsible for the observed inhibition 
233
. 
Future studies should aim to characterise what receptor is governing the IgM-
dependent inhibition of lymphocytes, possibly through the use of blocking Abs 
specific for CD22- and/or galectin.  
Since glycosylation did not impact on IgM internalisation by hFcμR, there is scope 
to modify this multivalent immunoglobulin for therapeutic application. The addition 
of α2,6-linked sialic acid glycans to Fcμ-drug candidates for CLL 321 could also 
function to induce a negative feedback loop for CLL proliferation through CD22 
binding 
233
. A similar approach was adopted for the Bruton tyrosine kinase (BTK) 
inhibitor drug ibrutinib, which was shown to down-regulate BCR signalling in CLL 
cells resulting in significantly decreased tumour proliferation 
327
. Alternatively, as 
sialylation of IgM was implicated recently in T cell inhibition 
286
, the excessive 
sialylation of IgM could be used to inhibit auto-reactive T cells governing certain 
autoimmune diseases 
328, 329
. This interesting topic is discussed further in Chapter 7. 
FcμR is unique from other FcR in its exclusive expression on adaptive immune cells 
137
. Here, we confirmed the expression of hFcμR on B cells, T cells, and NK cells 
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using the commercially available anti-FAIM3 mAb. In addition, we further 
characterised expression of hFcμR on B cell subsets and characterised the hierarchy 
of expression on B cells in blood: naive < resting memory < activated memory B 
cells < and atypical memory B cells < plasmablasts. This hierarchy differs from 
previous data which characterised hFcμR downmodulation upon B cell activation 137, 
288
. Plasmablasts were found to fall into two populations; those expressing high 
levels of hFcμR and those expressing low levels, which supports the findings that 
subpopulations of plasma cells (CD38
hi
) express hFcμR 288. In addition, we did not 
observe enhanced cell surface levels of FcμR on B cell subsets following overnight 
culture in serum-free media, contrasting previous findings 
137
. Possible explanations 
for the differences in hFcμR expression reported here could be owing to the use of a 
commercial anti-FAIM3 (hFcμR) mAb, different gating strategies for lymphocyte 
subsets, different serum-free media, or the lack of a FcγR-blocking method used 
previously 
137
. Therefore, future studies should duplicate the staining methods used 
by Kubagawa et al. with the anti-FAIM3 mAb to determine what is governing these 
differences in expression 
137
. 
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Chapter 7: Discussion and conclusion 
7.1. Objectives 
Why P. falciparum express IgM-binding proteins has received considerable attention 
over the last decade. Although the IgM-binding properties of PfEMP1 expressed on 
the surface of infected erythrocytes has been well characterised 
120, 123, 130, 284
, 
significantly less is known about two IgM-binding proteins expressed on the surface 
of the merozoite. The expression of DBLMSP and DBLMSP2 on merozoites has 
been linked to permitting interactions with erythrocytes 
147
, complement activation 
and camouflaging critical epitopes from immune responses 
146
. However, whether 
the binding of these molecules to the Fc portion of IgM could affect subsequent 
interactions with IgM receptors had not been investigated. Moreover, the mechanism 
of IgM binding to and the function of human FcR, as well as the identification of 
novel IgM receptors remain unclear.  
The overall aim of this study was to characterise the DBLMSP-IgM interaction, and 
to determine why P. falciparum merozoites express DBL domains that bind non-
immune human IgM. In particular, the specific objectives included: 
I. Assess the structural and biochemical requirements for IgM binding to 
IgM-receptors 
II. Investigate the requirements for DBLMSP and DBLMSP2 binding to 
human IgM 
III. Determine if IgM-binding by DBLMSP and/or DBLMSP2 mediates 
immune evasion by: 
 Blocking interactions of IgM with receptors 
 Targeting IgM on hFcμR expressed on human lymphocytes 
 Promoting immunomodulation through binding lymphocytes 
IV. Characterise the function(s) of human FcμR 
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7.2.  Main findings and significance 
Improving our understanding of the host-parasite relationship is crucial to develop 
better methods for controlling malaria. Strategies to overcome the extensive immune 
evasion mechanisms employed by P. falciparum will aid in the development of 
highly effective vaccines, which has so far been difficult to attain. 
Here, we show for the first time that merozoite surface proteins are able to bind to 
adaptive immune cells. Intriguingly, the DBL domains alone were unable to bind 
IgM on hFcμR, implying a role for the SPAM domains in oligomerisation of the full-
length proteins. Even though we were unable to characterise any biological 
consequences of DBLMSP and DBLMSP2 binding to lymphocytes, the data 
generated in this study indicates that these proteins do not function to block 
interactions between IgM and hFcμR. Furthermore, we show the potential of 
DBLMSP and DBLMSP2 to engage dendritic cells via interactions with IgM on DC-
SIGN. Since these malaria proteins do not appear to be involved in erythrocyte 
invasion, or mediate functional effects by binding IgM-positive lymphocytes, it may 
be more likely that they have evolved to interact with other cell types such as 
dendritic cells. However, the lack of functionality of these proteins on lymphocytes 
could be owing to the fact that additional malarial proteins are in native IgM-
DBLMSP complexes. The presence of additional parasite proteins within the IgM-
DBLMSP complex does not affect its binding to hFcμR, supporting the potential of 
IgM-DBLMSP complexes to engage hFcμR on expressed lymphocytes in vivo. 
In addition, this study provided some insight into the requirements for IgM binding 
by hFcμR. The Cμ4 domain of hIgM was identified as the domain which bound 
hFcμR, with a partial contribution made by the Cμ2 and/or Cμ3 domain. This 
interaction was not dependent on the glycosylation of IgM. Both IgM and IgM-
immune complexes were seen to bind to hFcμR, confirming hFcμR as a bona fide 
receptor for IgM and signifying the receptor may play a role in initial immune 
responses. Through the assessment of IgM binding to lymphocyte subsets known to 
express hFcμR, we also observed binding of IgM to monocytes. As far as we are 
aware, there has been no characterisation of an IgM receptor expressed on monocytes 
to date, although IgM is known to bind murine monocytes and macrophages 
226
. The 
identification of DC-SIGN as a novel ligand for IgM could offer one explanation as 
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to how monocytes bind hIgM. DC-SIGN bound IgM-Fc at high affinity (Kd 
~0.26μM), which was found to be dependent on IgM glycosylation. Although a 
subset of monocytes express DC-SIGN 
167, 237
, whether the expression of DC-SIGN 
by monocytes can account for the observed IgM binding is still unknown. 
As there is currently no crystal structure for hFcμR, molecular dynamic simulations 
were used to provide structural insights into how IgM engages FcμR. The models 
generated using the Phyre2 Server suggested that hFcμR is expressed as a dimer, 
owing to its striking homology to the transmembrane region of the epidermal growth 
factor receptor erbb1, which exists as a dimer on cell surfaces 
241
.  Moreover, the 
integration of the DBL domains of DBLMSP into this model revealed that these 
proteins might bind to a different region of the Cμ4 domain of IgM than that bound 
by hFcμR. The Cμ2/Cμ4 interface was predicted as the target of FcμR, as the 
Cμ3/Cμ4 interface is completely buried by the DBLMSP domains, and the FcμR 
interaction with IgM does not completely prevent DBLMSP interaction with IgM. A 
similar association of dimeric FcμR with this Cμ2/Cμ4 interface also shows partial 
overlap with the DBLMSP, thus the model(s) confirmed that it is structurally viable 
for the DBLMSP proteins to bind to IgM bound to hFcμR, and provides an 
explanation as to why there is a reduction, but not complete blocking, of IgM-
DBLMSP complexes to hFcμR. Due to the steric constraints imposed by the 
experimental data, the model could aid the identification of the IgM-binding domain 
of DBLMSP/DBLMSP2.  
In order to gain a better understand into how the binding of DBLMSP and/or 
DBLMSP2 to hFcμR could possibly benefit parasite survival, the role of receptor 
was further investigated. Here, we confirmed that hFcμR is expressed on adaptive 
immune cells and mediates the endocytosis of IgM and artificially-induced IgM-
immune complexes. IgM was not recycled to the cell surface following 
internalisation, supporting previous findings that internalised IgM is shuttled through 
the endocytic pathway to lysosomes for degradation 
183
. Taken together, the findings 
presented here strengthen the previous data generated in FcμR-deficient mice which 
implicated the receptor in the homeostasis of IgM 
138
. The  data showed that IgM 
internalisation is enhanced upon lymphocyte activation, implying the importance of 
the mechanism in early immune responses, such as the cross-presentation of foreign 
207 
 
 
antigens via MHC molecules or by delivering antigens to TLR receptors (e.g. 
TLR7/9) which also residue within lysosomes 
183
. However, T cell activation resulted 
in the externalisation of IgM following initial internalisation. This surprising result 
was observed using two different stimuli (PHA and anti-CD3 Abs) and was 
hypothesised to occur due to the rapid release of intracellular stores of hFcμR-IgM 
complexes 
183
. Although this is yet to be determined, the presence of IgM on 
activated T cell surfaces could function to facilitate T and B cell interactions which 
could help enhance B cell activation, as previously described 
137
. 
Finally, we showed a role for IgM in the inhibition of B cell and T cell proliferation. 
Whether or not this inhibitory effect was owing to the interaction of IgM with hFcμR 
remains to be determined. Despite this, these results confirmed previous findings that 
IgM inhibited T cell activation 
286
. The authors concluded that the sialic acid-
dependent inhibitory effect of IgM on T cell activation may have been a result of the 
internalisation of IgM by hFcμR. However, we showed that glycosylation of IgM 
had no effect on the initial internalisation of IgM by hFcμR-transfected cells or 
lymphocytes known to express the receptor. Therefore, we hypothesise that the 
inhibitory effects of IgM are governed through interactions with unidentified 
receptors, most likely galectins on T cells 
323, 324, 326
 or the inhibitory receptor CD22 
on B cells 
233
. Alternatively, the direct binding of IgM to stimulants such as PHA or 
PWM could prevent their binding to receptors on lymphocyte surfaces, thus 
preventing the initiation of activation. 
7.3. Applications 
The fact that the DBL domains alone were unable to engage IgM bound to cell-
surface receptors signified a role of the SPAM domain in the oligomerisation of 
malaria proteins. Therefore, the fusion of SPAM domains to malaria vaccine 
candidate antigens could promote their oligomerisation, thus increasing the overall 
size of the complex which in turn could enhance its immunogenicity, as shown for 
other vaccines 
330, 331
. Moreover, the SPAM domain itself has been shown to elicit 
cross-reactive Abs capable of generating Ab-dependent cellular inhibition of parasite 
growth 
148
. Therefore, there is potential for the SPAM domain of DBLMSP and/or 
DBLMSP2 to be utilised in vaccine design. In addition, the ability of hFcμR to 
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internalise both IgM and IgM-immune complexes could be exploited to deliver 
therapeutic targets to adaptive immune cells. This concept has already been explored 
by Vire et al., who used IgM-Fc as a scaffold to deliver cytotoxic drugs to CLL cells 
which overexpress hFcμR 321.  
Glycosylation of immunoglobulins can dramatically alter their function. Excessive 
sialylation of immunoglobulins stimulates immune suppression as demonstrated by 
the anti-inflammatory effects of IVIG, which are commonly used as a therapeutic for 
certain autoimmune and inflammatory diseases 
303, 332, 333
. In light of the recent report 
of the effect of sialylation of IgM on T cell activation 
286
, the excessive sialylation of 
IgM could be used to inhibit auto-reactive T cells implicated in pathologies such as 
diabetes mellitus 
328, 329
 and multiple sclerosis 
334, 335. Further, the addition of α2,6-
linked glycans to IgM could permit B cell inhibition through cross-linking of the 
inhibitory receptor CD22 
233
, which could be used for treatment of 
hypergammaglobulinemia. As CLL cells overexpress hFcμR 178, 313, the addition of 
α2,6-linked sialic acid glycans to IgM-Fc could promote cross-linking of hFcμR and 
CD22 
233
, which in turn could induce a negative feedback loop for B cell activation 
resulting in decreased tumour proliferation. Although IgM is heavily glycosylated 
168
, de-glycosylation did not affect the binding or internalisation of IgM to hFcμR. 
Therefore, modifying the glycans on the IgM-Fc to enhance its binding to glycan 
receptors would not interfere with IgM-hFcμR interactions. Further work is required 
to evaluate the potential of glycosylated IgM-fusions in therapeutics.  
7.4. Limitations 
A major limitation in this study was the inability to produce recombinant DBLMSP 
and DBLMSP2. The downstream effects of lack of protein meant that we were 
unable to further explore the immune subsets binding DBLMSP and/ or DBLMSP2, 
to determine whether binding of these proteins correlated with hFcμR expression, to 
repeat assays to determine the function of these proteins, or to investigate the 
biological consequences of binding to NK cells.  In addition, the inability to produce 
recombinant DBLMSP and/or DBLMSP2 proteins lacking DBL domains meant that 
we were unable to confirm the role of the SPAM domain in oligomerisation.  
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Another limitation included the restricted assays we were able to perform to 
determine the function of hFcμR. Previous studies have utilised genetically altered 
mice lacking the expression of FcμR to investigate the function of the receptor. Here, 
we focused on investigating the ability of the receptor to internalise IgM by 
monitoring levels of IgM and/or hFcμR on cell surfaces. However, the expression of 
the IgM
+
 BCR on B cells resulted in high levels of background staining when 
detecting for cell surface levels of IgM. Therefore, future studies may want to utilise 
RNA interference technology to knock out the expression of hFcμR on lymphocytes 
to further clarify its role in humans. Another limiting factor was that only one anti-
hFcμR (FAIM3) Ab is available commercially, which is not directly conjugated to a 
fluorochrome. It is possible that difference in hFcμR expression on B cell subset 
featured here compared to that described previously 
137
 was attributed to the use of 
different anti-hFcμR mAbs.  
7.5. Future work 
Although this thesis has provided an insight into the role of IgM-binding proteins in 
malaria, there are still a number of outstanding questions. For example, it is still 
unclear at what concentration DBLMSP and DBLMSP2 are present in the periphery 
of an individual with high parasitemia, or what proportion of these proteins complex 
with IgM. It is important to evaluate this to understand how these complexes may 
interact with hFcμR. As hFcμR was characterised as an endocytosis receptor, it will 
be interesting to determine whether the binding of DBLMSP and/or DBLMSP2 to 
IgM can prevent its internalisation by hFcμR. As these proteins are expected to form 
complexes with IgM in the periphery, their function may be to block internalisation 
of IgM-opsonised antigens in order to delay immune detection. Alternatively, 
internalisation of native IgM-immune complexes containing malarial proteins could 
promote TLR activation within lysosomes resulting in excessive B cell and/ or T cell 
activation.  
Another outstanding question is the identity of the additional malarial proteins 
contained within the IgM-DBLMSP complex. Characterizing these proteins by mass 
spectrometry will enable a better understanding of the interaction between merozoite 
surface proteins, and could help identify novel IgM-binding proteins expressed on 
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the surface of merozoites. Future studies should repeat the functional assays 
performed here to determine whether the presence of these unidentified proteins 
within IgM-complexes serve to bind to receptors on lymphocytes, which could 
initiate biological consequences such as proliferation or apoptosis.  
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Appendix I 
DBLMSP and DBLMSP2 sequences (Dr Cecile Crosnier, Welcome 
Trust Sanger Institute) 
 
P. falciparum 3D7 DBLMSP amino acid sequence 
Red=DBL domain Green= SPAM domain 
MKKIYSIFFSLFILNLHIYIKNIKCNDLINYNDSNLRNGLLNNSLDLTNGLNNKDNSFIDSKIEEHEN
KSYQNKDNNISIVGQDVPITSVYSSKIINANDLEGNSIDDTKGLSVTNSGFDDGSAFGGGLPFSGYSP
LQGNHNKCPDENFCKGIKNVLSCPPKNSTGRNGDWISVAVKESSTTNKGVLVPPRRTKLCLRNINKVW
HRIKDEKNFKEEFVKVALGESNALMKHYKEKNLNALTAIKYGFSDMGDIIKGTDLIDYQITKNINRAL
DKILRNETSNDKIKKRVDWWEANKSAFWDAFMCGYKVHIGNKPCPEHDNMDRIPQYLRWFREWGTYVC
SEYKNKFEDVIKLCNIQQFTNQDDSQLLEISKKDKCKEALKHYEEWVNRRRPEWKGQCDKFEKEKSKY
EDTKSITAEKYLKEICSECDCKYKDLDNTFKEFKDNVTLLKAVIDNKKNQDSLTTTSLSTSINSVRDS
SNLDQRGNITTSQGNSHRATVVQQVDQTNRLDNVNSVTQRGNNNYNNNLERGLGSGALPGTNIITEEK
YSLELIKLTSKDEEDIIKHNEDVREEIEEQQEDIEEDEEELENEGEETKEEDDEEKNETNDTEDTDDT
EDTEDIEEENKEKELSNQQQSEKKSISKVDEDSYRILSVSYKDNNEVKNVAESIVKKLFSLFNDNNNL
ETIFKGLTEDMTDLFQK 
 
 
P. falciparum 3D7 DBLMSP2 amino acid sequence 
Red=DBL domain Green= SPAM domain 
MIYILSIVFYIFFLHIDIYVNIYSTCFVVNEGNPNLRNNIINDDELKGKAYNNTIDANNQNIEYNKNL
KHNVNSSHISKFSDIMDQEDKGDNENSHDIKFEEKKNINKSLDAESNYGINEISITGNDSNSDNSNQN
IFPDGSELAGGIPRSIYTINLGFNKCPTEEICKDFSNLPQCRKNVHERNNWLGSSVKNFSSDNKGVLV
PPRRQSLCLRITLQDFRTKKKKEGDFEKFIYSYASSEARKLRTIHNNNLEKAHQAIRYSFADIGNIIR
GDDMMDTPTSKETITYLEKVLKIYNENNDKPKDAKKWWTENRHHVWEAMMCGYQSAQKDNQCTGYGNI
DDIPQFLRWFREWGTYVCEESEKNMNTLKAVCFPKQPRTEANPALTVHENEMCSSTLKKYEEWYNKRK
TEWTEQSIKYNNDKINYTDIKTLSPSEYLIEKCPECKCTKKNLQDVFELTFDGKALLEKLKKEESPVS
NSVNALPEPGQITLPDPSLKQTTQQENQPVVETPVTTAVINEHQGQTEPNKGDNNNERENHESNVGSI
QEVNQGSVSEESHSKTIDPSKIDDRLELSSGSSSLEQHSKEDVKKGCALELVPLSLSDIEQIANESED
VLEEIEEEINTDGEIEYITEEEIKEDIEEETEEDIEEETEEETEEETEEEADEETVKEIEDKPEQEIK
NKSLEEKQIDKNTDTSEKKGFNNSEKDEKARNLISKNYKNYNELDKNVHTLVNSIISLLEEGNGSDST
LNSLSKDITNLFKN 
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Appendix II 
Vector maps and sequences 
Creation of pcDNA 3.1(+) vector containing DBLMSP and DBLMSP2 
Full-length DBLMSP and DBLMSP2 (FL), and DBLMSP and DBLMSP lacking DBL 
domains (C), were synthesised and cloned into pcDNA 3.1(+) vector with flanking 
BamHI and XhoI cloning sites (LifeTechnologies).  
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pcDNA 3.1(+)-DBLMSP-FL 
BamHI      Insert      DBL      SPAM    2x c-myc    6x His      XhoI 
   
GGATCCGCCACCATGAAGAAGATCTACTCCATCTTCTTCTCCCTGTTCATCCTGAACCTGCACATCTACATCAAGA
ACATCAAGTGCAACGACCTGATCAACTACAACGACAGCAACCTGAGAAACGGCCTGCTGAACAACAGCCTGGACCT
GACCAACGGCCTGAACAACAAGGACAACAGCTTCATCGACAGCAAGATCGAGGAACACGAGAACAAGAGCTACCAG
AACAAGGATAACAACATCAGCATCGTGGGCCAGGACGTGCCCATCACCAGCGTGTACAGCTCCAAGATCATCAACG
CCAACGATCTGGAAGGCAACAGCATCGACGACACCAAGGGCCTGAGCGTGACCAACAGCGGCTTCGACGATGGCTC
TGCTTTCGGCGGAGGCCTGCCTTTCAGCGGCTACAGTCCTCTGCAGGGCAACCACAACAAGTGCCCCGACGAGAAC
TTCTGCAAGGGAATCAAGAACGTGCTGAGCTGCCCCCCCAAGAACAGCACCGGCAGAAACGGCGACTGGATCAGCG
TGGCCGTGAAAGAGAGCAGCACCACCAACAAGGGCGTGCTGGTGCCCCCTAGAAGGACCAAGCTGTGCCTGAGGAA
CATCAACAAAGTGTGGCACAGGATCAAGGACGAGAAGAACTTCAAAGAGGAATTCGTGAAGGTGGCCCTGGGCGAG
AGCAACGCCCTGATGAAGCACTACAAAGAGAAGAACCTGAACGCTCTGACCGCCATTAAGTACGGCTTCAGCGACA
TGGGCGACATCATCAAGGGCACAGATCTGATCGACTACCAGATCACCAAGAATATCAACCGGGCCCTGGACAAGAT
CCTGCGGAACGAGACAAGCAACGACAAGATCAAGAAACGAGTGGATTGGTGGGAGGCCAACAAGAGCGCCTTCTGG
GACGCCTTCATGTGCGGCTACAAGGTGCACATCGGCAACAAGCCCTGCCCCGAGCACGACAACATGGACAGAATCC
CCCAGTACCTGAGATGGTTCCGCGAGTGGGGCACCTACGTGTGCAGCGAGTACAAGAACAAGTTCGAGGACGTGAT
CAAGCTGTGTAACATCCAGCAGTTCACCAACCAGGACGACAGCCAGCTGCTGGAAATCAGCAAGAAAGACAAGTGC
AAAGAGGCCCTGAAACACTACGAGGAATGGGTCAACAGACGCAGACCCGAGTGGAAGGGCCAGTGCGATAAGTTCG
AGAAAGAGAAGTCTAAGTACGAGGACACCAAGAGCATCACCGCCGAGAAGTATCTGAAAGAAATCTGCTCCGAGTG
CGACTGCAAGTACAAGGACCTGGACAACACATTCAAAGAATTCAAGGACAATGTGACCCTGCTGAAGGCCGTGATC
GACAACAAGAAGAACCAGGACAGCCTGACCACCACCAGCCTGAGCACCTCCATCAACTCCGTGCGGGACTCCTCCA
ACCTGGACCAGAGAGGCAACATCACCACCTCCCAGGGCAACAGCCACAGAGCCACAGTGGTGCAGCAGGTGGACCA
GACAAACAGACTGGACAACGTGAACAGCGTGACCCAGCGGGGCAACAACAATTACAACAACAACCTGGAAAGGGGC
CTGGGCTCTGGCGCTCTGCCTGGCACCAACATCATCACCGAGGAAAAGTACTCCCTGGAACTGATTAAGCTGACCA
GCAAGGACGAAGAGGATATCATCAAGCACAATGAGGACGTGCGGGAAGAGATTGAGGAACAGCAGGAAGATATTGA
AGAGGACGAGGAAGAACTGGAAAACGAGGGCGAGGAAACAAAAGAAGAGGACGACGAGGAAAAGAACGAGACAAAC
GACACCGAGGACACCGACGATACAGAGGATACCGAAGATATCGAGGAAGAGAACAAAGAAAAAGAGCTGAGCAACC
AGCAGCAGAGCGAGAAGAAATCCATCAGCAAGGTGGACGAGGACAGCTACAGAATCCTGTCCGTGTCCTACAAAGA
CAACAACGAAGTGAAGAACGTGGCCGAGAGCATCGTGAAGAAGCTGTTCAGCCTGTTCAACGACAACAACAATCTG
GAAACCATCTTCAAGGGCCTGACCGAGGACATGACCGACCTGTTCCAGAAGGCCGAGCAGAAGCTGATCTCCGAAG
AGGACCTGGCTGAACAGAAACTGATCAGCGAGGAAGATCTGGCCCACCACCACCATCACCACTGACTCGAG 
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pcDNA 3.1(+)-DBLMSP-C 
GGATCCGCCACCATGAAGAAGATCTACTCCATCTTCTTCTCCCTGTTCATCCTGAACCTGCACATCTACATCAAGA
ACATCAAGTGCAACGACCTGATCAACTACAACGACAGCAACCTGAGAAACGGCCTGCTGAACAACAGCCTGGACCT
GACCAACGGCCTGAACAACAAGGACAACAGCTTCATCGACAGCAAGATCGAGGAACACGAGAACAAGAGCTACCAG
AACAAGGATAACAACATCAGCATCGTGGGCCAGGACGTGCCCATCACCAGCGTGTACAGCTCCAAGATCATCAACG
CCAACGATCTGGAAGGCAACAGCATCGACGACACCAAGGGCCTGAGCGTGACCAACAGCGGCTTCGACGATGGCTC
TGCTTTCGGCGGAGGCCTGCCTTTCAGCGGCTACAGTCCTCTGCAGGGCAACCACAACAAGTGCCCCGACGAGAAC
TTCTGCAAGGGAATCAAGAACGTGCTGAGCTGCGACTGCAAGTACAAGGACCTGGACAACACATTCAAAGAATTCA
AGGACAATGTGACCCTGCTGAAGGCCGTGATCGACAACAAGAAGAACCAGGACAGCCTGACCACCACCAGCCTGAG
CACCTCCATCAACTCCGTGCGGGACTCCTCCAACCTGGACCAGAGAGGCAACATCACCACCTCCCAGGGCAACAGC
CACAGAGCCACAGTGGTGCAGCAGGTGGACCAGACAAACAGACTGGACAACGTGAACAGCGTGACCCAGCGGGGCA
ACAACAATTACAACAACAACCTGGAAAGGGGCCTGGGCTCTGGCGCTCTGCCTGGCACCAACATCATCACCGAGGA
AAAGTACTCCCTGGAACTGATCAAGCTGACCAGCAAGGACGAAGAGGACATCATCAAGCACAATGAGGACGTGCGG
GAAGAGATCGAAGAACAGCAGGAAGATATTGAAGAGGACGAGGAAGAACTGGAAAACGAGGGCGAGGAAACAAAAG
AAGAGGACGACGAGGAAAAGAACGAGACAAACGACACCGAGGACACAGACGATACAGAGGACACTGAGGACATCGA
AGAGGAAAACAAAGAGAAAGAGCTGAGCAACCAGCAGCAGAGCGAGAAGAAATCCATCAGCAAGGTGGACGAGGAC
AGCTACAGAATCCTGTCCGTGTCCTACAAAGACAACAACGAAGTGAAGAACGTGGCCGAGAGCATCGTGAAGAAGC
TGTTCAGCCTGTTCAACGACAACAACAATCTGGAAACCATCTTCAAGGGCCTGACCGAGGACATGACCGACCTGTT
CCAGAAAGAGCAGAAGCTGATCTCCGAAGAGGACCTGGAACAGAAACTGATCAGCGAGGAAGATCTGCACCACCAT
CACCATCACTGACTCGAG 
 
 
 
pcDNA 3.1(+)-DBLMSP2-C 
GGATCCGCCACCATGATCTACATCCTGTCTATCGTGTTCTACATCTTCTTTCTGCACATCGACATCTACGTGAACA
TCTACAGCACCTGTTTCGTCGTGAACGAGGGCAACCCCAACCTGAGAAACAACATCATCAACGACGACGAGCTGAA
GGGCAAGGCCTACAACAACACCATCGACGCCAACAACCAGAACATCGAGTACAACAAGAACCTGAAGCACAACGTG
AACAGCAGCCACATCAGCAAGTTCAGCGACATCATGGACCAGGAAGATAAGGGCGACAACGAGAACTCCCACGACA
TCAAGTTCGAGGAAAAGAAGAACATCAACAAGAGCCTGGACGCCGAGAGCAACTACGGCATCAACGAGATCAGCAT
CACCGGCAACGACAGCAACAGCGACAACAGCAACCAGAATATCTTCCCCGACGGCAGCGAGCTGGCTGGCGGCATC
CCTAGATCCATCTACACCATCAACCTGGGCTTCAACAAGTGCCCCACCGAGGAAATCTGCAAGGACTTCAGCAACC
TGCCCCAGGTGTTCGAGCTGACCTTCGACGGCAAGGCCCTGCTGGAAAAGCTGAAGAAAGAGGAATCCCCCGTGTC
CAACAGCGTGAACGCCCTGCCTGAGCCTGGCCAGATCACACTGCCTGACCCCAGCCTGAAGCAGACCACCCAGCAG
GAAAACCAGCCCGTGGTGGAAACCCCTGTGACCACCGCCGTGATCAACGAGCACCAGGGCCAGACCGAGCCCAACA
AGGGCGATAACAACAACGAGAGAGAGAACCACGAGTCCAACGTGGGCAGCATCCAGGAAGTGAACCAGGGCAGCGT
GTCCGAGGAAAGCCACAGCAAGACCATCGACCCCAGCAAGATCGACGACAGACTGGAACTGAGCAGCGGCAGCAGC
AGCCTGGAACAGCACAGCAAAGAAGATGTGAAGAAGGGCTGCGCCCTGGAACTGGTGCCTCTGAGCCTGAGCGACA
TCGAGCAGATCGCCAACGAGAGCGAGGACGTGCTGGAAGAGATCGAGGAAGAGATTAACACCGACGGCGAGATCGA
GTATATCACCGAAGAGGAAATCAAAGAGGACATCGAAGAAGAGACAGAAGAGGATATTGAGGAAGAAACCGAAGAA
GAAACTGAGGAAGAGACAGAGGAAGAGGCCGACGAGGAAACCGTGAAAGAAATCGAGGACAAGCCCGAGCAGGAAA
TCAAGAACAAGTCCCTGGAAGAGAAGCAGATCGACAAGAACACCGACACCAGCGAGAAGAAGGGATTCAACAACTC
CGAGAAGGACGAGAAGGCCAGAAACCTGATCAGCAAGAACTACAAGAATTACAACGAGCTGGACAAGAACGTGCAC
ACCCTCGTGAACTCCATCATTAGCCTGCTGGAAGAAGGCAACGGCAGCGACAGCACCCTGAACAGCCTGAGCAAGG
ACATCACAAACCTGTTCAAGAACGAGCAGAAGCTGATCTCTGAAGAGGATCTGGAACAGAAACTGATTAGCGAAGA
GGACCTGCACCACCACCATCACCACTGACTCGAG 
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pcDNA 3.1(+)-DBLMSP2-FL 
GGATCCGCCACCATGATCTACATCCTGTCTATCGTGTTCTACATCTTCTTTCTGCACATCGACATCTACGTGAACA
TCTACAGCACCTGTTTCGTCGTGAACGAGGGCAACCCCAACCTGAGAAACAACATCATCAACGACGACGAGCTGAA
GGGCAAGGCCTACAACAACACCATCGACGCCAACAACCAGAACATCGAGTACAACAAGAACCTGAAGCACAACGTG
AACAGCAGCCACATCAGCAAGTTCAGCGACATCATGGACCAGGAAGATAAGGGCGACAACGAGAACTCCCACGACA
TCAAGTTCGAGGAAAAGAAGAACATCAACAAGAGCCTGGACGCCGAGAGCAACTACGGCATCAACGAGATCAGCAT
CACCGGCAACGACAGCAACAGCGACAACAGCAACCAGAATATCTTCCCCGACGGCAGCGAGCTGGCTGGCGGCATC
CCTAGATCCATCTACACCATCAACCTGGGCTTCAACAAGTGCCCCACCGAGGAAATCTGCAAGGACTTCAGCAACC
TGCCCCAGTGCCGGAAGAACGTGCACGAGAGGAACAACTGGCTGGGCAGCAGCGTGAAGAACTTCAGCTCCGACAA
CAAGGGCGTGCTGGTGCCCCCTAGAAGGCAGAGCCTGTGCCTGAGAATCACCCTGCAGGACTTCCGCACCAAGAAG
AAGAAAGAGGGCGACTTCGAGAAGTTCATCTACTCCTACGCCAGCAGCGAGGCCAGAAAGCTGAGAACCATCCACA
ACAACAATCTGGAAAAGGCCCACCAGGCCATCAGATACAGCTTCGCCGACATCGGCAATATCATCAGAGGCGACGA
CATGATGGACACCCCCACCAGCAAAGAGACAATCACCTACCTGGAAAAAGTGCTGAAGATCTACAATGAGAACAAC
GACAAGCCCAAGGACGCCAAGAAGTGGTGGACCGAGAACAGACACCACGTGTGGGAGGCCATGATGTGCGGCTACC
AGAGCGCCCAGAAAGACAACCAGTGCACCGGCTACGGCAACATCGACGATATCCCCCAGTTCCTGAGATGGTTCCG
CGAGTGGGGCACCTACGTGTGCGAGGAATCCGAGAAGAATATGAACACCCTGAAGGCCGTGTGCTTCCCCAAGCAG
CCTAGAACCGAGGCCAACCCTGCCCTGACCGTGCACGAAAACGAGATGTGCAGCAGCACACTGAAGAAATACGAGG
AATGGTATAACAAGCGCAAGACCGAGTGGACAGAGCAGTCCATCAAGTATAACAACGATAAGATCAACTACACAGA
CATCAAGACCCTGAGCCCCAGCGAGTACCTGATCGAGAAGTGCCCCGAGTGCAAGTGCACCAAAAAGAACCTGCAG
GATGTGTTCGAGCTGACCTTCGACGGCAAGGCCCTGCTGGAAAAGCTGAAAAAAGAGGAATCCCCCGTGTCCAACA
GCGTGAACGCCCTGCCTGAGCCTGGCCAGATCACACTGCCTGACCCCAGCCTGAAGCAGACCACCCAGCAGGAAAA
CCAGCCCGTGGTGGAAACCCCTGTGACCACCGCCGTGATCAACGAGCACCAGGGCCAGACCGAGCCCAACAAGGGG
GATAACAACAACGAGAGAGAGAACCACGAGTCCAACGTGGGCAGCATCCAGGAAGTGAACCAGGGCAGCGTGTCCG
AGGAAAGCCACAGCAAGACCATCGACCCCAGCAAGATCGACGACAGACTGGAACTGAGCAGCGGCAGCAGCAGCCT
GGAACAGCACAGCAAAGAAGATGTGAAGAAGGGCTGCGCCCTGGAACTGGTGCCTCTGAGCCTGAGCGACATCGAG
CAGATCGCCAACGAGAGCGAGGACGTGCTGGAAGAGATCGAGGAAGAGATTAACACCGACGGCGAGATCGAGTATA
TCACCGAAGAGGAAATCAAAGAGGACATCGAAGAAGAGACAGAAGAGGATATTGAGGAAGAAACTGAAGAAGAAAC
AGAGGAAGAGACTGAGGAAGAGGCCGACGAGGAAACCGTGAAAGAGATTGAGGACAAGCCCGAGCAGGAAATCAAG
AACAAGTCCCTGGAAGAGAAGCAGATCGACAAGAACACCGACACCAGCGAGAAGAAGGGATTCAACAACTCCGAGA
AGGACGAGAAGGCCCGGAACCTGATCAGCAAGAACTACAAGAATTACAACGAGCTGGACAAGAATGTGCACACACT
CGTGAACTCCATCATTAGCCTGCTGGAAGAAGGCAACGGCAGCGACAGCACCCTGAACAGCCTGAGCAAGGACATC
ACAAACCTGTTCAAGAACGAGCAGAAGCTGATCTCTGAAGAGGATCTGGAACAGAAACTGATCAGCGAAGAGGACC
TGCACCACCACCATCACCACTGACTCGAG 
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Creation of pFUSE-MCS vector containing DBLMSP and DBLMSP2 
The sequences encoding full-length DBLMSP and DBLMSP2 (FL), and DBLMSP and 
DBLMSP lacking DBL domains (C), were subcloned into the pFUSE-MCS vector 
(Invivogen) to create the pFUSE-DBLMSP-FL, pFUSE-DBLMSP-C, pFUSE-
DBLMSP2-FL, pFUSE-DBLMSP2-C expression vectors. 
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pFUSE-MCS-DBLMSP-FL  
GGATCCCGCCACCATGAAGAAGATCTACTCCATCTTCTTCTCCCTGTTCATCCTGAACCTGCACATCTACATCAAGA
ACATCAAGTGCAACGACCTGATCAACTACAACGACAGCAACCTGAGAAACGGCCTGCTGAACAACAGCCTGGACCTG
ACCAACGGCCTGAACAACAAGGACAACAGCTTCATCGACAGCAAGATCGAGGAACACGAGAACAAGAGCTACCAGAA
CAAGGATAACAACATCAGCATCGTGGGCCAGGACGTGCCCATCACCAGCGTGTACAGCTCCAAGATCATCAACGCCA
ACGATCTGGAAGGCAACAGCATCGACGACACCAAGGGCCTGAGCGTGACCAACAGCGGCTTCGACGATGGCTCTGCT
TTCGGCGGAGGCCTGCCTTTCAGCGGCTACAGTCCTCTGCAGGGCAACCACAACAAGTGCCCCGACGAGAACTTCTG
CAAGGGAATCAAGAACGTGCTGAGCTGCCCCCCCAAGAACAGCACCGGCAGAAACGGCGACTGGATCAGCGTGGCCG
TGAAAGAGAGCAGCACCACCAACAAGGGCGTGCTGGTGCCCCCTAGAAGGACCAAGCTGTGCCTGAGGAACATCAAC
AAAGTGTGGCACAGGATCAAGGACGAGAAGAACTTCAAAGAGGAATTCGTGAAGGTGGCCCTGGGCGAGAGCAACGC
CCTGATGAAGCACTACAAAGAGAAGAACCTGAACGCTCTGACCGCCATTAAGTACGGCTTCAGCGACATGGGCGACA
TCATCAAGGGCACAGATCTGATCGACTACCAGATCACCAAGAATATCAACCGGGCCCTGGACAAGATCCTGCGGAAC
GAGACAAGCAACGACAAGATCAAGAAACGAGTGGATTGGTGGGAGGCCAACAAGAGCGCCTTCTGGGACGCCTTCAT
GTGCGGCTACAAGGTGCACATCGGCAACAAGCCCTGCCCCGAGCACGACAACATGGACAGAATCCCCCAGTACCTGA
GATGGTTCCGCGAGTGGGGCACCTACGTGTGCAGCGAGTACAAGAACAAGTTCGAGGACGTGATCAAGCTGTGTAAC
ATCCAGCAGTTCACCAACCAGGACGACAGCCAGCTGCTGGAAATCAGCAAGAAAGACAAGTGCAAAGAGGCCCTGAA
ACACTACGAGGAATGGGTCAACAGACGCAGACCCGAGTGGAAGGGCCAGTGCGATAAGTTCGAGAAAGAGAAGTCTA
AGTACGAGGACACCAAGAGCATCACCGCCGAGAAGTATCTGAAAGAAATCTGCTCCGAGTGCGACTGCAAGTACAAG
GACCTGGACAACACATTCAAAGAATTCAAGGACAATGTGACCCTGCTGAAGGCCGTGATCGACAACAAGAAGAACCA
GGACAGCCTGACCACCACCAGCCTGAGCACCTCCATCAACTCCGTGCGGGACTCCTCCAACCTGGACCAGAGAGGCA
ACATCACCACCTCCCAGGGCAACAGCCACAGAGCCACAGTGGTGCAGCAGGTGGACCAGACAAACAGACTGGACAAC
GTGAACAGCGTGACCCAGCGGGGCAACAACAATTACAACAACAACCTGGAAAGGGGCCTGGGCTCTGGCGCTCTGCC
TGGCACCAACATCATCACCGAGGAAAAGTACTCCCTGGAACTGATTAAGCTGACCAGCAAGGACGAAGAGGATATCA
TCAAGCACAATGAGGACGTGCGGGAAGAGATTGAGGAACAGCAGGAAGATATTGAAGAGGACGAGGAAGAACTGGAA
AACGAGGGCGAGGAAACAAAAGAAGAGGACGACGAGGAAAAGAACGAGACAAACGACACCGAGGACACCGACGATAC
AGAGGATACCGAAGATATCGAGGAAGAGAACAAAGAAAAAGAGCTGAGCAACCAGCAGCAGAGCGAGAAGAAATCCA
TCAGCAAGGTGGACGAGGACAGCTACAGAATCCTGTCCGTGTCCTACAAAGACAACAACGAAGTGAAGAACGTGGCC
GAGAGCATCGTGAAGAAGCTGTTCAGCCTGTTCAACGACAACAACAATCTGGAAACCATCTTCAAGGGCCTGACCGA
GGACATGACCGACCTGTTCCAGAAGGCCGAGCAGAAGCTGATCTCCGAAGAGGACCTGGCTGAACAGAAACTGATCA
GCGAGGAAGATCTGGCCCACCACCACCATCACCACTGACTCGAG 
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pFUSE-MCS-DBLMSP2-FL 
GGATCCGCCACCATGATCTACATCCTGTCTATCGTGTTCTACATCTTCTTTCTGCACATCGACATCTACGTGAACAT
CTACAGCACCTGTTTCGTCGTGAACGAGGGCAACCCCAACCTGAGAAACAACATCATCAACGACGACGAGCTGAAGG
GCAAGGCCTACAACAACACCATCGACGCCAACAACCAGAACATCGAGTACAACAAGAACCTGAAGCACAACGTGAAC
AGCAGCCACATCAGCAAGTTCAGCGACATCATGGACCAGGAAGATAAGGGCGACAACGAGAACTCCCACGACATCAA
GTTCGAGGAAAAGAAGAACATCAACAAGAGCCTGGACGCCGAGAGCAACTACGGCATCAACGAGATCAGCATCACCG
GCAACGACAGCAACAGCGACAACAGCAACCAGAATATCTTCCCCGACGGCAGCGAGCTGGCTGGCGGCATCCCTAGA
TCCATCTACACCATCAACCTGGGCTTCAACAAGTGCCCCACCGAGGAAATCTGCAAGGACTTCAGCAACCTGCCCCA
GTGCCGGAAGAACGTGCACGAGAGGAACAACTGGCTGGGCAGCAGCGTGAAGAACTTCAGCTCCGACAACAAGGGCG
TGCTGGTGCCCCCTAGAAGGCAGAGCCTGTGCCTGAGAATCACCCTGCAGGACTTCCGCACCAAGAAGAAGAAAGAG
GGCGACTTCGAGAAGTTCATCTACTCCTACGCCAGCAGCGAGGCCAGAAAGCTGAGAACCATCCACAACAACAATCT
GGAAAAGGCCCACCAGGCCATCAGATACAGCTTCGCCGACATCGGCAATATCATCAGAGGCGACGACATGATGGACA
CCCCCACCAGCAAAGAGACAATCACCTACCTGGAAAAAGTGCTGAAGATCTACAATGAGAACAACGACAAGCCCAAG
GACGCCAAGAAGTGGTGGACCGAGAACAGACACCACGTGTGGGAGGCCATGATGTGCGGCTACCAGAGCGCCCAGAA
AGACAACCAGTGCACCGGCTACGGCAACATCGACGATATCCCCCAGTTCCTGAGATGGTTCCGCGAGTGGGGCACCT
ACGTGTGCGAGGAATCCGAGAAGAATATGAACACCCTGAAGGCCGTGTGCTTCCCCAAGCAGCCTAGAACCGAGGCC
AACCCTGCCCTGACCGTGCACGAAAACGAGATGTGCAGCAGCACACTGAAGAAATACGAGGAATGGTATAACAAGCG
CAAGACCGAGTGGACAGAGCAGTCCATCAAGTATAACAACGATAAGATCAACTACACAGACATCAAGACCCTGAGCC
CCAGCGAGTACCTGATCGAGAAGTGCCCCGAGTGCAAGTGCACCAAAAAGAACCTGCAGGATGTGTTCGAGCTGACC
TTCGACGGCAAGGCCCTGCTGGAAAAGCTGAAAAAAGAGGAATCCCCCGTGTCCAACAGCGTGAACGCCCTGCCTGA
GCCTGGCCAGATCACACTGCCTGACCCCAGCCTGAAGCAGACCACCCAGCAGGAAAACCAGCCCGTGGTGGAAACCC
CTGTGACCACCGCCGTGATCAACGAGCACCAGGGCCAGACCGAGCCCAACAAGGGGGATAACAACAACGAGAGAGAG
AACCACGAGTCCAACGTGGGCAGCATCCAGGAAGTGAACCAGGGCAGCGTGTCCGAGGAAAGCCACAGCAAGACCAT
CGACCCCAGCAAGATCGACGACAGACTGGAACTGAGCAGCGGCAGCAGCAGCCTGGAACAGCACAGCAAAGAAGATG
TGAAGAAGGGCTGCGCCCTGGAACTGGTGCCTCTGAGCCTGAGCGACATCGAGCAGATCGCCAACGAGAGCGAGGAC
GTGCTGGAAGAGATCGAGGAAGAGATTAACACCGACGGCGAGATCGAGTATATCACCGAAGAGGAAATCAAAGAGGA
CATCGAAGAAGAGACAGAAGAGGATATTGAGGAAGAAACTGAAGAAGAAACAGAGGAAGAGACTGAGGAAGAGGCCG
ACGAGGAAACCGTGAAAGAGATTGAGGACAAGCCCGAGCAGGAAATCAAGAACAAGTCCCTGGAAGAGAAGCAGATC
GACAAGAACACCGACACCAGCGAGAAGAAGGGATTCAACAACTCCGAGAAGGACGAGAAGGCCCGGAACCTGATCAG
CAAGAACTACAAGAATTACAACGAGCTGGACAAGAATGTGCACACACTCGTGAACTCCATCATTAGCCTGCTGGAAG
AAGGCAACGGCAGCGACAGCACCCTGAACAGCCTGAGCAAGGACATCACAAACCTGTTCAAGAACGAGCAGAAGCTG
ATCTCTGAAGAGGATCTGGAACAGAAACTGATCAGCGAAGAGGACCTGCACCACCACCATCACCACTGACTCGAG 
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pFUSE-MCS-DBLMSP-C 
GGATCCGCCACCATGAAGAAGATCTACTCCATCTTCTTCTCCCTGTTCATCCTGAACCTGCACATCTACATCAAGAA
CATCAAGTGCAACGACCTGATCAACTACAACGACAGCAACCTGAGAAACGGCCTGCTGAACAACAGCCTGGACCTGA
CCAACGGCCTGAACAACAAGGACAACAGCTTCATCGACAGCAAGATCGAGGAACACGAGAACAAGAGCTACCAGAAC
AAGGATAACAACATCAGCATCGTGGGCCAGGACGTGCCCATCACCAGCGTGTACAGCTCCAAGATCATCAACGCCAA
CGATCTGGAAGGCAACAGCATCGACGACACCAAGGGCCTGAGCGTGACCAACAGCGGCTTCGACGATGGCTCTGCTT
TCGGCGGAGGCCTGCCTTTCAGCGGCTACAGTCCTCTGCAGGGCAACCACAACAAGTGCCCCGACGAGAACTTCTGC
AAGGGAATCAAGAACGTGCTGAGCTGCGACTGCAAGTACAAGGACCTGGACAACACATTCAAAGAATTCAAGGACAA
TGTGACCCTGCTGAAGGCCGTGATCGACAACAAGAAGAACCAGGACAGCCTGACCACCACCAGCCTGAGCACCTCCA
TCAACTCCGTGCGGGACTCCTCCAACCTGGACCAGAGAGGCAACATCACCACCTCCCAGGGCAACAGCCACAGAGCC
ACAGTGGTGCAGCAGGTGGACCAGACAAACAGACTGGACAACGTGAACAGCGTGACCCAGCGGGGCAACAACAATTA
CAACAACAACCTGGAAAGGGGCCTGGGCTCTGGCGCTCTGCCTGGCACCAACATCATCACCGAGGAAAAGTACTCCC
TGGAACTGATCAAGCTGACCAGCAAGGACGAAGAGGACATCATCAAGCACAATGAGGACGTGCGGGAAGAGATCGAA
GAACAGCAGGAAGATATTGAAGAGGACGAGGAAGAACTGGAAAACGAGGGCGAGGAAACAAAAGAAGAGGACGACGA
GGAAAAGAACGAGACAAACGACACCGAGGACACAGACGATACAGAGGACACTGAGGACATCGAAGAGGAAAACAAAG
AGAAAGAGCTGAGCAACCAGCAGCAGAGCGAGAAGAAATCCATCAGCAAGGTGGACGAGGACAGCTACAGAATCCTG
TCCGTGTCCTACAAAGACAACAACGAAGTGAAGAACGTGGCCGAGAGCATCGTGAAGAAGCTGTTCAGCCTGTTCAA
CGACAACAACAATCTGGAAACCATCTTCAAGGGCCTGACCGAGGACATGACCGACCTGTTCCAGAAAGAGCAGAAGC
TGATCTCCGAAGAGGACCTGGAACAGAAACTGATCAGCGAGGAAGATCTGCACCACCATCACCATCACTGACTCGAG 
 
 
pFUSE-MCS-DBLMSP2-C 
GGATCCGCCACCATGATCTACATCCTGTCTATCGTGTTCTACATCTTCTTTCTGCACATCGACATCTACGTGAACA
TCTACAGCACCTGTTTCGTCGTGAACGAGGGCAACCCCAACCTGAGAAACAACATCATCAACGACGACGAGCTGAA
GGGCAAGGCCTACAACAACACCATCGACGCCAACAACCAGAACATCGAGTACAACAAGAACCTGAAGCACAACGTG
AACAGCAGCCACATCAGCAAGTTCAGCGACATCATGGACCAGGAAGATAAGGGCGACAACGAGAACTCCCACGACA
TCAAGTTCGAGGAAAAGAAGAACATCAACAAGAGCCTGGACGCCGAGAGCAACTACGGCATCAACGAGATCAGCAT
CACCGGCAACGACAGCAACAGCGACAACAGCAACCAGAATATCTTCCCCGACGGCAGCGAGCTGGCTGGCGGCATC
CCTAGATCCATCTACACCATCAACCTGGGCTTCAACAAGTGCCCCACCGAGGAAATCTGCAAGGACTTCAGCAACC
TGCCCCAGGTGTTCGAGCTGACCTTCGACGGCAAGGCCCTGCTGGAAAAGCTGAAGAAAGAGGAATCCCCCGTGTC
CAACAGCGTGAACGCCCTGCCTGAGCCTGGCCAGATCACACTGCCTGACCCCAGCCTGAAGCAGACCACCCAGCAG
GAAAACCAGCCCGTGGTGGAAACCCCTGTGACCACCGCCGTGATCAACGAGCACCAGGGCCAGACCGAGCCCAACA
AGGGCGATAACAACAACGAGAGAGAGAACCACGAGTCCAACGTGGGCAGCATCCAGGAAGTGAACCAGGGCAGCGT
GTCCGAGGAAAGCCACAGCAAGACCATCGACCCCAGCAAGATCGACGACAGACTGGAACTGAGCAGCGGCAGCAGC
AGCCTGGAACAGCACAGCAAAGAAGATGTGAAGAAGGGCTGCGCCCTGGAACTGGTGCCTCTGAGCCTGAGCGACA
TCGAGCAGATCGCCAACGAGAGCGAGGACGTGCTGGAAGAGATCGAGGAAGAGATTAACACCGACGGCGAGATCGA
GTATATCACCGAAGAGGAAATCAAAGAGGACATCGAAGAAGAGACAGAAGAGGATATTGAGGAAGAAACCGAAGAA
GAAACTGAGGAAGAGACAGAGGAAGAGGCCGACGAGGAAACCGTGAAAGAAATCGAGGACAAGCCCGAGCAGGAAA
TCAAGAACAAGTCCCTGGAAGAGAAGCAGATCGACAAGAACACCGACACCAGCGAGAAGAAGGGATTCAACAACTC
CGAGAAGGACGAGAAGGCCAGAAACCTGATCAGCAAGAACTACAAGAATTACAACGAGCTAGACAAGAACGTGCAC
ACCCTCGTGAACTCCATCATTAGCCTGCTGGAAGAAGGCAACGGCAGCGACAGCACCCTGAACAGCCTGAGCAAGG
ACATCACAAACCTGTTCAAGAACGAGCAGAAGCTGATCTCTGAAGAGGATCTGGAACAGAAACTGATTAGCGAAGA
GGACCTGCACCACCACCATCACCACTGACTCGAG 
 
 
237 
 
 
Creation of pRSET EmGFP bacterial expression vector containing DBLMSP and 
DBLMSP2 
The sequences encoding full-length DBLMSP and DBLMSP2 (FL), and DBLMSP and 
DBLMSP lacking DBL domains (C), were subcloned into the pRSET-GFP bacterial 
expression vector (Invitrogen) to create the pRSET-DBLMSP-FL, pRSET-DBLMSP-
C, pRSET-DBLMSP2-FL, pRSET-DBLMSP2-C expression vectors. 
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pRSET-DBLMSP-FL 
GGATCCCGCCACCATGAAGAAGATCTACTCCATCTTCTTCTCCCTGTTCATCCTGAACCTGCACATCTACATCAAG
AACATCAAGTGCAACGACCTGATCAACTACAACGACAGCAACCTGAGAAACGGCCTGCTGAACAACAGCCTGGACC
TGACCAACGGCCTGAACAACAAGGACAACAGCTTCATCGACAGCAAGATCGAGGAACACGAGAACAAGAGCTACCA
GAACAAGGATAACAACATCAGCATCGTGGGCCAGGACGTGCCCATCACCAGCGTGTACAGCTCCAAGATCATCAAC
GCCAACGATCTGGAAGGCAACAGCATCGACGACACCAAGGGCCTGAGCGTGACCAACAGCGGCTTCGACGATGGCT
CTGCTTTCGGCGGAGGCCTGCCTTTCAGCGGCTACAGTCCTCTGCAGGGCAACCACAACAAGTGCCCCGACGAGAA
CTTCTGCAAGGGAATCAAGAACGTGCTGAGCTGCCCCCCCAAGAACAGCACCGGCAGAAACGGCGACTGGATCAGC
GTGGCCGTGAAAGAGAGCAGCACCACCAACAAGGGCGTGCTGGTGCCCCCTAGAAGGACCAAGCTGTGCCTGAGGA
ACATCAACAAAGTGTGGCACAGGATCAAGGACGAGAAGAACTTCAAAGAGGAATTCGTGAAGGTGGCCCTGGGCGA
GAGCAACGCCCTGATGAAGCACTACAAAGAGAAGAACCTGAACGCTCTGACCGCCATTAAGTACGGCTTCAGCGAC
ATGGGCGACATCATCAAGGGCACAGATCTGATCGACTACCAGATCACCAAGAATATCAACCGGGCCCTGGACAAGA
TCCTGCGGAACGAGACAAGCAACGACAAGATCAAGAAACGAGTGGATTGGTGGGAGGCCAACAAGAGCGCCTTCTG
GGACGCCTTCATGTGCGGCTACAAGGTGCACATCGGCAACAAGCCCTGCCCCGAGCACGACAACATGGACAGAATC
CCCCAGTACCTGAGATGGTTCCGCGAGTGGGGCACCTACGTGTGCAGCGAGTACAAGAACAAGTTCGAGGACGTGA
TCAAGCTGTGTAACATCCAGCAGTTCACCAACCAGGACGACAGCCAGCTGCTGGAAATCAGCAAGAAAGACAAGTG
CAAAGAGGCCCTGAAACACTACGAGGAATGGGTCAACAGACGCAGACCCGAGTGGAAGGGCCAGTGCGATAAGTTC
GAGAAAGAGAAGTCTAAGTACGAGGACACCAAGAGCATCACCGCCGAGAAGTATCTGAAAGAAATCTGCTCCGAGT
GCGACTGCAAGTACAAGGACCTGGACAACACATTCAAAGAATTCAAGGACAATGTGACCCTGCTGAAGGCCGTGAT
CGACAACAAGAAGAACCAGGACAGCCTGACCACCACCAGCCTGAGCACCTCCATCAACTCCGTGCGGGACTCCTCC
AACCTGGACCAGAGAGGCAACATCACCACCTCCCAGGGCAACAGCCACAGAGCCACAGTGGTGCAGCAGGTGGACC
AGACAAACAGACTGGACAACGTGAACAGCGTGACCCAGCGGGGCAACAACAATTACAACAACAACCTGGAAAGGGG
CCTGGGCTCTGGCGCTCTGCCTGGCACCAACATCATCACCGAGGAAAAGTACTCCCTGGAACTGATTAAGCTGACC
AGCAAGGACGAAGAGGATATCATCAAGCACAATGAGGACGTGCGGGAAGAGATTGAGGAACAGCAGGAAGATATTG
AAGAGGACGAGGAAGAACTGGAAAACGAGGGCGAGGAAACAAAAGAAGAGGACGACGAGGAAAAGAACGAGACAAA
CGACACCGAGGACACCGACGATACAGAGGATACCGAAGATATCGAGGAAGAGAACAAAGAAAAAGAGCTGAGCAAC
CAGCAGCAGAGCGAGAAGAAATCCATCAGCAAGGTGGACGAGGACAGCTACAGAATCCTGTCCGTGTCCTACAAAG
ACAACAACGAAGTGAAGAACGTGGCCGAGAGCATCGTGAAGAAGCTGTTCAGCCTGTTCAACGACAACAACAATCT
GGAAACCATCTTCAAGGGCCTGACCGAGGACATGACCGACCTGTTCCAGAAGGCCGAGCAGAAGCTGATCTCCGAA
GAGGACCTGGCTGAACAGAAACTGATCAGCGAGGAAGATCTGGCCCACCACCACCATCACCACTGACTCGAG 
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pRSET-DBLMSP2-FL 
GGATCCGCCACCATGATCTACATCCTGTCTATCGTGTTCTACATCTTCTTTCTGCACATCGACATCTACGTGAACA
TCTACAGCACCTGTTTCGTCGTGAACGAGGGCAACCCCAACCTGAGAAACAACATCATCAACGACGACGAGCTGAA
GGGCAAGGCCTACAACAACACCATCGACGCCAACAACCAGAACATCGAGTACAACAAGAACCTGAAGCACAACGTG
AACAGCAGCCACATCAGCAAGTTCAGCGACATCATGGACCAGGAAGATAAGGGCGACAACGAGAACTCCCACGACA
TCAAGTTCGAGGAAAAGAAGAACATCAACAAGAGCCTGGACGCCGAGAGCAACTACGGCATCAACGAGATCAGCAT
CACCGGCAACGACAGCAACAGCGACAACAGCAACCAGAATATCTTCCCCGACGGCAGCGAGCTGGCTGGCGGCATC
CCTAGATCCATCTACACCATCAACCTGGGCTTCAACAAGTGCCCCACCGAGGAAATCTGCAAGGACTTCAGCAACC
TGCCCCAGTGCCGGAAGAACGTGCACGAGAGGAACAACTGGCTGGGCAGCAGCGTGAAGAACTTCAGCTCCGACAA
CAAGGGCGTGCTGGTGCCCCCTAGAAGGCAGAGCCTGTGCCTGAGAATCACCCTGCAGGACTTCCGCACCAAGAAG
AAGAAAGAGGGCGACTTCGAGAAGTTCATCTACTCCTACGCCAGCAGCGAGGCCAGAAAGCTGAGAACCATCCACA
ACAACAATCTGGAAAAGGCCCACCAGGCCATCAGATACAGCTTCGCCGACATCGGCAATATCATCAGAGGCGACGA
CATGATGGACACCCCCACCAGCAAAGAGACAATCACCTACCTGGAAAAAGTGCTGAAGATCTACAATGAGAACAAC
GACAAGCCCAAGGACGCCAAGAAGTGGTGGACCGAGAACAGACACCACGTGTGGGAGGCCATGATGTGCGGCTACC
AGAGCGCCCAGAAAGACAACCAGTGCACCGGCTACGGCAACATCGACGATATCCCCCAGTTCCTGAGATGGTTCCG
CGAGTGGGGCACCTACGTGTGCGAGGAATCCGAGAAGAATATGAACACCCTGAAGGCCGTGTGCTTCCCCAAGCAG
CCTAGAACCGAGGCCAACCCTGCCCTGACCGTGCACGAAAACGAGATGTGCAGCAGCACACTGAAGAAATACGAGG
AATGGTATAACAAGCGCAAGACCGAGTGGACAGAGCAGTCCATCAAGTATAACAACGATAAGATCAACTACACAGA
CATCAAGACCCTGAGCCCCAGCGAGTACCTGATCGAGAAGTGCCCCGAGTGCAAGTGCACCAAAAAGAACCTGCAG
GATGTGTTCGAGCTGACCTTCGACGGCAAGGCCCTGCTGGAAAAGCTGAAAAAAGAGGAATCCCCCGTGTCCAACA
GCGTGAACGCCCTGCCTGAGCCTGGCCAGATCACACTGCCTGACCCCAGCCTGAAGCAGACCACCCAGCAGGAAAA
CCAGCCCGTGGTGGAAACCCCTGTGACCACCGCCGTGATCAACGAGCACCAGGGCCAGACCGAGCCCAACAAGGGG
GATAACAACAACGAGAGAGAGAACCACGAGTCCAACGTGGGCAGCATCCAGGAAGTGAACCAGGGCAGCGTGTCCG
AGGAAAGCCACAGCAAGACCATCGACCCCAGCAAGATCGACGACAGACTGGAACTGAGCAGCGGCAGCAGCAGCCT
GGAACAGCACAGCAAAGAAGATGTGAAGAAGGGCTGCGCCCTGGAACTGGTGCCTCTGAGCCTGAGCGACATCGAG
CAGATCGCCAACGAGAGCGAGGACGTGCTGGAAGAGATCGAGGAAGAGATTAACACCGACGGCGAGATCGAGTATA
TCACCGAAGAGGAAATCAAAGAGGACATCGAAGAAGAGACAGAAGAGGATATTGAGGAAGAAACTGAAGAAGAAAC
AGAGGAAGAGACTGAGGAAGAGGCCGACGAGGAAACCGTGAAAGAGATTGAGGACAAGCCCGAGCAGGAAATCAAG
AACAAGTCCCTGGAAGAGAAGCAGATCGACAAGAACACCGACACCAGCGAGAAGAAGGGATTCAACAACTCCGAGA
AGGACGAGAAGGCCCGGAACCTGATCAGCAAGAACTACAAGAATTACAACGAGCTGGACAAGAATGTGCACACACT
CGTGAACTCCATCATTAGCCTGCTGGAAGAAGGCAACGGCAGCGACAGCACCCTGAACAGCCTGAGCAAGGACATC
ACAAACCTGTTCAAGAACGAGCAGAAGCTGATCTCTGAAGAGGATCTGGAACAGAAACTGATCAGCGAAGAGGACC
TGCACCACCACCATCACCACTGACTCGAG 
 
 
 
 
 
 
 
 
 
 
 
 
240 
 
 
pRSET-DBLMSP-C 
GGATCCGCCACCATGAAGAAGATCTACTCCATCTTCTTCTCCCTGTTCATCCTGAACCTGCACATCTACATCAAGA
ACATCAAGTGCAACGACCTGATCAACTACAACGACAGCAACCTGAGAAACGGCCTGCTGAACAACAGCCTGGACCT
GACCAACGGCCTGAACAACAAGGACAACAGCTTCATCGACAGCAAGATCGAGGAACACGAGAACAAGAGCTACCAG
AACAAGGATAACAACATCAGCATCGTGGGCCAGGACGTGCCCATCACCAGCGTGTACAGCTCCAAGATCATCAACG
CCAACGATCTGGAAGGCAACAGCATCGACGACACCAAGGGCCTGAGCGTGACCAACAGCGGCTTCGACGATGGCTC
TGCTTTCGGCGGAGGCCTGCCTTTCAGCGGCTACAGTCCTCTGCAGGGCAACCACAACAAGTGCCCCGACGAGAAC
TTCTGCAAGGGAATCAAGAACGTGCTGAGCTGCGACTGCAAGTACAAGGACCTGGACAACACATTCAAAGAATTCA
AGGACAATGTGACCCTGCTGAAGGCCGTGATCGACAACAAGAAGAACCAGGACAGCCTGACCACCACCAGCCTGAG
CACCTCCATCAACTCCGTGCGGGACTCCTCCAACCTGGACCAGAGAGGCAACATCACCACCTCCCAGGGCAACAGC
CACAGAGCCACAGTGGTGCAGCAGGTGGACCAGACAAACAGACTGGACAACGTGAACAGCGTGACCCAGCGGGGCA
ACAACAATTACAACAACAACCTGGAAAGGGGCCTGGGCTCTGGCGCTCTGCCTGGCACCAACATCATCACCGAGGA
AAAGTACTCCCTGGAACTGATCAAGCTGACCAGCAAGGACGAAGAGGACATCATCAAGCACAATGAGGACGTGCGG
GAAGAGATCGAAGAACAGCAGGAAGATATTGAAGAGGACGAGGAAGAACTGGAAAACGAGGGCGAGGAAACAAAAG
AAGAGGACGACGAGGAAAAGAACGAGACAAACGACACCGAGGACACAGACGATACAGAGGACACTGAGGACATCGA
AGAGGAAAACAAAGAGAAAGAGCTGAGCAACCAGCAGCAGAGCGAGAAGAAATCCATCAGCAAGGTGGACGAGGAC
AGCTACAGAATCCTGTCCGTGTCCTACAAAGACAACAACGAAGTGAAGAACGTGGCCGAGAGCATCGTGAAGAAGC
TGTTCAGCCTGTTCAACGACAACAACAATCTGGAAACCATCTTCAAGGGCCTGACCGAGGACATGACCGACCTGTT
CCAGAAAGAGCAGAAGCTGATCTCCGAAGAGGACCTGGAACAGAAACTGATCAGCGAGGAAGATCTGCACCACCAT
CACCATCACTGACTCGAG 
 
 
 
 
pRSET-DBLMSP2-C 
GGATCCGCCACCATGAAGAAGATCTACTCCATCTTCTTCTCCCTGTTCATCCTGAACCTGCACATCTACATCAAGA
ACATCAAGTGCAACGACCTGATCAACTACAACGACAGCAACCTGAGAAACGGCCTGCTGAACAACAGCCTGGACCT
GACCAACGGCCTGAACAACAAGGACAACAGCTTCATCGACAGCAAGATCGAGGAACACGAGAACAAGAGCTACCAG
AACAAGGATAACAACATCAGCATCGTGGGCCAGGACGTGCCCATCACCAGCGTGTACAGCTCCAAGATCATCAACG
CCAACGATCTGGAAGGCAACAGCATCGACGACACCAAGGGCCTGAGCGTGACCAACAGCGGCTTCGACGATGGCTC
TGCTTTCGGCGGAGGCCTGCCTTTCAGCGGCTACAGTCCTCTGCAGGGCAACCACAACAAGTGCCCCGACGAGAAC
TTCTGCAAGGGAATCAAGAACGTGCTGAGCTGCGACTGCAAGTACAAGGACCTGGACAACACATTCAAAGAATTCA
AGGACAATGTGACCCTGCTGAAGGCCGTGATCGACAACAAGAAGAACCAGGACAGCCTGACCACCACCAGCCTGAG
CACCTCCATCAACTCCGTGCGGGACTCCTCCAACCTGGACCAGAGAGGCAACATCACCACCTCCCAGGGCAACAGC
CACAGAGCCACAGTGGTGCAGCAGGTGGACCAGACAAACAGACTGGACAACGTGAACAGCGTGACCCAGCGGGGCA
ACAACAATTACAACAACAACCTGGAAAGGGGCCTGGGCTCTGGCGCTCTGCCTGGCACCAACATCATCACCGAGGA
AAAGTACTCCCTGGAACTGATCAAGCTGACCAGCAAGGACGAAGAGGACATCATCAAGCACAATGAGGACGTGCGG
GAAGAGATCGAAGAACAGCAGGAAGATATTGAAGAGGACGAGGAAGAACTGGAAAACGAGGGCGAGGAAACAAAAG
AAGAGGACGACGAGGAAAAGAACGAGACAAACGACACCGAGGACACAGACGATACAGAGGACACTGAGGACATCGA
AGAGGAAAACAAAGAGAAAGAGCTGAGCAACCAGCAGCAGAGCGAGAAGAAATCCATCAGCAAGGTGGACGAGGAC
AGCTACAGAATCCTGTCCGTGTCCTACAAAGACAACAACGAAGTGAAGAACGTGGCCGAGAGCATCGTGAAGAAGC
TGTTCAGCCTGTTCAACGACAACAACAATCTGGAAACCATCTTCAAGGGCCTGACCGAGGACATGACCGACCTGTT
CCAGAAAGAGCAGAAGCTGATCTCCGAAGAGGACCTGGAACAGAAACTGATCAGCGAGGAAGATCTGCACCACCAT
CACCATCACTGACTCGAG 
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Appendix III 
Supplementary data  
 
 
 
Figure A1 IgM/DBLMSP immune complexes did not induce proliferation. Purified CellTrace
TM
 
Violet-labelled PBMCs were cultured on 96-well plates (Nunc) coated with 50μg/ml of his-tagged 
DBLMSP or Cd4-d3+4 proteins, or IgM/DBLMSP or IgM/ Cd4-d3+4 immune complexes (1:5 ratio) 
for 5d at 37 ºC/ 5% CO2. Proliferation was not induced in CellTrace
TM
 Violet labelled PBMCs 
incubated with DBLMSP (pink trace, top panel), Cd4-d3+4 (green trace, top panel), IgM/DBLMSP 
(pink trace, lower panel), or IgM/Cd4-d3+4 (green trace, lower panel), whereas it was induced in cells 
incubated with PHA (black trace). Data shown is one of two repeat experiments.  
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Figure A2 hFcμR is not expressed on untransfected BW5147 cells. Untransfected BW5147 cells 
were washed and incubated with 1μg anti-FcμR mAb (Abnova) or medium alone for 1hr at 4˚C. Cells 
were then washed and labelled with anti-mouse IgG-APC for 1hr at 4˚C prior to subsequent washing 
and analysis by flow cytometry. Live cells were gated based on the SSC and FSC prolife (left panel), 
and were further gated into GFP-negative cells (middle gate). Expression of FcμR was investigated by 
staining with anti-mIgG-APC (right panel). Cells incubated with medium alone are shown as a grey 
trace, cells incubated with anti-mIgG-APC are shown as a black trace, and cells incubated with anti- 
mAb and anti-mIgG-APC are shown as a red trace (n= 3).  
 
 
 
Figure A3 IgM is internalised into lymphocytes. PBMCs were isolated from healthy donors were 
washed and incubated with media alone or supplemented with human IgM or human serum for 1hr at 
4
º
C. Cells were washed and incubated at 37
º
C for the indicated times. Cells were then washed 
extensively and labelled with markers specific for human IgM, CD3, and CD19. Surface levels of IgM 
on gated lymphocytes were determined by flow cytometry. IgM geometric mean fluorescence 
intensities (GMFI) were normalised to time 0 for T cells (A) and B cells (B). There was no significant 
differences in internalisation between cells incubated purified IgM or human serum (p > 0.05), as 
determined by one-way ANOVA. The mean ± SD of five independent repeats is shown. 
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Figure A4 Lower concentrations of IgM induce inhibition of T cell and B cell proliferation. The 
ability of IgM or BSA (10μg/ml) to inhibit proliferation of CellTrace™ Violet-labelled gated 
lymphocytes was investigated by flow cytometry. Data are represented as mean ± SD of two 
independent experiments. Multiple unpaired t-tests were used to determine significant differences in 
cellular proliferation (% proliferating cells) between samples. Statistical significance was determined 
as p < 0.05. 
 
 
Figure A5 PHA activation induces externalisation of IgM on gated T cells. PBMCs were 
incubated with medium alone or medium supplemented with 1μg/ml PHA for 5 min at 4°C, prior to 
incubation at 37
°
C for the indicated times. Following internalisation, cells were washed twice to 
remove unbound IgM. Subsequently, cells were labelled with F(ab’)2-anti-human IgM-RPE and anti-
CD3-APC. IgM levels on cell surfaces were determined by the geometric mean fluorescence intensity 
of RPE. Data shown is from one donor.  
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Abstract 
 
The remarkable clinical success of Fc-fusion proteins has driven intense investigation for 
even more potent replacements. Using quality-by-design (QbD) approaches, we generated 
hexameric-Fc (hexa-Fc), a ~20nm oligomeric Fcbased scaffold that we here show binds low-
affinity inhibitory receptors (FcRL5,FcγRIIb, and DC-SIGN) with high avidity and 
specificity, whilst eliminating significant clinical limitations of monomeric Fc-fusions for 
vaccine and/or cancer therapies, in particular their poor ability to activate complement. Mass 
spectroscopy of hexa-Fc reveals high-mannose, low-sialic acid content, suggesting that 
interactions with these receptors are influenced by the mannose-containing Fc. Molecular 
dynamics (MD) simulations provide insight into the mechanisms of hexa-Fc interaction with 
these receptors and reveals an unexpected orientation of high-mannose glycans on the human 
Fc that provide greater accessibility to potential binding partners. Finally, we show that this 
biosynthetic nanoparticle can be engineered to enhance interactions with the human neonatal 
Fc receptor (FcRn) without loss of the oligomeric structure, a crucial modification for these 
molecules in therapy and/or vaccine strategies where a long plasma half-life is critical. 
 
Key words: hexa-Fc; glycosylation; complement; FcRL5; FcγRIIb; DC-SIGN. 
